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Abstract
Monitoring the cancer response to treatment, non-invasively, by medical imag-
ing is a key element in the management of cancer. For patients undergoing
treatment, it is crucial to determine responders from non-responders in order to
guide treatment decisions. Currently, PET is the most widely used technique
for imaging tumor function by measuring the uptake of the glucose analogue
FDG. FDG-PET can visualize changes in metabolic activity and indicate if a
patient will respond to a particular therapy, sometimes within hours of the first
treatment. However, PET is not effective in all tumor types, and the patient
is exposed to ionizing radiation. The introduction of hyperpolarized 13C MRS
has opened completely new possibilities to study the biochemical changes in dis-
ease processes. Numerous 13C-labeled compounds were proposed to interrogate
various aspects of cancer cell metabolism.
The aim of this study is to investigate the relevance of [1-13C]pyruvate and
[1,4-13C2]fumarate in monitoring the changes in cellular metabolism and necro-
sis that may occur as a result of cancer therapy. This project also aims to
improve existing 13C MRSI methods to efficiently utilize the signal from hyper-
polarized 13C substrates.
Firstly, we investigate the effectiveness of hyperpolarized [1-13C]pyruvate in
detecting the treatment response in two types of NSCLC xenografted in mice,
in comparison with FDG- and FLT-PET. We show here a significant reduction
in tumor lactate levels, obtained by MRS, in HCC-827 tumors, as well as lower
FLT- and FDG-PET uptake with erlotinib treatment. These findings were vali-
dated ex vivo, where LDH activity level and Ki-67 IHC staining was significantly
lower in treated HCC-827 tumors. Furthermore, the reduction in LDH activity
levels correlated with the lactate levels found using 13C MRS. These findings
indicate the hyperpolarized [1-13C]pyruvate can be an alternative to FDG-PET.
In the second study, a polarization scheme for [1,4-13C2]fumarate in the SPIN-
lab polarizer is presented. The feasibility of using [1,4-13C2]fumarate as marker
for monitoring induced necrosis is demonstrated in vivo in two rat models; is-
chemia/reperfusion induced necrosis in kidneys and turpentine induced necrosis
in muscle. High polarization was achieved for [1,4-13C2]fumarate in the SPIN-
i
lab and high [1,4-13C2]malate signal was observed from the necrotic tissue in
both models. The elevated malate signal observed in the ischemia/reperfu-
sion induced injury in kidney showed high correlation with well-known blood
and urine bio-markers used to characterize acute kidney injuries. Moreover,
simultaneous assessment of metabolism and necrosis was achieved using dual
polarization of [1,4-13C2]fumarate and [1-
13C]pyruvate.
Finally, a symmetric echo planar spectroscopic imaging sequence for hyper-
polarized 13C spectroscopic acquisition in clinical scanners is presented with
a reconstruction algorithm that separately reconstruct the data from odd and
even echoes in order to reduce artifacts from gradient imbalances. The recon-
struction algorithm employs re-gridding in the spatio-temporal frequency space
to compensate for the chemical shift displacements. The sequence is compared
with conventional phase-encoded chemical shift imaging on a clinical PET/MRI
system in phantoms and a large animal model. The SNR per unit time of
EPSI for 13C at thermal equilibrium was comparable to CSI. The reconstruc-
tion pipeline improved the localization compared to direct FFT, which resulted
in spatial blurring. The encoding speed of EPSI allowed dynamic imaging of
tumor metabolism with high spatial and temporal resolutions and reduced blur-
ring due to T1 decay.
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2
1
Motivation and Outline
Much of the early classical methods used to characterize cancer and monitor
its progression or response to treatment, which are widely still in use [1], have
been based on anatomical imaging. In those methods, changes in tumor size
and texture, as it appears in x-ray computed tomography (CT) or magnetic
resonance (MR) images, were used in the assessment. However, it can take up
to several months before these methods can indicate whether the tumor is in re-
mission state or still progressing with treatment. Therefore, considerable efforts
are made to develop imaging modalities that can detect the cancer response to
treatment as early as possible to ensure that the patient is receiving the right
treatment without wasting valuable time.
These efforts led to advancements in fields like positron emission tomogra-
phy (PET) [2–5] and magnetic resonance spectroscopy (MRS) [6–8]. These
modalities can probe the tumor function, which is usually directly affected by
treatment. The most widely used method in the clinic is PET that utilizes
various radioactive tracers, with the most commonly used one being 2-deoxy-
2-[18F]fluoro-D-glucose (FDG). FDG-PET can show the high rates of glucose
uptake and utilization by most cancer types. Additionally, FDG uptake in some
types of cancers is reduced as early as 24 h after treatment [9,10], whereas it can
take weeks or months before the tumors shrink. FDG-PET, however, cannot
detect the presence and aggressiveness of some types of cancer because of their
relatively low uptake or because the signal from the surrounding tissues or organ
is high, making it difficult to distinguish the tumor. In addition, PET imaging
involves exposure to ionizing radiation, which makes multiple close examination
with this modality undesirable especially if the patient is young.
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Proton (1H) MRS has been successfully applied to assess the physiology of
some cancer types like brain [11] and prostate cancers [8, 12, 13] because of
their distinguishable metabolic profiles from normal cells. MRS also has the
advantage that, unlike PET, it can give more complete picture of the metabolic
pathways, since several metabolites can be quantified from the spectrum. How-
ever, a major obstacle with MRS is the inherently low sensitivity, which results
in images with poor spatial resolution and long acquisition times. The low
sensitivity also makes MRS with nuclei other than 1H unfeasible.
MRS has been combined with hyperpolarization techniques to enhance the
signal by several orders of magnitude [14]. Hyperpolarization has since been
applied in in vivo imaging of 13C labeled organic substrates that lie at crossroads
of major metabolic pathways. The most notable example is [1-13C]pyruvate,
which has been widely used to observe the increased [1-13C]lactate production
in cancer due to the increased aerobic glycolysis [15–20]. Another promising
substrate is [1,4-13C2]fumarate that allows monitoring cellular necrosis in vivo
[21–24].
The purpose of this study is to investigate the non-invasive imaging of hyper-
polarized 13C substrates, namely [1-13C]pyruvate and [1,4-13C2]fumarate, and
their relevance in monitoring tumor response to treatment. In chapter 2 of the
thesis, a background is given about some of the hallmarks of cancer related to
proliferation and metabolism. A short background is also given on the use of
PET to monitor cancer response to treatment with focus on two traces, FDG
and 3’-[18F]Fluoro-3’-deoxythymidine (FLT), which were used in the first study
conducted in this PhD. Chapter 3 gives an introduction to nuclear magnetic
resonance and hyperpolarization using the dissolution Dynamic Nuclear Polar-
ization (dDNP) method. This chapter also highlights some of the promising
13C substrates and their role in assessing cancer physiology with focus on [1-
13C]pyruvate and [1,4-13C2]fumarate. Finally, an introduction to
13C MRS is
given. In chapter 4 a study is presented in which the 13C MRS of hyperpolar-
ized [1-13C]pyruvate was compared with FDG- and FLT-PET in monitoring the
response of cancer to treatment. This comparison study was performed in two
cell lines of non-small-cell lung cancer (NSCLC). Chapter 5 details the optimiza-
tion of the chemical formulation of [1,4-13C2]fumarate and its polarization in
the clinical SPINlab polarizer, since unlike [1-13C]pyruvate, [1,4-13C2]fumarate
has not been widely used in SPINlab. Then, the use of hyperpolarized [1,4-
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13C2]fumarate to monitor necrosis is demonstrated in two models. The first one
is turpentine induced necrosis in rat muscles and the second is ischemia/reper-
fusion (IR) induced necrosis in rat kidneys. Chapter 6 provides a detailed im-
plementation of echo planar spectroscopic imaging (EPSI) sequence with robust
reconstruction in a clinical MR system. Chapter 7 draws some perspectives and
future work.
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Cancer Pathophysiology
Cancer is believed to be a result of genetic alterations that manifest itself in
a number of physiological characteristics [25, 26]. These characteristics or phe-
notypes drive the progressive transformation of normal human cells into highly
malignant tumor1. The most prominent of them is the high proliferation rate
achieved through self-sufficiency in growth signals, insensitivity to anti-growth
signals, ability to evade programmed cell death and limitless replicative poten-
tial. Another important characteristics of cancer is the alteration in the energy
metabolism to cope with the high rate of proliferation.
2.1 Proliferation in Cancer
Normal cells require growth signals or factors, typically produced by other cells
and conveyed via certain types of proteins, before they can move from a dor-
mant quiescent state into an active proliferative state [27–29]. These signals
are transmitted into the cell by transmembrane receptors. Once the signal is
received, it triggers a series of cascaded biological reactions within the cell that
ends with DNA synthesis and cell multiplication, see Figure 2.1.
To maintain increased proliferation rates, cancer cells need to achieve self-
sufficiency in growth stimulation and can acquire this in a number of ways
[30,31]. For instance, genetic modifications can result in structural alteration in
the growth receptors on the cellular membranes making them fire continuously.
1We cover here some of the cancer phenotypes relevant to the studies presented in the
following chapters. For more comprehensive review on cancer hallmarks refer to [25,26].
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In some cancer types, receptor overexpression may enable the cancer cells to
become responsive to the normal levels of growth factor that normally will not
cause proliferation. Moreover, cancer cells may acquire the ability to synthesize
their own growth factors to which they are sensitive, unlike the case with normal
cells where growth factors are synthesized externally by other types of cells.
Another mechanism is to alter the components of the downstream reactions in
the cytoplasm to induce proliferation without signal from upstream.
Figure 2.1: Proliferation controlling receptors in the cell membrane and signal
transduction in the cytoplasm. This figure is a simplification of the cell sig-
naling pathways diagram by Hanahan and Weinberg [25]. Growth factors and
inhibitors (e.g. TGFβ) are received by transmembrane receptors and these in
turn deliver it to intracellular circuits. Apoptosis is controlled by a sensory
mechanism that senses the extracellular and intracellular environments [32–34].
Extracellular sensors include survival and death signal receptors. Intracellular
sensors monitor the cell condition, i.g. DNA damage, survival factor insuffi-
ciency, or hypoxia. The most important regulator here is the p53 tumor sup-
pressor protein [35]. The protein p53, in response to DNA damage, signals to
initiate DNA repair or apoptosis if the damage is irreparable.
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Cellular proliferation does not depend only on growth stimulatory signals
but also is governed by growth inhibition, which works in a similar manner to
stop proliferation [36, 37]. Moreover, Programmed cell death like apoptosis is
an important mechanism that control the size of the cell population and guard
against abnormalities [38, 39]. The cells must also evade these two mechanisms
for the cancer to grow vigorously [40,41].
Figure 2.2: Encoding gene of epidermal growth factor receptor in Non Small
Cell Lung Cancer including extracellular binding domain, the trans-membrane
domain and intracellular tyrosine kinase domain. HCC-827 cancer cells are
activated by delE746-A750 deletion mutation in exon 19, were as NCI-H1975
is activated by L858R substitution in exon 21. Additionally, NCI-H1975 has a
substitution mutation T790M in exon 20, which gives this cell line resistance to
treatment by TKI.
The overexpression in the epidermal growth factor receptors (EGFR) is an
example of up-regulation in growth factor receptor that can be seen many cancer
types, namely NSCLC, due to mutations in the four exons 18-21, which are in
the encoding domain of the tyrosine kinase activity of the EGFR, see Figure 2.2.
The most common of these mutations are delE746-A750 deletions in exon 19 as
in HCC827 cells and L858R substitution in exon 21 as in NCI-H1975 cell [42–44],
see chapter 4. EGFR has an intrinsic tyrosine kinase function. When activated,
it transfers a phosphate group from adenosine triphosphate (ATP) and attached
it to the amino acid tyrosine, which is a key step that initiates a cascaded
signal that ends with DNA synthesis. The function of EGFR can effectively be
inhibited by tyrosine kinase inhibitors (TKIs) like elrotinib that out-competes
EGFR for ATP. Therefore, many types of NSCLC like HCC827 typically have
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good response to therapy with TKIs [42,45,46]. However some types of NSCLC
like NCI-H1975 has acquired resistance to TKIs due to T790M atypical mutation
in exon 20 [47–50]. T790M increases the affinity of EGFR for ATP, therefore
restoring its enzymatic function.
2.2 Cancer Metabolism
The alterations that cancer cells exhibit include modification in the energy
metabolism that fuels cell growth and division. In normal cell, when oxygen is
abundant, glucose is processed in the cytosol via glycolysis into pyruvate, pro-
ducing 2 ATP units per glucose molecule. Pyruvate is then dispatched to the
mitochondria where it enters the tricarboxylic acid (TCA) cycle that consumes
oxygen and produce 18 ATP units per 1 pyruvate molecule. Under anaerobic
conditions, glycolytic flux is increased to produce more ATP and most of the
pyruvate is converted into lactate, Figure 2.3. This is catalyzed by lactate de-
hydrogenase (LDH). However, even in the presence of oxygen, most cancer cells
limit their energy metabolism largely to glycolysis rather than the oxidative
phosphorylation of pyruvate in the mitochondria [52]. This is done by upreg-
ulating the glucose transporters in the cell membranes to increase the glucose
transfer to the cytoplasm.
Figure 2.3: Metabolism in normal cell (A) and cancer metabolic phenotype (B)
with high glycolytic flux and increased lactate production.
When noticing this metabolic phenotype Warburg hypothesized that can-
cer cells may have defective mitochondria incapable of maintaining oxidative
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respiration. Most cancer cells, however, do not necessarily have compromised
mitochondria [53]. The reason behind favoring the poor efficiency of ATP pro-
duction by glycolysis over the oxidative phosphorylation is that the former is
more capable of supporting the proliferation process [54, 55]. Glycolysis pro-
vides the intermediates needed for the biosynthesis like ribose for nucleotides
and glycerol for lipids and cell membranes. Moreover, the rate of ATP pro-
duction in glycolysis can be increased high enough to produce an amount of
ATP that exceed that produced from oxidative phosphorylation [56,57]. It has
also been established that signaling pathways that affect proliferation also af-
fect metabolism [58]. Perhaps the rationale behind the conversion of private
into lactate and not oxidizing it to enhance the production of ATP is that,
pyruvate oxidation cannot cope with the high glycolysis flux. Therefore, over-
expression of lactate dehydrogenase A (LDH-A) in many cancer types is used
as a mechanism to avoid accumulation of pyruvate [59].
2.3 Monitoring Cancer Response to Treatment
with PET
PET is a functional imaging modality in which tracers, analogous to biological
compounds, are labeled with isotopes that emit positrons. A positron from these
isotopes travels a short distance, typically less than 1 mm, before it is annihilated
when it interacts with an electron of a nearby atom. The annihilation results in
a pair of gamma rays emitted in opposite directions, which can be detected using
a gamma camera. After intravenous injection, these tracers can be entrapped in
certain tissues or cells and then tomographic images of their distribution within
the body can be obtained.
Examples of PET tracers are 11C-thymidine [61, 62] and FLT [63] that are
used to characterize proliferation, since thymidine can be taken up into the DNA
during synthesis. [18F]fluorotyrosine, L-[11C]tyrosine and 11C-methionine are
examples of amino acids analogues that have been studied in oncology [64, 65],
since the increased proliferation in cancer requires active protein synthesis, and
therefore increased amino acid uptake by overexpression of amino acid trans-
porters. Beside protein synthesis, lipids synthesis from choline as constituent
of cellular membranes is also important during cell division and multiplication.
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Therefore, choline 11C and 18F isotopes [66–68] has been used as markers for
tumor malignancy. The major drawback with 11C labeled tracers is their very
short half-life. For this reason, 18F labeled agents are commonly used. Here,
more focus will be given to FDG and FLT tracers used in the first study of this
PhD project, 4.
2.3.1 FDG
The most commonly used PET tracer in oncology is the glucose analogue, FDG.
After injection, FDG leaks from the vasculature to the extracellular space. From
there, glucose transporters, which are overexpressed in cancer, transport it into
the cells. FDG is not fully processed via glycolysis. Unlike glucose, FDG lacks
a hydroxyl group in position 2, which is required in the second step of the
glycolysis. Therefore, FDG is trapped within the cells. Typically the uptake
of FDG within tumor tissue is higher than for normal tissue, because of the
overexpression in glucose transporters and the increased glycolysis.
A problem with FDG is its susceptibility to false-positive from normal body
functions. For example, large muscle groups require more glucose when they
are overexerted, which increases their FDG uptake. It is also well known that
inflammation, e.g. resulting from cancer treatment via radiofrequency ablation
or surgery, can lead to false positive, even if the treatment is working. Moreover,
the tumor can be masked in some cases by its neighboring tissue, as in the case
of the brain and the heart, where the cells have high metabolic demand and
therefore require large amounts of glucose.
2.3.2 FLT
FLT tracer, a Thymidine (or deoxyribosylthymine) analogue, is increasingly be-
ing used clinically to target proliferation, which is the key biological process
upregulated in cancer. When injected, FLT nucleoside is taken up by the cells
and phosphorylated by thymidine kinase 1 with one, two, or three phosphoric
acid groups, creating thymidine mono-, di-, or tri-phosphate (TMP, TDP, or
TTP) nucleotide, respectively. It cannot be used further in the synthysis of
DNA because its ribose sugar is lacking a hydroxyl group needed for bonding
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with phosphate group in another nucleotide molecule to form the phosphate-
deoxyribose backbone of DNA. FLT is trapped after phosphorylation, and the
retention of FLT within the cell provides a measure of thymidine kinase 1 activ-
ity. Due to the increased proliferation in cancer, thymidine kinase 1 activity can
increase about 10-fold during DNA synthesis [69, 70]. The DNA synthesis de-
scribed above is the salvage pathway, since the cells to use thymidine nucleosides
produced elsewhere. Thymidine nucleotides can also be produced endogenously
in the cell, i.e. de novo, from deoxyuridine monophosphate [71,72], Figure 2.4.
Compared to FDG, the uptake of FLT after an inflammatory response is less,
which makes false positives less likely. Moreover, most of the chemotherapeu-
tics drugs directly impact the proliferation. Therefore, FLT might be a better
monitoring tracer in these cases.
One issue with FLT is its reliance on the thymidine salvage pathway, while
ignoring the de novo pathway. Different cancer types can utilize either pathways
to a varying degree. This make the FLT data difficult to interpret sometimes.
For example, FLT cannot discriminate between moderately proliferating thymi-
dine salvage-driven tumors and high proliferating tumors that rely on the de
novo thymidine synthesis [73]. Moreover, some types of chemotherapies that
inhibit the de novo path can cause increase in the synthesis from the salvage
path and thus FLT, despite the overall reduction of proliferation [74,75].
Figure 2.4: DNA synthesis from de novo and salvage pathways.
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Imaging Cancer with Hyperpolarized 13C
MRS
3.1 NMR
Magnetic resonance imaging is based on nuclei with spin quantum number I ≥
1/2. These nuclei, also called spins, possess angular momentum, ~L, and can
be thought of as spinning around a spin axis. Due to this angular momentum,
spins also have magnetic dipole moment, ~µ,
~µ = γ~L (3.1)
where γ, called the gyromagnetic ratio, is the ratio between the magnetic
dipole moment and the angular momentum and it is a property of the nucleus.
The resultant of the magnetic dipole moments from spins in an ensemble, also
termed the magnetization ~M , is what gives rise to the signal in MR. In the
absence of an external magnetic field, the spins are randomly oriented and the
resultant magnetization , ~M , is zero (see Figure 3.1). When a static field ~B0
is applied, they start precessing around this field and the previously randomly
oriented spins tend to slightly point more toward ~B0 and less away from it,
Figure 3.2, therefore making the resultant magnetization non zero.
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Figure 3.1: Randomly oriented spins in the absence of an external magnetic
field. The resultant magnetization from superposition of the magnetic dipole
moments of the spins in the ensemble is zero. The figure was reproduced with
permission from [78].
Figure 3.2: Spins orientation with the application of a magnetic field ~B0. The
resultant magnetization from the spins’ magnetic dipole moments points in the
direction of the magnetic field. The figure was reproduced with permission
from [78].
From quantum mechanics point of view1, there are two eigenstates for spins
with quantum number I = 1/2. The energy difference, δE, between the two is
a function of the applied magnetic field ~B0,
1See [79] for more complete interpretation on this non trivial split in the eigenstates.
16
Chapter 3. Imaging Cancer with Hyperpolarized 13C MRS
δE = γ~B0 (3.2)
where γ is the gyromagnetic ratio of a given isotope and ~ is Planck’s con-
stant. The distribution of population between the two levels is described by
Boltzmann equation,
N
N
= eγ~B0/kT (3.3)
where k is Boltzmann’s constant and T is the absolute temperature. The two
energy levels are almost equally populated in ambient temperature. This makes
the net magnetization of an ensemble very small. The degree of spin alignment
is termed the polarization, P , and it can be derived from 3.3,
P =
N −N
N +N
= tanh(
γ~B0
KT
) (3.4)
Therefore, the magnetization, M , can be expressed in terms of the polariza-
tion, P , as follows
~M = NP~µ (3.5)
where N is the total number of spins in the volume.
What makes the MR sensitivity inherently low is this low alignment of spins
in the ensemble for most of the biologically relevant nuclei. For nuclei such as
1H and 13C the polarization value at ambient temperature is in the range of
(10−6 − 10−5).
3.2 DNP
It has been known since the middle of the last century that polarization can be
increased artificially by orders of magnitude above thermal equilibrium [80]. A
number of techniques have been used to achieve this. These techniques work
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by transferring the polarization to the nuclei of interest from spins that can be
highly polarized under certain conditions. The source of polarization can be
the electron spins in a paramagnetic agent as in dynamic nuclear polarization
(DNP) [14,81–83], or in alkali metal vapor as in spin-exchange optical pumping
[84–86]. Another source that has been used for polarization is parahydrogen as
in parahydrogen induced polarization based methods [87–93].
DNP, the hyperpolarization method used here, makes use of the fact that
the polarization of electron spins is significantly large than 1H or 13C nuclear
spins at the same temperature, Figure 3.3, due to the high gyromagnetic ratio
of the electron. For example, in a 14 T magnetic field at 10 K the electron’s
spins has almost achieved 100% polarization, while at the same temperature the
polarization of 1H spins is around 0.2%.
Figure 3.3: Polarization values of proton and electron spins at 14 T magnet. In
the high temperature approximation, the polarization of electron spins is 658
times greater than proton spins. At low temperature, < 10 K, electron spins
has already achieved full polarization.
In the dDNP technique, a biological compound of interest is mixed with a
hydrophilic and chemically stable substance, such as trityl or nitroxide radicals,
that has abundance of unpaired electron spins. The mixture is then cooled
18
Chapter 3. Imaging Cancer with Hyperpolarized 13C MRS
to a very low temperature, around 1 K, in a magnetic field to achieve unity
polarization for the electron spins. The sample is then subjected to microwave
irradiation close to the resonance frequency of the electron spin, which leads
to the transfer of polarization to the nuclear spins of interest (e.g. 13C, 1H
or 15N) through various mechanisms [95]. Once the sample is polarized, it is
rapidly dissolved (hence, dissolution DNP, dDNP) in a heated buffer that also
ensures the right physiological pH and osmolarity/tonicity for in vivo use. The
hyperpolarzied compound is then injected, typically intravenously, in a subject
and its cellular uptake and enzymatic pathways is monitored using magnetic
resonance spectroscopy.
3.3 Characterization of Cancer with Hyperpo-
larized 13C Substrates
Numerous compounds have been polarized with dDNP and used in cancer stud-
ies. [U-2H, U-13C]Glucose has been used to image the glycolytic fluxes in cancer
in vitro [97] and in vivo to study the variation in these fluxes following treat-
ment [98, 99]. Another molecule that has been used to investigate the glycol-
ysis in tumor cells is [2-13C]fructose [100]. Since cancer cells tend to deplete
much of the intermediates in the TCA cycle while using them as precursors
for bio-synthetic and proliferation pathways (cataplerosis), most cancer types
exhibit an increased anaplerosis, the biochemical reactions used to refuel the
TCA cycle with intermediates. This has been studied using hyperpolarized glu-
tamine [101,102], [1-13C]glutamine and [5-13C]glutamine, and its oxidation (glu-
taminolysis) into glutamate, which is a precursor for α-ketoglutarate, a TCA cy-
cle intermediate. Hyperpolarized [1-13C] ketoisocaproate [103] and its increased
transamination into leucine, which is associated with the increased conversion of
glutamate into α-ketoglutarate has also been used to characterize cancer. More-
over, hyperpolarized [1-13C]dehydroascorbic acid was proposed as a noninvasive
biomarker of redox status in vivo, and it was shown that tumor has increased
conversion rate of dehydroascorbic acid to ascorbic acid due to its high reducing
environment [104–106]. [13C]bicarbonate is another important substrate that
can be used to probe the tissue pH homeostasis in vivo, and it has been used
to demonstrate the alterations in the extracellular pH in cancer [107,108].
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3.3.1 Monitoring Cancer Metabolism with Hyperpolar-
ized Pyruvate
The most commonly used substrate in dDNP studies is [1-13C]pyruvate. Pyru-
vate, which is the final product of the glycolysis, is the main fuel for the TCA
cycle that takes place inside the mitochondria to generate energy in the form
of ATP. When pyruvate crosses the membranes of the mitochondria, it is de-
carboxylated by the pyruvate dehydrogenase enzyme complex into acetyl-CoA.
Pyruvate can also be converted into lactate via the lactate dehydrogenase en-
zyme and into alanine via the alanine transaminase enzyme in the cytoplasmic
matrix.
It has been shown that tumors have increased [1-13C]lactate production
[16, 18, 109], and in some type of cancer also increased [1-13C]alanine produc-
tion [16,110], after in vivo injection of hyperpolarized [1-13C]pyruvate. There is
also evidence that the relative amount of lactate produced with respect to pyru-
vate can reflect the tumor grade in some cancer types [16]. Moreover, it have
been shown in numerous studies [15,20,24,111–118] that the conversion rate of
hyperpolarized [1-13C]pyruvate into lactate can provide an early prediction for
the response of cancer to treatment, and thus offering a valuable modality to
assess cancer therapy. Hyperpolarized [1-13C]pyruvate has already been used in
the clinic to study prostate cancer [17].
3.3.2 [1,4-13C2]Fumarate as a Marker for Necrosis
Necrosis was once thought of as non-programmed cell death. Evidence now
suggests that there is some degree of programming involved in necrosis, and
that it serves important biological processes, like the induction of inflammatory
responses [119]. In necrosis, the cellular membranes are broken, which results
in the cells spilling their contents into their neighborhood. Due to the cessation
of active processes in the cell, digestive enzymes are released and the cell is
destroyed. This process can potentially cause inflammatory response, which
can be damaging. In apoptosis, a programmed death mechanisms, the cell
condenses and collapses on itself forming number of apoptotic bodies that are
phagocytosed and digested neatly without damaging its neighbors.
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Necrosis has been shown to play a role in many pathological processes like
neurodegenerative disorders [120, 121], ischemia/reperfusion injuries [122], and
viral and microbial infections [123, 124]. Necrosis may also play an important
role in many physiological processes like ovulation [125] and embryogenesis [126].
In addition, many chemotheributical agents used for cancer treatment are known
to induce death in cancer cells through necrosis [127–129]. A common method to
study necrosis in vivo is by diffusion weighted imaging, which can image the loss
of cellularity [130–133]. However, it may take some time, after necrosis, before
any sign can be seen in these images [134]. Hyperpolarized [1,4-13C2]fumarate
has been shown to allow early detection of necrosis and has been used in vivo
to monitor the necrosis in cancer induced by chemotherapy [21, 22, 114]. Hy-
perpolarized [1,4-13C2]fumarate has also been used in vivo in early detection
of renal acute tubular necrosis [23]. The conversion of fumarate into malate,
catalyzed by fumarase, is one of the steps in the mitochondrial TCA cycle. The
amount of [1,4-13C2]malate produced in normal intact cells following the injec-
tion of [1,4-13C2]fumarate is very low due to the limited amount of fumarate
that crosses the cellular and mitochondrial membranes. As fumarase is exposed
by cells that undergo necrosis, an increased [1,4-13C2]malate production can be
observed from necrotic tissue.
3.4 Magnetic Resonance Spectroscopic Imaging
When the magnetization from an isochromat2 of spins in a magnetic field, ~B0,
is excited, it precesses around this field with a frequency, fσ, dictated by the
gyromagnetic ratio, γ, of the spins and the strength of the magnetic field, Bσ,
that the spins experience.
fσ = γBσ (3.6)
The magnetic field strength Bσ that the spins experience can be slightly
different from the strength of the applied static magnetic field, B0, due to the
fact that the electron clouds around the spins reorient themselves to slightly
oppose and thus weaken the field B0.
2Isochromat in this context refers to spins that have the same chemical shift and experience
the same magnetic field.
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Bσ = B0 + (∆B)σ (3.7)
Here (∆B)σ is the field due to the electron cloud. If the magnetization, after
excitation, is observed from a reference frame rotating with frequency equal to
γB0, which is the case with MR imaging due to signal demodulation, then the
magnetization will appear to be precessing with a frequency given by
fσ = γ(∆B)σ (3.8)
Then, neglecting the relaxation, the magnetization vector in the transverse
plane, xy, at any time t will be
Mxy(t) = M0(fσ)e
−i2pifσt (3.9)
where M0(fσ) is the amplitude of the equilibrium magnetization from the
spins with chemical shift fσ and it is proportional to the number of spins in this
population as in equation 3.5. We can write the signal received in time as3,
s(t) = M0(fσ)e
−i2pifσt (3.10)
If more than one isochromat of spins with different chemical shifts are present
in the ensemble, then the signal collected will be a superposition of the magne-
tizations precessing at the different frequencies as
s(t) =
∫
fσ
M0(fσ)e
−i2pifσtdfσ (3.11)
Equation 3.11 shows the Fourier nature by which the signal collected in the
time domain and the magnitude of the magnetizations from the different spin
isochromats in the frequency domain are related. Direct Fourier transform can
be applied on the signal collected to obtain the magnetization of each spin
isochromat and thus their relative populations.
3The signal received is proportional to the magnetization,s(t) ∝Mxy(t), but for simplicity
we can write s(t) = Mxy(t)
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Up till now we considered the case of single point spectroscopy, where the
signal is assumed to be originating from a single point source. In MR imaging,
spatial localization is achieved by applying gradient magnetic fields. In the case
of two dimensional MR imaging gradients, for instance Gx and Gy, are employed
along two directions, x and y. The effect of these gradient is that, the magnetic
field experienced by the spins will be a function of the position in addition to
the chemical shift. Again assuming the rotating frame of reference,
B = (∆B)σ +Gzx+Gyy (3.12)
After excitation the precession frequency of the magnetization at any position
(x,y) for a metabolite with chemical shift frequency fσ is
f = fσ + γGxx+ γGyy (3.13)
and the magnetization vector will be
Mxy(x, y, fσ, t) = M0(x, y, fσ)e
−i(2pifσt+γ
∫ t
0
Gxdt x+γ
∫ t
0
Gydt y) (3.14)
where t = 0 is time the receiver was turned on. We can define k-space
coordinates, kx and ky, at which the signal is collected in time as function of
the applied gradients, Gx and Gy, as follows
kx =
γ
2pi
∫ t
0
Gx(t)dt (3.15)
and
ky =
γ
2pi
∫ t
0
Gy(t)dt (3.16)
The signal received is derived from the contributions of the transverse mag-
netizations precessing at all metabolic frequencies in the excited space.
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s(kx, ky, t) =
∫
fσ
∫
y
∫
x
M0(x, y, fσ)e
−i2pi(fσt+kxx+kyy)dxdydfσ (3.17)
The last equation shows that the signal can be collected in the temporal
and k-space domains, kx − ky − t, and then transformed into the spatial and
frequency domain, x− y− fσ, to obtain spectroscopic images of the spins in the
ensemble.
Due to Fourier relationship, it can be shown that the spatial and frequency
resolutions, ∆x, ∆y and ∆f are dictated by the extend of the k-space and the
total acquisition duration T ,
∆x =
1
kx,max − kx,min (3.18)
∆y =
1
ky,max − ky,min (3.19)
∆f =
1
T
(3.20)
Similarly the spectral bandwidth, BW (the extend in the frequency domain),
and the fields of view, FOVx and FOVy (the extend in spatial domain), are
related to the resolution in k-space, ∆kx and ∆ky, and the dwell time, ts (the
time elapsed between the successive acquisitions of the same point in k-space),
as follows
FOVx =
1
∆kx
(3.21)
FOVy =
1
∆ky
(3.22)
BW =
1
ts
(3.23)
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3.4.1 k-t Sampling Schemes for Hyperpolarized 13C
The different spectroscopic imaging methods adopt various techniques to fill the
data in kx−ky−t space. The classical 2D phase-encoded chemical shift imaging
(CSI) [136,137] sequence works by traversing the k-space via two phase encod-
ing gradients. One point in k-space is sampled for each excitation, see Figure
3.4a. With a high sampling rate along the temporal dimension, the spectral
bandwidth with phase encoded CSI is very large. However, obtaining high spa-
tial resolution with CSI requires additional phase encoding steps. sampling only
one point in the k-space at each excitation makes the total imaging duration of
CSI relatively long.
In the case of 1H magnetic resonance spectroscopic imaging (MRSI), where
long acquisition durations can be tolerable, the robust CSI sequence can be used
with no severe penalty. However, since the enhanced magnetization obtained
from hyperpolarization methods is short lived, and the magnetization spent on
excitations is non-recoverable. This dictates the use of faster MRSI sequences
that can efficiently utilize the decaying signal.
In fast MRSI methods, the gradients are employed to collect the data from
more than one k-space point at each excitation. For instance, in echo planar
spectroscopic imaging (EPSI) [138–142], the gradients are oscillated to traverse
back and forth along one line in the k-space while the data are collected, Figure
3.4b. This is also the case with multi-echo b-SSFP [143–145]. This sampling
scheme requires less excitations to cover all the k-space and therefore the to-
tal acquisition duration with EPSI is relatively short compared with CSI. The
points along the time dimension are typically sampled with a dwell time dictated
by the echo spacing, which can be in the order of hundreds of microseconds to
milliseconds. Thus, EPSI typically has a narrow bandwidth compared to CSI.
Spiral spectroscopic imaging [146–149] and IDEAL spiral [150] pushes the
demand on gradients further by acquiring few full k-space frames in each exci-
tation using a spiral trajectory, Figure 3.4c. Since the sampling rate along the
time axis is very low with spiral spectroscopic imaging, additional interleaved
acquisitions are made in which the data collected in k-t space are shifted along
the time axis to increase the spectral bandwidth.
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The short imaging time and fewer excitations of such fast sequences make
them more attractive for imaging of hyperpolarized nuclear spins, since they
facilitate observing the conversion of the hyperpolarized substrates to their
metabolic products with reasonable temporal resolution. These sequences, how-
ever, are characterized by a limited spectral bandwidth due to gradient slew rate
constraints, which requires spectral prior knowledge to be taken into considera-
tion for spatial-spectral reconstruction. This reduced spectral bandwidth is not
usually a limitation for hyperpolarized MRI, since the spectrum of the hyperpo-
larized 13C substrate and its metabolic products is sparse and spectral aliasing
can be controlled to avoid peak overlap. However, compared to conventional
CSI, these fast acquisition sequences are more demanding on gradient strength
and slew rate, and require extensive ramp sampling on clinical MR scanners
as opposed to preclinical systems, which reduces the SNR per unit square root
time. The limitations on gradient performance make it challenging to translate
the use of these sequences from animal to human studies.
3.4.2 Echo Planar Spectroscopic Imaging
EPSI is one of the most established sequence to achieve dynamic imaging of
the metabolism clinical studies with hyperpolarized [1-13C]pyruvate [17]. The
sequence was first introduced to 13C hyperpolarized imaging by Cunningham et
al [138]. It has been combined with various excitation modules like double spin
echo [139], variable flip angle [141] and multiband excitation [140]. Compared
with other fast acquisition techniques, EPSI can be easily incorporated with
acceleration schemes like parallel imaging [151] and compressed sensing [152]
to achive fast dynamic 3D MR spectroscopic imaging. In a study by Durst et
al [153], EPSI, spiral and IDEAL spiral spectroscopic imaging were compared
with respect to SNR, encoding efficiency, demand on gradients, and artifact
behavior. They reported that these sequences were are not very different in
terms of SNR. Moreover, EPSI was the most robust choice compared to spiral
and IDEAL spiral imaging, which were most prone to artifacts.
EPSI with symmetric readout gradients typically suffer from ghosting arti-
facts [154, 155] due to gradient imperfection, which require reference scans to
estimate and correct the discrepancies between the odd and even echoes [156].
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Figure 3.4: Different k-t space acquisition schemes. CSI (a) has the highest
spectral bandwidth, but require more excitations. EPSI (b) achieves a good
compromise between the encoding efficiency and robustness by filling the data
in on line in k-space at each excitation. Spiral spectroscopic imaging (c) can
fill the k-t space in one excitation, but the resultant spectral bandwidth is
very narrow, which dictates the use of interleave acquisitions. In centric ring
acquisition (d), circles in the k-space are covered at the successive excitations
using sinusoidal oscillating gradients.
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Flyback EPSI is sometimes preferred over symmetric EPSI to avoid the need
to correct these differences [153,157]. However, flyback EPSI suffers from lower
SNR because the receiver is idle for longer duration [138,158]. Symmetric EPSI
with separate reconstruction of the odd and even echo data is sufficient and
simple, if the resultant smaller spectral bandwidth is acceptable. The simplest
way to reconstruct the even and odd data is via FFT assuming that the data are
collected on a Cartesian grid. However, the data in the k-t space are acquired
on a zig-zag trajectory, so the phase evolution during the acquisition of indi-
vidual k-space lines must be corrected before carrying out FFT to avoid spatial
blurring due to chemical shift artefacts in opposite directions for odd and even
gradient echoes [159,160]. Chapter 6 details the implementaion and the design
consideration of a symmetric EPSI in a clinical MR system with k-t re-gridding
to correct for the chemical shift artefacts.
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Treatment Response in Non-Small-Cell
Lung Cancer with Hyperpolarized
[1-13C]Pyruvate, FLT- and FDG-PET
4.1 Objective
This chapter investigates the effectiveness of hyperpolarized [1-13C]pyruvate in
detecting the treatment response in two NSCLC tumors, HCC-827 and NCI-
H1975, xenografted in a mice. In addition, hyperpolarized [1-13C]pyruvate was
compared with FDG and FLT-PET. HCC827 have previously been shown to
elicit a high response to inhibition of the EGFR by tyrosine kinase inhibitors,
such as erlotinib, whereas H-1975 shows little response to similar treatment, due
to a secondary mutation, see section 2.1. Additional ex vivo signatures, LDH
activity level (a marker for aerobic glycolysis) and Ki-67 staining (a marker
for proliferation), are compared between the treated and untreated groups of
HCC-827 tumors and correlated with the in vivo imaging signatures.
4.2 Animal Population
58 Nude NMRI mice (Taconic, Denmark) weighing about 20-25 g were inocu-
lated subcutaneously in the two flank regions with either HCC-827 or H-1975
cells. When the tumors reached a size of about 300 mm3 (about 5 weeks af-
ter inoculation) the mice were randomized in two groups, one group for PET
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imaging and the other for hyperpolarized 13C MRS. Each group was again ran-
domly divided into two subgroups. One subgroup received Erlotinib treatment
(50 mg/kg) in a phosphate buffered saline (PBS, 0.5% Tween 20), 24 hours be-
fore imaging. The other was a control group, which received a sham treatment
(PBS, 0.5% Tween 20) of the same volume. The animals were fasted overnight
before scanning.
Figure 4.1: Representative 13C metabolic maps of pyruvate and lactate for both
treated and untreated HCC-827 and H-1975 xenografted tumors. The metabolic
maps are overlaid on proton images acquired at the same position as the CSI,
with white arrows indicating the tumor position.
4.3 Hyperpolarization and MR Experiment
The pyruvate sample, consisting of 14 M [1-13C]pyruvic acid (Sigma Aldrich,
Denmark), 15 mM trityl radical OX063 (Oxford Instruments, UK), and 1.5 mM
Dotarem (Guerbet, France), was polarized in a HyperSense polarizer (Oxford
Instruments, UK). The MR imaging was conducted in a 4.7 T small animal scan-
ner (Agilent Technologies, US). During the MR experiment, proton images were
acquired to locate the two tumors. After dissolution, each animal received 200
µL injection of hyperpolarized [1-13C]pyruvate, 80 mM. Then, CSI acquisition
was made 8 s after the end of the injection. The duration of each injection was
about 6-8 s. The CSI acquisitions were made with matrix size 16x16, repetition
time (TR) 70 ms, echo time (TE) 0.65 ms, field of view (FOV) 35x35 mm2 and
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slice thickness 5-6 mm. In addition, T1-weighted dynamic proton images, 12 s
per frame, were acquired after the injection of 200 µL of 0.1 mM gadolinium
(Dotarem, Guerbet, France) to assess tumor perfusion.
Figure 4.2: Quantitative evaluation of pyruvate, lactate and their ratio in HCC-
827 (A) and H-1975 (B) tumors. A significant reduction in lactate level (p <
0.005) was observed for treated HCC-827 tumors compared to untreated. No
significant change in metabolite levels was seen for H-1975 tumors. (C) Levels
of LDH enzyme normalized to total protein content in HCC-827 tumor samples.
A significant reduction was found in the treated tumors compared to untreated
tumors (p < 0.05). (D) Correlation between levels of LDH enzyme normalized
to the total protein content and lactate level evaluated by 13C MRSI (p < 0.01).
A clear lactate signal was observed in the tumors of both models, see Figure
4.1. When quantified, the average level of lactate detected in the untreated
HCC-827 tumors was 1.52 ± 0.17 (n=18), see Figure 4.2A. This is significantly
higher than the levels found in treated HCC-827 tumors, which was 0.76 ± 0.04
(n=14, p < 0.005). This is contrasted by the pattern seen in the H-1975 model
(Figure 4.2B), where the lactate levels were found to be similar with treatment,
1.03 ± 0.18 and 0.95 ± 0.12 respectively (n=8 both groups, p = 0.718).
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Figure 4.3: Quantification of perfusion imaging, showing inflow (A) and outflow
(B) coefficients for treated and untreated HCC-827 and H-1975 tumors. No
significant difference in coefficients was found between cell lines and treatment.
(C) shows a representative temporal development in signal enhancement, as well
as the fitted, gamma-variate curves. Corresponding representative images are
shown for three time points in (D), with arrows indicating the tumors.
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The ratio of lactate to pyruvate was also calculated. However, in HCC-827
tumors the difference between the groups in the lactate/pyruvate ratio was less
significant than the lactate difference, probably due to the observed increase in
the pyruvate level in the untreated HCC-827 tumors compared to the treated.
The ratio was 1.57 ± 0.22 in the untreated group, versus 1.06 ± 0.07 in the
treated tumors (Figure 4.2). For the H-1975 tumors, the ratios were found to
be 1.01 ± 0.06 and 1.00 ± 0.08 for the vehicle and treated group, respectively.
For the analysis of the LDH activity level and its correlation with the lactate
levels from 13C MRS, see section 4.5.
The analysis of T1-weighted dynamic contrast enhancement (DCE) imaging
showed that both groups of tumors (treated and untreated) exhibit typical DCE
curves with fast wash-in and slow wash-out, indicating well-perfused tumors
(Figure 4.3). Furthermore, the analysis of the perfusion curves did not show a
significant difference between the two groups of tumors.
4.4 FLT- and FDG-PET Experiment
The mice in the PET group were intravenously injected with 10-15 MBq of 18F-
FDG or 18F-FLT, one hour before PET imaging. A 5-7 min PET scan was then
acquired using a PET/CT scanner (Inveon MM , Siemens Medical Solutions,
Germany), followed by a CT scan for anatomical reference and attenuation
correction.
The FDG level was found to be significantly lower with treatment, 1.37 ± 0.13
%ID/g and 0.85 ± 0.05 %ID/g, for the vehicle and treated group, respectively
(p < 0.002, n=10 in each group). For H-1975, the FDG levels were similar, 1.94
± 0.09 %ID/g in the vehicle group and 1.91 ± 0.06 %ID/g in the treated group
(p = 0.766, n=8 in each group).
Similar results were obtained for FLT. The FLT uptake levels for HCC-827
was found to be 2.45 ± 0.22 %ID/g and 1.12 ± 0.28 %ID/g for the vehicle and
treated group, respectively (p < 0.002, n=8 in each group). For H-1975, the
levels were 2.39 ± 0.13 %ID/g in the vehicle group and 2.39 ± 0.11 %ID/g in
the treated group (p = 0.965, n = 8 in each group).
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4.5 LDH and Ki-67 Signatures
The mice with HCC-827 tumor that underwent hyperpolarized 13C MRS were
euthanized after experiment and the tumors were extracted and frozen. Later,
LDH activity in each sample was estimated using a NADH-colorimetric assay
(Sigma-Aldrich, Copenhagen, Denmark) according to the instructions of the
manufacturer. Similar procedures were followed with the mice that underwent
FLT-PET to estimated the cellular proliferation in HCC-827 tumors using Ki-67
assay.
The Ki-67 levels for HCC-827 tumors that underwent FLT-PET imaging
were found to be 9.6 ± 0.6 (n=5) and 6.6 ± 0.7 (n=6) for the untreated and
treated groups, respectively (p< 0.02), Figure 4.4C. Whereas, The levels of LDH
normalized to the total protein content in the HCC-827 tumors that underwent
13C MRS were found to be 0.54 ± 0.03 (n = 18) and 0.45 ± 0.03 (n=14) for
the untreated and treated group, respectively (p < 0.05) (Figure 4.2C). The
normalized LDH values were correlated to the levels of lactate from 13C MRS,
yielding a positive correlation (R2 = 0.20, p < 0.05), Figure 4.2D.
4.6 Discussion
In many studies, the reduction in pyruvate to lactate conversion has been ob-
served in response to chemo- or radiation therapies [15, 20, 24, 111–118]. The
main objective in this study was to validate these findings and investigate the
effectiveness of hyperpolarized [1-13C]pyruvate in monitoring the response of
non-small-cell lung cancer to erlotininb treatment, in comparison with FDG-
and FLT-PET. All the investigated imaging modalities were able to identify the
response to treatment after 24 hours, which agrees with literature [162]. As
expected from other reports [163, 164], the most prominent response to treat-
ment was observed from PET imaging using the thymidine analog FLT. The
response seen using FDG-PET, which reflect the glucose uptake, was less pro-
nounced but still significant. We confirmed that the response to treatment could
also be detected using [1-13C]pyruvate MRS. We observed that [1-13C]pyruvate
and FDG-PET showed comparable response to treatment. We found that the
level of lactate obtained by 13C MRS correlated with the normalized LDH activ-
ity obtained ex vivo, as reported in other studies [117, 118, 165]. This confirms
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the role of LDH as one of the primary mechanisms behind [1-13C]pyruvate MRS
contrast.
Figure 4.4: (A) and (B) quantitative comparison between FDG and FLT uptake
for treated and untreated HCC-827 and H-1975 tumors in units of % ID / g.
Significant reduction in uptake was seen for both FDG and FLT (both p< 0.002)
in treated HCC-827 tumors compared to untreated. No significant change in
uptake was observed for H-1975 tumors. (C) Quantitative evaluation of Ki-
67 staining showed a significantly reduced number of stained cells in treated
HCC-827 tumors compared to the untreated ones (p < 0.05).
The ratios between lactate and pyruvate were shown to be less significantly
different between treated and untreated groups with p = 0.058, compared to
p = 0.001 for lactate difference between the two groups. This can be due
to the significantly lower pyruvate uptake in the treatment group. This may
indicate that the transport of pyruvate into the cells, as facilitated by the mono-
carboxylate transporters, might also be affected by treatment with erlotinib.
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Further studies are needed to clarify if this is indeed the case, and explain the
mechanisms behind.
Contrast-enhanced perfusion imaging showed similar perfusion in both the
treated and untreated groups. As further expected, we also observed a signifi-
cantly slower washout of the gadolinium in tumors compared to muscle tissue.
This could be attributed to the enhanced permeability and retention of the
tumor.
Both FDG-PET and 13C MRS of hyperpolarized [1-13C]pyruvate are valu-
able in monitoring the glycolysis. FDG-PET can assess the beginning of gly-
colysis, i.e., the delivery and uptake of glucose and its phosphorylation by hex-
okinase, which is the first step in this process. 13C MRS of hyperpolarized
[1-13C]pyruvate can monitor the end of glycolysis, i.e., the exchange between
pyruvate and lactate catalyzed by LDH. Therefore, the two might be used to-
gether for better assessment of the entire glycolytic pathway and a combined
PET/MR setup is well suited to achieve such task. However, since an increased
metabolic activity is seen in many physiological states, such as inflammation
and muscle activity, the lactate levels are more specific cancer marker due to
specific imaging of the Warburg effect.
In this study, we were not able to evaluate the markers from 13C MRS and
PET in the same animal. This was impractical, since the imaging with the
two modalities took place at different sites. Therefore, the study population
had to be divided into two separate groups for MR and PET examinations.
In the subsequent studies, that involved both PET and MR acquisition, these
modalities were acquired simultaneously in a combined PET/MR setup.
4.7 Conclusion
In this study, we showed the reduction in lactate level following the injection of
hyperpolarized [1-13C]pyruvate can be used as marker to monitor the response
to erlotinib in two different tumor models of NSCLC. We also found that the
reduction in lactate levels was comparable to the reduction in the glucose uptake
as monitored by FDG-PET. The difference in FLT-PET between the treated
and untreated group was the most significant, whereas the reduction in the
lactate-to-pyruvate ratio with treatment was found to be insignificant.
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Necrosis Monitoring with hyperpolarized
[1,4-13C2]fumarate
5.1 Objectives
The objective of the studies introduced in this chapter is to investigate the effec-
tiveness of [1,4-13C2]fumarate as a marker for monitoring necrosis. These studies
were performed in models in which the necrotic process is well understood by
our group.
The chapter first presents a polarization scheme for [1,4-13C2]fumarate in the
SPINlab polarizer, since there is no previous work published on this. Moreover,
the sparsity that is often seen in hyperpolarized 13C spectra will be exploited by
adopting a co-polarization scheme for [1,4-13C2]fumarate and [1-
13C]pyruvate
to simultaneously assess their enzymatic pathways in a combined PET/MR
setup. Phantom experiments are conducted to ensure that there is no signifi-
cant difference in the polarization values between the dual and single substrate
polarization. In vivo assessment is performed in necrotic rat muscles.
This chapter also investigates the use of hyperpolarized [1,4-13C2]fumarate in
quantifying necrosis associated with acute kidney injury (AKI). Here, AKI was
induced in rats via ischemia/reperfusion (IR), which is one of the main causes
of cellular necrosis in renal tubular cells due to severe ATP depletion. Hyper-
polarized [1,4-13C2]fumarate is compared in this study with widely used blood
biomarkers for AKI such as plasma creatinine, creatinine clearance (CrCl), and
blood urea nitrogen (BUN). Moreover, biomarkers from renal biopsies such as
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kidney injury molecule 1 (KIM-1), and neutrophil gelatinase-associated lipocalin
(NGAL) expression levels in the RNA were also investigated to see if there is
correlation with the 13C MRS signature.
5.2 Formulation of [1,4-13C2]Fumarate and [1-
13C]Pyruvate
Fumarate was prepared by dissolving [1,4-13C2]fumaric acid (FA) (Cambridge
Isotope Laboratories, MA, USA) in dimethyl sulfoxide (Sigma Aldrich, Den-
mark). Sonication and vortex mixing were used until all the FA crystals had
dissolved. AH111051 trityl radical (GE Healthcare, US) was then added and
dissolved in the solution. Three different batches were prepared with FA/rad-
ical concentrations of 3.6 M/8 mM, 3.6 M/12 mM and 2.8 M/15 mM to see if
there is difference in the polarization performance. For pyruvate preparation,
AH111501 was added to a sample of 14 M [1-13C]pyruvic acid (PA) (Sigma
Aldrich, Denmark) to a final concentration of 15 mM.
5.3 Single [1,4-13C2]Fumarate Polarization
The polarization was made in a SPINlab polarizer (GE Healthcare, US). Figure
5.1A shows the fluid path assembly designed for use with the SPINlab. The fluid
path consists of a vial (1) containing the sample and connected to the dissolution
syringe (2) via two concentric tubes (3). The tubes can be pushed into the
polarizer through the dynamic seal (4) without compromising the vacuum. The
syringe has an port that connects to an exit tube (5) for the transfer of the
hyperpolarized solution.
The regular sample preparation procedure for the SPINlab fluid path requires
that the vial, after adding the 13C substrate, is frozen in liquid nitrogen (LN2).
This freezing is necessary to perform pressure check and helium purging. Helium
purging is needed to have a helium exchange gas inside the fluid path when the
vial is cooled to less than 1 K. Then the loading of the sample into the SPINlab
involves lowering the sample vial into the sample pot (see Figure 5.1C), were the
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hyperpolarization takes place, through multiple steps (gradual insertion over 15
min) to avoid excessive increase in the helium temperature. This multi-step
lowering process was found to result in FA crystallization. To avoid this, the
sample preparation and loading was modified as follows.
Figure 5.1: (A) The fluid path that goes into the SPINlab. The path consists of
a syringe that contains the dissolution media and sample vial that contains the
13C substrate to be polarized. The two are connected by two concentric tubes.
During the dissolution, the dissolution medium is transferred through the inner
tube to the sample vial where it dissolves the hyperpolarized substrate. The
dissolved material flows back through the outer tube lumen toward the syringe
and out of the SPINlab via the exit tube. (B) shows schematic draw of the
sample vial. The vial is prepared, in the dual polarization scheme, by first
adding the PA and then freezing it in LN2 and then adding the FA. The vial is
then kept in LN2 during the rest of preparation of the fluid path to attain two
separate layers in the vial. (C) shows the path of the vial once it is inserted
in the SPINlab. The vial is initially placed in the airlock for 20 min to allow
the sample to melt. Then, it is lowered in multiple steps, back and forth, along
the path until it settles at the He sample pot to avoid excessive increase in
temperature at the He pot.
The fluid path was prepared by placing 100 µL (about 350 µmol) of the FA
solution in the sample cup and then freezing it in liquid nitrogen. The vial is
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then glued to the tube set with the tip immersed in LN2 and the neck above
the liquid surface. The rest of the fluid path preparations (pressure check and
He purging) were done according to the manufactures instructions. After the
preparation, the fluid path was placed in the SPINlab and the vial containing the
compound was initially placed at the airlock for 20 to 30 min, thus allowing the
substrate to thaw before lowering the sample vial into the helium pot. Then the
sample vial was directly lowered into the helium bath in either one (A: directly
to the 1 K pot) or two steps (B: directly to the 1 K pot and then retracted
to the 4 K thermal link for 10 min), instead of the normal scheme of going
through multi-steps lowering process, to avoid the crystallization of the FA in
the sample.
The dissolution syringe was filled with approximately 15 g of a dissolution
media, sterile water with 0.1 g/L ethylenediaminetetraacetic acid disodium salt
dehydrate (EDTA) (Sigma Aldrich, Denmark). After dissolution, the sample
was mixed with 0.54 g of neutralizing buffer, sterile water with 0.72 M NaOH,
0.4 M 2-Amino-2-(hydroxymethyl)-1,3-propanediol (Tris) (Sigma Aldrich, Den-
mark), and 0.1 g/L EDTA.
The solid-state polarization of samples containing 600 mg of FA from the
three different batches (with fumarate/AH111051 concentrations of 2.8M/15mM,
3.6M/8mM and 3.6M/12mM) resulted in build-up time constants and final solid-
state polarization values detailed in Table 5.1, for one and two insertion steps.
No dissolution is done here. There was some difference between the one (A) and
two (B) lowering steps in the characteristics of the build-up curves. However,
the solid state NMR signals vary significantly between measurements due to the
uncontrolled position of the sample within the NMR coil that is dimensioned to
hold up to four samples. Therefore, the comparison is based on the liquid state
polarization obtained post dissolution of the 100 µL samples.
Table 5.1 shows these liquid state polarization measurements obtained for
the three formulations of fumarate via dynamic acquisition of 13C spectra in
the PET/MR scanner 30 s after dissolution, see the setup in section 5.5. There
was no difference in the measured polarization between the batches. Since they
gave similar polarization results, the subsequent experiments were conducted
with the 3.6M/12mM fumarate/AH111051 batch and with two insertion steps.
This batch gives higher concentration of fumarate. In addition, this batch had
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relatively faster polarization build-up.
batch 2.8 M/15 mM 3.6 M/8 mM 3.6 M/12 mM
insertion steps one two one two one two
pol time constant (s) 9448 5913 6718 6765 2725 3659
S(t =∞) (a.u.) 1311 1054 740 1140 969 993
liquid-state pol (%) 39 38 37
Table 5.1: Solid state DNP build-up data for three different samples with two
different loading profiles.
5.4 Dual [1,4-13C2]Fumarate and [1-
13C]Pyruvate
Polarization
In the dual co-plarization scheme, the fluid path was prepared by first placing 25
µL (around 350 µmol) of PA in the sample vial and then freezing it in LN2. 100
µL (about 350 µmol) of FA was then added on top of the PA, see Figure 5.1B,
and the vial was placed in LN2 again. Pressure check and He purging were then
performed. When the fluid path was placed in the SPINlab, the substrates were
allowed to thaw by placing the vial in the airlock for 20-30 minutes. The sample
vial was then lowered in a fast two-step scheme to avoid the crystallization of
the FA in the sample. The sample was polarized for approximately 4 hours by
microwave irradiation at 139.64 GHz and 40 mW (the two samples have the
same optimal microwave frequency). The dissolution syringe was filled with
about 15 g of a dissolution medium. The dissolved sample was mixed with 0.95
g of neutralizing medium.
5.5 Phantom MR Experiments for polarization
and T1 measurements
A phantom experiment was performed to measure the polarization and T1 values
of fumarate, and to ensure that here are no differences in polarization between
41
Chapter 5. Necrosis Monitoring with hyperpolarized [1,4-13C2]fumarate
single and dual substrate polarization schemes. The imaging was performed in
a clinical 3T PET/MR scanner (Siemens mMR Biograph, Siemens, Erlangen,
Germany). A dual-tuned transmit/receive flex surface coil (RAPID Biomedical)
was used for both 1H and 13C acquisitions. Phantoms were placed in the center
of the 11 cm loop coil.
About 5 mL of the polarized material, either fumarate or dually polarized
fumarate and pyruvate, was injected into a previously shimmed phantom tube,
approximately 30 s after the dissolution. A 13C-urea phantom (4 M) was placed
next to the tube with the hyperpolarized solution and was used to calibrate
the 90o flip angle and as a reference to measure the polarization. Dynamic 13C
spectra were acquired without spatial encoding using an excitation pulse with
5o flip angle and TR of 5 s. The sampling spectral window was set to 6000 Hz
with 512 spectral points. To quantify the polarization, the initial signal of the
hyperpolarized sample was compared to the urea signal and corrected for the
concentration difference.
n=5 fumarate pyruvate
scheme dual single dual
T1 (s) 57± 2 58± 2 70± 3
Polarization (%) 35± 5 37± 6 37± 6
Table 5.2: Liquid state polarization and T1 measurements for the sample with
FA (3.6 M) with 8 mM of AH111501 radical.
The results of the experiment to determine whether there is a difference in the
polarization and T1 values between the dual and single substrate polarization is
summarized in Table 5.2. No significant difference was found in the measured
values of polarization of FA for single and dual FA/PA polarization schemes.
The polarization level of pyruvate, 37%, obtained with the dual polarization
scheme agrees with the SPINlab polarization values of PA found in the literature
[166].
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5.6 Necrosis Imaging in Rat Muscles
5.6.1 Animal Model
The first in vivo [1,4-13C2]fumarate study to quantify necrosis was conducted in
two rats weighing 400 g. One rat was only injected with hyperpolarized FA. The
second rat received two injections separated by 10 min. The first injection was
only hyperpolarized FA, and the second injection was dual polarized FA and PA.
Necrosis was induced by intramuscular injection of 200 µL of sterile turpentine
oil in one of the hind legs. This was followed by subcutaneous injection of 400 µL
of buprenorphine hydrochloride (TEMGESIC, 0.03 mg/ml) to control the acute
pain from the turpentine injection. Two hours later, the animal was transferred
to the PET/MR scanner to acquire 13C MRS and PET images.
Figure 5.2: The anatomical axial image of the first rat (A) acquired at the
location of the necrotic tissue. The image was acquired with turbo spin echo
(TR= 5.7 s, TE= 84 ms, echo train length of 18, number of phase encoding
steps 234, Number of averages of 5, final matrix size of 256x256 covering a FOV
of 100 mm x 100 mm with slice thickness of 2 mm). (B) shows the spectrum
at the necrotic tissue with the fumarate peak the malate doublet. Clear malate
signal can be observed in the spectrum. The small peak at the right of the
spectrum at 164 ppm is due to fold over of the 13C-urea phantom. (C) and (D)
show the metabolic maps of fumarate and malate, respectively. Notice that the
malate production is confined to the necrotic region.
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Figure 5.3: The anatomical axial image of the second rat (A) acquired at the
location of the necrotic tissue. The proton image was acquired similar to Figure
5.2A. A coronal maximum intensity projection image, which shows the FDG
uptake by the different organs is illustrated in (B). (C) shows an axial slice
(thickness of 12 mm, sum of 6 frames) with the FDG uptake in a plane containing
the necrotic tissue. (D) and (E) show the phased real part spectra at the necrotic
tissue, the blue box in (A), acquired for single injection of FA and dual injection
of FA and PA, respectively. The malate signal can be seen in both spectra. In
the dual FA and PA experiment, additional peaks are observed for lactate,
alanine, pyruvate-hydrate and bicarbonate. The metabolic map of pyruvate,
lactate, fumarate and malate, obtained from the dually polarization of FA and
PA, are shown in (F, G , H and I). High lactate and malate signals are observed
at the necrotic tissue.
5.6.2 Combined PET/MR Experiments
The imaging was performed in a clinical 3T PET/MR scanner (Siemens mMR
Biograph, Siemens, Erlangen, Germany) using a dual-tuned 1H and 13C trans-
mit/receive flex surface coil (RAPID Biomedical). During the MR scanning,
the animals were anaesthetized with 3 % Sevoflurane mixed in O2. A catheter
was inserted in the tail vein for the administration of the hyperpolarized mix-
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ture of pyruvate and fumarate or fumarate alone. 2 mL (0.14 mmol/kg) of the
co-polarized substrates was injected in the rat. This injection was done ap-
proximately 20 s after dissolution. During this period the co-polarized material
was transferred to the MRI room from the SPINlab in a syringe that was then
connected to the tail vein catheter. The hyperpolarized substrate was injected
manually over a period of 10 s.
Anatomical long axis proton MR images are acquired prior to the 13C MRS
scans for spatial localization of the necrotic tissue within muscle. CSI with FA
10◦, TR 80 ms, TE 1.4 ms, FOV 50 mm x 80 mm, matrix size 16x16, and
slice thickness 25 mm was acquired 20 s after the end of administration of the
hyperpolarised material. One hour before the PET/MR imaging session, the
rats were intravenously injected with 80 MBq of 18F-FDG. An 8 min PET scan
(2.0 mm resolution) was acquired during the acquisition of the MR images.
Figure 5.2 shows the anatomical image and the 13C spectrum at the necrotic
tissue for the rat that was injected with only hyperpolarized FA. The maps of
fumarate and malate distributions within a slice covering the necrotic region
are also shown in Figure 5.2. Figure 5.3, shows the anatomical image and the
13C spectrum at the necrotic tissue for the rat that received both FA and the
dually hyperpolarized FA and PA. The figure also shows the metabolic maps
of pyruvate, lactate, fumarate and malate. Clear malate signal was visible at
the necrotic site with both the single fumarate and dual pyruvate/fumarate
injections and no malate signal was observed elsewhere. Moreover, an increased
production of lactate is observed at the necrotic site. Figure 5.3 also shows the
PET images acquired for the same animal during the same MR imaging session.
The FDG uptake by the different organs is represented using maximum intensity
projection. There is no clear effect from the necrosis on the FDG-PET.
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5.7 Ischemia/Reperfusion Induced Necrosis in
Rat Kidneys
5.7.1 Animal Model
IR kidney injuries were induced surgically on male Wistar rats (weighing 200–250
g). Prior to surgery, the rats were kept in a metabolic cage. After 24 h in the
metabolic cage, urine was collected and the rats were anesthetized for blood
sample collection and surgery. During surgery, the animals were anesthetized
with sevoflurane (induction 6%, sustained 2.5%) mixed with air (2 L/min). A
surgical incision was made in the abdomen and the left renal artery was care-
fully dissected. A non-traumatic clamp was placed on the left artery for 40 min
to induce ischemia, after which the clamp was released. Reperfusion was visu-
ally confirmed. The incision was sutured separately through both the muscle
tissue and skin. The contralateral (CL) kidney was left intact, and was used as
control kidney. At the beginning of surgery buprenorphine hydrochloride was
provided subcutaneously (0.05 mg/kg) to control the pain. After surgery, the
rats were again put in metabolic cages, and buprenorphine hydrochloride was
supplied in the drinking water (0.3 mg/mL) until euthanization. At the time of
euthanization (24 h after surgery), arterial blood and urine was collected again.
Figure 5.4: Comparison between plasma creatinine, CrCl and BUN biomarkers
before and after surgery.
5.7.2 AKI Biomarkers
A total of seven animals were used for the imaging experiments. From six of
these animals, the urine and blood samples collected before and after surgery
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were used to measure fumarase activity. The blood samples were also used to
measure creatinine, CrCl, and BUN.
A 2 mm kidney section was dissected from both the CL kidney and post-
ischemic kidney. The dissected sections were used to evaluate the necrosis using
eosin and hematoxylin staining. Morever the RNA was isolated from the renal
cortex and the expression levels of KIM-1 and NGAL were quantified.
Figure 5.5: Representative histological sections are shown in (A) for a CL kidney
showing normal intact tubular cells and glomeruli, and (B) for a post-ischemic
kidney showing a cellular cast in the tubular lumina (green arrow), complete
sloughing of tubular epithelium (red arrow), interstitial edema (black arrow),
and glomerular edema (yellow arrow). The relative expression of injury markers,
in (C) and (D), indicated significant upregulation of NGAL (p = 0.0145, n = 6)
and KIM-1 (p = 0.0256, n = 6) respectively A paired two-sided Student’s t-test
was used to compare the CL and IR injured kidneys.
Functional kidney parameters showed consistent signs of renal injury with an
elevated plasma creatinine level of 91% (p = 0.0002) and a reduced CrCl and
BUN level of 44% (p = 0.04) and 30% (p = 0.003), respectively, when comparing
pre-surgical with post-surgical values, see Figure 5.4.
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Figure 5.5 shows representative histological sections with hematoxylin and
eosin stain from a CL kidney and a post-ischemic kidney. The CL kidney
showed normal intact tubular epithelial cells compared to the post-ischemic
kidney, with tubular lumina filled with cellular debris, complete sloughing of
tubular epithelium, interstitial edema, and glomerular edema, Figure 1A and B.
The classical cortical kidney injury markers NGAL and KIM-1 were significantly
elevated (p = 0.01 and p = 0.03) compared to those in the CL kidney, Figure
5.5C and D.
Figure 5.6: Anatomical 1H kidney sections overlaid with (A) 13C-labelled fu-
marate images and (B) 13C-labelled malate images. Red arrow indicates the
post-ischemic kidney and green arrow indicate contralateral kidney. (C) A
malate/fumarate ratio is calculated from each kidney, giving rise to an elevated
ratio in the post-ischemic kidney.
5.7.3 MR Experiment
At the MRI scanning session, 24 h after the surgery, tail vein catheterization was
performed for hyperpolarized [1,4-13C2]fumarate administration. Each animal
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was injected with 1.5 mL of hyperpolarized [1,4-13C2]fumarate. MRI scans were
performed using a 3T clinical MRI system (GE Healthcare, USA) equipped with
a dual tuned 13C/1H volume rat coil (GE Healthcare, USA). A slice-selective 13C
IDEAL spiral sequence was used to detect hyperpolarized [1,4-13C2]fumarate,
and images were acquired every 5 s, initiated 20 s after the start of injection.
The spiral acquisition was performed using a flip angle of 10◦, 11 IDEAL echoes,
and one initial spectrum per IDEAL encoding. The following parameters were
also used: TR/TE/∆TE 100 ms/0.9 ms/1.45 ms, field of view 80 x 80 mm2, 5 x
5 mm2 resolution, and an axial slice thickness of 15 mm covering both kidneys.
An elevated malate/fumarate ratio of 339% (p = 0.002) (Figure 5.6C) in the
ischemic kidneys relative to the CL kidney was found. In order to examine
the relationship between renal cortical injury and malate/fumarate ratio, the
correlation between NGAL and KIM-1 levels with the malate/fumarate ratio
was investigated. A linear correlation was found in both cases (R2 = 0.78, p =
0.008 and R2 = 0.80, p = 0.006, respectively), Figure 5.7A and B.
Figure 5.7: Correlation between renal injury and malate/fumarate ratio. A sig-
nificant correlation was found between (A) NGAL and malate/fumarate ratios,
(B) KIM-1 and malate/fumarate ratio.
Fumarase activity measured in urine samples collected immediately after sac-
rifice was correlated with malate/fumarate ratios (R2 = 0.77, p = 0.02) (Figure
5.8A), as was plasma fumarase activity (R2 = 0.72, p = 0.03) (Figure 5.8B).
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Figure 5.8: Correlation between urine and plasma fumarase activity. A signifi-
cant correlation was found between (A) Urine fumarase activity and (B) Plasma
fumarase activity.
5.8 Discussion
This study investigated the use of [1,4-13C2] fumarate to monitor necrosis in rat
muscles and kidneys. To be able to image necrosis with fumarate, we needed
to device a new scheme to polarize [1,4-13C2]fumarate in the SPINlab polarizer.
Our initial trials to polarize the [1,4-13C2]fumarate was not successful because
the freezing speed of the sample with the insertion procedure from the manu-
facturer was not sufficient to avoid the crystallization of the fumarate sample.
The new faster lowering scheme with fewer steps was sufficient for mitigating
this problem and for achieving high polarization values for [1,4-13C2]fumarate,
36±4%.
Moreover, simultaneous assessment of necrosis and metabolism has been
demonstrated using dually polarized [1,4-13C2]fumarate and [1,4-
13C]pyruvate
in rat models. We found no significant difference in the polarization values
between the dual and single substrate polarization. We also demonstrated the
feasibility of small animal research on a typical clinical scanner.
High [1,4-13C2]malate signal was observed from the necrotic tissue in both
muscle and kidney models. In the rat muscles, we noticed a reduction in the
amount of malate produced as time passes. We attribute this to the escape
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of fumarase from the extracellular space of the necrotic tissue into the plasma.
High lactate signal, and also high signal from other pyruvate products like ala-
nine and bicarbonate, was observed at the necrotic muscle tissue in the in vivo
experiment with dual FA and PA polarization. The increased signal from pyru-
vate products is not unexpected, since all intracellular enzymes like LDH also
escape to the extracellular space when the cellular membranes are broken [167].
This is important to bear in mind, since many types of therapies induce necrosis
in cancer tissue, which may result in elevated lactate production after injection
of hyperpolarized pyruvate. Moreover, there is also evidence that cancer cells
that survive the treatment, that induces necrosis, can benefit from the inflam-
matory response that follows, since it promote proliferation by providing the
tumor environment with growth factors, survival factors and proangiogenic fac-
tors [168, 169]. Therefore, simultaneous assessment of metabolism and necrosis
with the setup proposed here can give more complete picture and allow distin-
guishing whether the high lactate signal is because the necrosis process from
therapy is taking effect or because the tumor is thriving.
The necrosis was induced in the rat muscles with turpentine injection. Tur-
pentine is a mixture of alkylated aromatic hydrocarbons designed to dissolve
fat, and thus they can effectively cause lipid dissolution. Therefore, Turpen-
tine injection into living tissue provides a robust and easy to control method
that causes necrosis and inflammatory response, and can be useful in studying
cellular death via necrosis.
In the AKI model, all rats showed evidence of injury 24 h after surgery ac-
cording to the functional kidney parameters plasma creatinine, CrCl, and BUN.
The elevated malate signal observed in the AKI model showed high correlation
with the well-known renal cortical injury markers; KIM- and NGAL. Addition-
ally, the histological hematoxylin and eosin-stained sections showed typical signs
of tubular necrosis. Plasma and urine fumarase activity levels were highly in-
creased after the onset of IR injury, and were correlated with the hyperpolarized
malate/fumarate ratios.
Although functional kidney parameters like plasma creatinine, CrCl, and
BUN provide measurement tool to characterize IR injuries, they are unable to
specify which kidney (or both) is suffering from necrotic injury. Therefore, the
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addition of hyperpolarized [1,4-13C2]fumarate for local necrosis examinations
further improves the characterization of IR injuries.
5.9 Conclusion
We demonstrated the feasibility of using [1,4-13C2]fumarate to characterize the
necrosis in rat muscles and kidneys. High polarization was obtained for [1,4-
13C2]fumarate in SPINlab polarizer with the new modified lowering scheme,
36±4%. Simultaneous polarization of [1,4-13C2]fumarate and [1,4-13C]pyruvate
was feasible with no significant deference in polarization values. High [1,4-
13C2]malate signal was observed from the necrotic tissue in both muscle and
kidney models. For the kidney model, the malate production correlated well
with the urine and blood parameters and other well-known renal cortical injury
markers like KIM- and NGAL. In the rat muscles, we observed high malate
production within an hour of inducing the necrosis by turpentine injection. We
also noticed an increase in the signal from pyruvate products due to the necrosis,
when we simultaneously polarized [1,4-13C2]fumarate and [1,4-
13C]pyruvate.
52
6
Implementation of 13C Echo Planar
Spectroscopic Imaging Sequence in a
Clinical System
6.1 Objective
This chapter details the development of a symmetric 13C EPSI sequence in a
clinical PET/MR platform with separate reconstruction of the odd and even
echo data, which provides acceptable spectral bandwidth with reduced artifacts
from gradient imbalances. Moreover, a correction is introduced for the phase
evolution during the acquisition of the zig-zag trajectory in k-t space [159,160],
to avoid spatial blurring due to chemical shift artifacts in opposite directions for
odd and even gradient echoes. Firstly, the design and optimization of the various
sequence components, i.e. encoding gradients, RF pulses and sampling events
are detailed. Secondly, a validation of the sequence on phantoms is presented,
in which the EPSI was compared with the conventional phase encoded CSI. The
sequence was also validated in vivo in a canine cancer patient after the injection
of hyperpolarized [1-13C]pyruvate.
6.2 Design of 13C EPSI
The sequence was designed for a 3 T PET/MR scanner (mMR Biograph, Siemens
Healthcare, Erlangen, Germany), with maximum gradient strength of 43 mT/m,
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maximum slew rate of 180 mT/m/ms, gradient raster time of 10 µs, analog-to-
digital converter (ADC) raster time of 100 ηs, and minimum delay between ADC
readout events of 100 µs. The raster time is the smallest temporal unit that can
be used to specify the timing of the ADC event. The acoustic resonances of the
gradient coil were in the frequency bands of 530-630 Hz and 1010-1230, which
should be avoided in the EPI readout spectrum.
6.2.1 Echo Planar Readout Gradient
The design of the echo planar readout gradient is dictated by the target spectral
bandwidth and the spatial resolution required. For a certain spectral bandwidth
(SW ),
SW =
1
2TES
(6.1)
where TES , which is the echo spacing, is the upper limit for readout time,
TRO. Thus, the target spectral bandwidth also sets the limit for the highest
spatial resolution achievable in the readout direction, ∆x, since∆x for a gradient
waveform, GRO, is given by
∆x =
1
γ
∫ t=TRO
t=0
GRO(t)dt
(6.2)
where γ is the gyromagnetic ratio, and t = 0 is the time of the start of
recording of the signal.
A SW of about 500 Hz in a 3 T magnet is acceptable for the case of hy-
perpolarized [1-13C]pyruvate. The pyruvate and its products alanine, pyruvate-
hydrate and lactate are located at 171.1, 176.3, 177.6, and 183.2 ppm respec-
tively (i.e. a range of 372 Hz in a 3 T scanner).
The iterative optimization of the gradient waveform under the given hardware
constraints, yielded a spectral bandwidth of 495 Hz corresponding to gradient
lobe duration of 1010 µs, see Figure 6.1. Using trapezoidal gradients with
ramp up and ramp down durations of 170 µs, the maximum gradient strength
achievable during ramping at the maximum slew rate was 30 mT/m. The ADC
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was switched on 57 µs after the start of the gradient and switched off 57 µs before
the end of the gradient lobe to ensure more than 100 µs between successive ADC
periods. The effective gradient moment accumulated during the readout was
26.6 mTs/m, which provided a maximum achievable spatial resolution of 3.75
mm with 495 Hz spectral bandwidth on the mMR Biograph. The corresponding
ADC period was 896 µs.
Figure 6.1: Design of even and odd lobes of the readout gradient with the ADC
readout events.
6.2.2 Phase Encoding Gradient
The total duration of the phase encoding gradient was set to 1700 µs (ramp time
of 200 µs and flat plateau duration of 1300 µs). The smallest resolution that
can be attained in the phase encoding direction is 1.9 mm. An EPSI version
with centric phase encoding was designed and used in the hyperpolarization
experiments in phantom and in vivo.
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6.2.3 RF Pulses
An excitation RF pulse (Hanning-filtered sinc pulse with time bandwidth prod-
uct of 4) with total duration of 1280 µs and central lobe duration of 640 µs was
used. The smallest slice thickness achievable with this pulse was 6 mm.
The excitation pulse had an approximate bandwidth (BW ) of 3000 Hz. The
chemical shift displacement δp,l between pyruvate and lactate in the slice direc-
tion is
δp,l =
∆fp,l
γGz
(6.3)
where ∆fp,l is the chemical shift between pyruvate and lactate (372 Hz at 3
T).
We can rewrite the chemical shift displacement between pyruvate and lactate
in terms of the slice thickness ∆z for the above pulses as,
δp,l =
∆fp,l
BW
∆z = 0.12∆z (6.4)
Figure 6.2 shows the pulse sequence diagram of the EPSI FID with an echo
train length (ETL) of 128.
Figure 6.2: Pulse sequence diagram of the EPSI-FID with ETL = 128.
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6.3 SNR Efficiency
The theoretical SNR analysis of EPSI was done based on the work by Pohmann
et al. [170] and Pipe and Duerk [171]. Pohmann et al. compared different
chemical shift imaging methods and analyzed their sensitivity with respect to
the conventional phase encoded CSI. For an EPSI sequence, the sensitivity,
ΨEPSI , with respect to the CSI sensitivity, ΨCSI , can be written as
ΨEPSI =
ΨEPSI
ΨCSI
=
√
1− τs
TES
(6.5)
where τs is the time needed for gradient switching and TES is the echo spacing.
Pipe and Duerk showed that the variance in the reconstructed image depends
on the shape of the gradient waveform used to record the signal. The smallest
variance for even sampling occurs in the case of constant gradient, in which case
the variance in the reconstructed image is equal to the variance of the thermal
noise, σ2. They also showed that the variance in the reconstructed image, σ2i ,
can be expressed in terms of the first and second moments of the gradients
waveform, G(t), and thermal noise variance σ2 as,
σ2i
T
=
σ2
∫ T
0
G2(t)dt
(
∫ T
0
G(t)dt)2
(6.6)
6.4 Reconstruction and Postprocessing
Initially, 1D regridding was applied to compensate uneven k-space sampling
over the ramp. After regridding, the odd and even echoes were separated into
two matrices. Time reversal was performed on the odd echo data. Temporal
Fourier transformation was applied to the two data sets to obtain two kx−ky−f
arrays. Before applying the spatial Fourier transform, a linear phase correction
was introduced along the readout direction kx [159,160] to account for the time
evolution, which would otherwise results in a chemical shift displacement in the
spatial domain, differing between even and odd numbered echoes. If b is the
acquisition bandwidth per pixel, given by b = 1/TRO, then for a metabolite at
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frequency f the spatial chemical shift is f/b. This chemical shift corresponds to
a linear phase roll exp(−ikf/b) in the k-space. Therefore, the Corrected signal
arrays S¯even and S¯odd can be constructed from the even and odd echo signal
arrays, Seven and Sodd according to,
S¯odd(kx, ky, f) = e
ikxf/bSodd(kx, ky, f) (6.7)
S¯even(kx, ky, f) = e
−ikxf/bSeven(kx, ky, f) (6.8)
Subsequently, 2D spatial Fourier transform was applied to obtain odd and
even x − y − f arrays. The data corresponding to odd and even echoes, Iodd
and Ieven, were then summed, after matching the phase, to obtain a
13C spec-
troscopic image, I.
I(x, y, f) = Ieven(x, y, f) + e
i2pifTESIodd(x, y, f) (6.9)
Figure 6.3 shows the reconstruction pipeline used. The chemical shift correc-
tion described above assumes there is no aliasing of metabolites in the spectrum,
which may occur in practice since the spectral bandwidth is relatively small.
Therefore, any aliased peaks should be unfolded to its true frequency position
before applying the corrections. This can be done if peaks do not overlap in the
aliased spectra by simply applying phase ramps corresponding to spatial shifts
of non-aliased peak frequencies.
6.5 SNR Phantom Experiment
6.5.1 MR Acquisition Method
A phantom experiment was conducted to compare EPSI with CSI in terms of
SNR and localization robustness. The 13C images were acquired using a 270 mm
diameter 13C birdcage head coil (RAPID Biomedical, Germany). The phantom
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Figure 6.3: The
pipeline used for
the reconstruction
of the raw data and
the correction of the
broadening due to
chemical shifts in
opposite directions in
the odd and even data.
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used was a cylinder with diameter of 250 mm and length of 200 mm. It has
four cylindrical compartments with inner diameters of 19 mm each. The outer
volume of the phantom was filled with ethylene glycol with natural abundance
of 13C, and three of the inner compartments were filled with 13C-bicarbonate,
[1-13C]acetate and 13C-urea. The concentration of each substrate is 1.0 M. The
fourth compartment was left empty.
The product CSI sequence served as the SNR reference. The CSI data were
acquired with TR of 1000 ms, FOV 100x100 mm2, spatial matrix 16x16, flip
angle 90◦, slice thickness 100 mm, spectral bandwidth 5000 Hz, number of
spectral points 512, sampling time of 102.4 ms, and no averaging, resulting in
a CSI scan time of 4 min and 16 s. The time between excitation and sampling
was 2.3 ms. EPSI data were acquired with TR of 1000 ms, FOV 100x100 mm2,
spatial matrix 16x16, flip angle 90◦, slice thickness 100 mm, ETL 128, TES
1010 µs, and 16 averages, resulting in a scan time of 4 min and 16 s, echo train
duration of 129.3 ms and a spectral bandwidth of 495 Hz. The time between
excitation and the start of the first readout gradient lobe was 2.4 ms. For noise
estimation, both CSI and EPSI sequences were run after nulling the transmitted
signal.
6.5.2 Results of SNR Comparison
Figure 6.4 shows the comparison between EPSI reconstruction algorithms. Di-
rect FFT reconstruction, Figure 6.4A, results in spatial blurring of the substrates
in the 13C image due to chemical shifts in opposite directions. On the other
hand, spectral-spatial regridding using the apparent frequency positions, Fig-
ure 6.4B, results in narrower and more accurate spatial representation of 13C
urea and 13C bicarbonate. [1-13C]Acetate, however, was outside of the critically
sampled bandwidth and aliased, which resulted in increased spatial broadening.
When accounting for aliasing by using the actual frequency offset of the non-
aliased peak, the chemical shift displacement of [1-13C]acetate was compensated
as well, Figure 6.4C.
To calculate the theoretical relative SNR between the CSI and the EPSI, (Eq-
6.5) was used. The EPSI acquisition time was 896 µs with 114 µs delay between
acquisitions reducing the SNR by 5% compared to CSI. To account for sampling
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Figure 6.4: A comparison of chem-
ical shift displacement with (A) di-
rect FFT reconstruction and (B
and C) with reconstruction after
spectral-spatial regridding. The
images from odd (green) and even
(magenta) echoes are overlaid. The
locations of overlap appear in
white and the non-overlap loca-
tions appear colored. In (B)
spectral-spatial regridding removes
the chemical shift displacement of
bicarbonate and urea, which are
within the spectral bandwidth, but
increases the chemical shift dis-
placement of acetate that is aliased.
In (C) the chemical shift displace-
ment of the acetate peak is ad-
ditionally corrected using its non-
aliased frequency location in the re-
construction.
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over the ramps, (Eq-6.6) was used to calculate the SNR efficiency relative to
a square readout gradient waveform, which amounts to 94%. Therefore, the
relative theoretical SNR of EPSI with respect to CSI is 89%.
Figure 6.5: The [1- 13C]acetate, 13C-bicarbonate and 13C-urea maps acquired
by CSI and EPSI. Only the central part of the phantom is shown. The signal
level in the maps is normalized with respect to the bicarbonate signal acquired
with CSI. The spectrum from a single voxel at the center of each substrate is
also shown for both CSI and EPSI. The line width (full width at half height)
obtained with CSI was 12.2 Hz, 9.2 Hz and 10.6 Hz for [1-13C]acetate, 13C-
bicarbonate and 13C-urea respectively, whereas the line width obtained with
EPSI was 11.7 Hz, 8.7 Hz and 9.8 Hz.
Figure 6.5 shows the signal for the three substrates 13C-urea, 13C-bicarbonate
and [1-13C]acetate in the multi-compartments phantom obtained with CSI and
EPSI using the birdcage coil, superimposed on the proton image. The strength
of the signal varied between the substrates due to differences in T1 relaxation
time constants and line width. To quantify the SNR of each substrate, the signal
was estimated at each voxel from the peak amplitude (real phased spectrum).
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Then the signal was averaged in a 4x4 pixel region of interest encompassing
the substrate, and normalized by the noise standard deviation in the spectra
in the same region. For the CSI, the SNR values were 290, 153 and 113 for
13C-bicarbonate, 13C-urea and [1-13C]acetate, respectively. For EPSI the SNR
values were 257, 135 and 99 for the three phantoms respectively. This corre-
sponds to relative SNR values of 0.89, 0.87, and 0.88 respectively, which are
close to the theoretical values.
6.5.3 Localization Assessment
To assess the localization of the spectroscopic sequences, the proton image was
taken as a reference. For each substrate, the location of the center of the cylinder
in the 13C image and proton image were compared. The shift in millimeters
between the two locations was reported. Since each substrate is in a cylinder, a
circle was fitted to the contour spatial distribution and the center of the circle
was taken as the location in the proton image. The 13C images were obtained
using general linear model (GLM) fitting. Then spline fitting was applied to the
13C spatial distribution of each substrate to achieve sub-voxel precision at the
same resolution as the proton image. The position of the peak intensity in the
metabolite distribution after spline fitting was used as the substrate location in
the 13C image.
Figure 6.6: The center of each substrate as obtained from the proton image
(blue dot) and the position of the substrate obtained from the CSI and EPSI
acquisitions (green dot).
Figure 6.6 shows the locations of the three substrates obtained with the CSI
and EPSI sequences with respect to the true position obtained from the proton
image. The CSI sequence has the smallest offsets with 0.8 mm for [1-13C]-
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acetate, 0.9 mm for 13C-bicarbonate and 1.5 mm for 13C-urea. The offsets are
higher for the EPSI sequence; 1.9 mm, 1.7 mm and 3.1 mm, respectively.
6.6 Phantom Experiment with Hyperpolarized
[1-13C]Pyruvate
6.6.1 Hyperpolarized Phantom Preparation
A phantom experiment was conducted with hyperpolarized [1-13C]pyruvate and
dual tuned 1H/13C surface coil (RAPID Biomedical, Germany). A hyperpolar-
ized phantom made from a rectangular bottle (200x185x125 mm3) was initially
filled with 4.5 L of saline solution. A hyperpolarized sample containing 14
mmol of [1-13C]pyruvate was added to the phantom after dissolution. Then the
phantom was briefly shaken, placed on top of the surface 1H/13C coil and the
dynamic imaging was acquired. To prepare the hyperpolarized sample, 1 mL
of [1-13C]pyruvic acid with 15 mM of electron paramagnetic agent, AH111501
(Syncom BV, Netherlands), was polarized in a SPINlab polarizer (GE Health-
care, USA) for 4 hours. The sample was then dissolved in 49.8 mL of dissolution
media containing 0.1 g/L of EDTA in water. The sample was neutralized with
14.6 mL of neutralizing media containing 0.72 M NaOH, 0.4 M Tris and 0.1 g/L
EDTA disodium salt in water.
Two different dynamic measurements were acquired, one with EPSI and the
second with CSI. The EPSI acquisition was made using a FOV 200x200 mm2,
32x32 matrix with central phase encoding, ETL 64, flip angle 6◦, TR 80 ms,
and TE 2.4 ms. The acquisition time per frame was 2.5 s and an image was
acquired every 5 s. The CSI was acquired using FOV 200x200 mm2, truncated
16x16 matrix, flip angle 3◦, TR 80 ms, and TE 2.3 ms. The acquisition time
per frame was 12 s and 3 images were acquired sequentially without delay.
The dynamic frames acquired with EPSI and CSI for hyperpolarized [1-
13C]pyruvate in the 4.5 L rectangular phantom are shown in Figure 6.7. The
signal decay (sum of the signal over the phantom) with both CSI and EPSI is
shown in Figure 6.8B. For the dynamic measurements obtained with CSI, the
time resolution was very coarse, 12 s, despite the smaller matrix size used, and
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thus coarser spatial resolution. The coil profile derived from the EPSI image of
the phantom is shown in Figure 6.8A.
Figure 6.7: Dynamic images acquired for hyperpolarized [1-13C]pyruvate in a
4.5 L phantom with EPSI and CSI.
Figure 6.8: (A) The the coil profile first dynamic image acquired for hyper-
polarized [1-13C]pyruvate as obtained with EPSI (A). (B) shows the decay of
the signal from hyperpolarized pyruvate obtained by both EPSI and CSI. An
exponential function was fitted to EPSI signal giving a time constant of 52 s.
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6.7 Animal experiment
6.7.1 Animal Model
An animal experiment was conducted to test the EPSI sequence on a 27 kg dog
with acanthotic ameloblastoma. The dog underwent PET/MRI as part of the
diagnostic and staging work-up and hyperpolarized 13C-MRSI was included in
a combined PET/MR examination. The owner gave informed consent and the
study was approved by the relevant ethics and administrative committee.
6.7.2 Hyperpolarzed Media Preparation
Three 500 µL samples of [1-13C]pyruvic acid with 15 mM of AH111501 were
hyperpolarized in the SPINlab polarizer for 4 hours. The samples were dissolved
in 29.1 mL dissolution media and neutralized with 7.3 mL of neutralizing media.
After dissolution, 18 mL (0.68 mL/kg) of 250 mM [1-13C]pyruvate was injected
intravenously over 7–8 s.
6.7.3 PET/MR Acquisition
The 1H/1313C dual tuned flex coil was used again for imaging. Coronal, transver-
sal and sagittal anatomic 1H MR images were acquired for planning using a T2
weighted turbo spin-echo sequence (TR 4,000 ms; TE 89 ms; voxel size 0.5 x
0.5 mm2; 19 slices of 3 mm thickness).
The dog received three injections of hyperpolarized [1-13C]pyruvate with 10
min intervals. A dynamic FID sequence with no in-plane spatial encoding was
started at the beginning of the sample injection with the following parameters:
slice thickness 4 cm, TR 1 s, flip angle 5◦, acquisition delay 2.3 ms, spectral
bandwidth of 6000 Hz and 512 points. The purpose of the dynamic FID was to
find the time point with maximum lactate signal, which was used to determine
the start time of the subsequent CSI acquisition. Acquisition of a CSI data
set was initiated 30 s after the start of the injection of the second pyruvate
sample with TR 80 ms, FOV 150x180 mm2, matrix size 16x16, slice thickness
15 mm, flip angle 10◦, acquisition delay 2.3 ms, spectral bandwidth 10000 Hz,
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and number of spectral points 512. A dynamic EPSI acquisition was started
at the end of the injection of the third hyperpolarized sample using a FOV of
150x180 mm2, 16x32 matrix with central phase encoding, slice thickness 15 mm,
ETL 64, flip angle 6◦, TR 80 ms, and acquisition delay 2.4 ms. The acquisition
time per frame was 1.3 s and a frame was acquired every 3 s (with idle time of
1.7 s between frames).
PET images were acquired as a single-bed with 5 min acquisition duration,
after intravenous injection of 216 MBq (8 MBq/kg) of 18F-FDG, 1 hour prior to
imaging. The resolution of PET images was 2.1x2.1 mm2 and the slice thickness
was 2.0 mm.
Figure 6.9: The anatomical images (transversal, coronal and sagittal) acquired
with TSE and used to position the spectroscopic grids for both CSI and EPSI
(A, B and C). The green box is at the location of the tumor.
6.7.4 Results from Canine Cancer Patient
Figure 6.9 shows the anatomical images used to plan the positioning of the
spectroscopic grids for both CSI and EPSI. The 16x12 mm tumor is located at
the buccal side of the left mandible, as shown in Figure 6.10A. The dynamic FID
(Figure 6.12A) shows that pyruvate starts accumulating in the slab containing
the tumor about 10 s after the start of the injection, and reaches a peak value 9 s
later. Lactate starts building up 22 s after the start of the injection and reaches
a maximum value after 32 s. The CSI acquisition was timed to start 30 s after
injection to obtain the highest possible lactate signal from the slice. Figure 6.10
(B and E) shows the pyruvate and lactate signals at the slice containing the
tumor. Relatively high pyruvate uptake and an increased lactate production
can be observed at the tumor site. Additionally, lactate signal can be seen at
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the masticator muscle in the lower right region. The PET-FDG image (Figure
6.10D) also shows high metabolism at the tumor site in addition to the typical
high FDG uptake in the brain.
Figure 6.10: The acanthomatous ameloblastoma in the left mandible of the
canine cancer patient (A). The PET-FDG image (slice thickness 2 mm) with
high uptake in the tumor and brain regions is shown in (D). (B and E) show
the pyruvate and lactate signals, obtained from the CSI acquisition using GLM,
at the slice containing the tumor. Increased lactate production can be observed
at the tumor and muscle sites. (C and F) show pyruvate and lactate images
calculated from the dynamic EPSI by integrating over the frames in Figure 6.11.
In Figures 6.11, the series of metabolic maps obtained with EPSI are given.
These maps show the buildup and decay of pyruvate and lactate across the
slice. To allow for comparison with the dynamic FID, the pyruvate and lactate
signals in each frame were summed over the entire frame, to obtain the time plots
shown in Figure 6.12B. The pyruvate and lactate signals were also integrated at
the tumor to obtain the dynamic build-up and decay at this site, Figure 6.12C.
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Moreover, the pyruvate and lactate series were integrated into one pyruvate and
one lactate image, Figure 6.10 (C and F), for comparison with the corresponding
CSI maps in Figure 6.10 (B and E). The signal level in all the metabolic maps
in Figures 6.10 and 6.11 were normalized with respect to the standard deviation
of the noise.
Figure 6.11: Pyruvate and lactate build-up and decay across the slice containing
the tumor. The figure also shows the spectrum with GLM fitting at the tumor
site in the EPSI frame acquired 27 s after the end of injection.
6.8 Discussion
An implementation was presented of a symmetric EPSI sequence for hyperpolar-
ized 13C in a hybrid clinical PET/MR system, and was evaluated in phantoms
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and in vivo. To our knowledge this is the first 13C EPSI sequence implemented
in a clinical Siemens platform. The SNR obtained with this sequence was around
88% compared to CSI, and this agrees with the theoretical estimation.
The reconstruction employed in this work provides better accuracy compared
to direct FFT. However, the bandwidth in EPSI is relatively small and aliasing
may occur. Aliased metabolites cause an error in the spatial-spectral regridding.
However, the 13C spectrum in hyperpolarization experiments is often sparse and
the metabolite frequencies known a priori, and thus aliasing can be corrected
before applying the reconstruction algorithm.
Figure 6.12: (A) The build-up of pyruvate and its conversion to lactate obtained
with dynamic FID acquisition over a 4 cm axial slab that includes the tumor
region. (B and C) show the time curves for lactate and pyruvate obtained from
the EPSI series (Figure 6.11) by integrating the pyruvate and lactate signals in
each frame at the whole image and at the tumor region, respectively.
In the phantom experiment with hyperpolarized [1-13C]pyruvate and in vivo
canine experiment, EPSI allowed dynamic imaging with reasonable temporal
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resolution. Moreover, higher spatial resolution was achieved for the metabolic
maps obtained with EPSI compared to CSI in the these experiments. Despite
employing dynamic acquisition with EPSI in the in vivo hyperpolarization ex-
periment, using a larger matrix size was feasible, compared to the matrix size
of CSI. Moreover, CSI is prone to blurring from T1 decay due to the relatively
long acquisition duration per frame. Therefore, the pyruvate and lactate sig-
nals were sharper and better localized in the EPSI metabolic maps, whereas the
maps obtained from the CSI acquisition were blurry.
Both the EPSI and the CSI sequences showed similar metabolite distributions
in the in vivo experiment. The slight differences could be because the imaging
windows for the two sequences were different: CSI was acquired over 12 s from
30 s after injection, whereas EPSI was acquired over 60 s from the end of the
injection. Also, the spatial resolution of CSI was lower than that of EPSI, 10x9
mm2 and 5x9 mm2 for the two sequences respectively.
6.9 Conclusion
A symmetric 13C EPSI sequence was presented. The sequence mitigates the
artifacts from the imbalanced gradients by separate reconstruction of odd and
even echo data. The reconstruction algorithm employed with the sequence pro-
vides better accuracy compared to direct FFT even for aliased peaks. The SNR
of the EPSI sequence was comparable to the CSI SNR in the phantom exper-
iment at thermal equilibrium. In the in vivo experiment with hyperpolarized
[1-13C]pyruvate, EPSI allowed imaging with higher spatial and temporal reso-
lutions compared to CSI, 5x9 mm2 1.3 s per frame for EPSI and 10x9 mm2 and
12 s per frame for CSI.
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7
Perspectives and Future Work
We have evaluated [1-13C]pyruvate as marker to monitor the response of cancer
to treatment. We also presented a comparison between the [1-13C]pyruvate and
the more clinically established FDG- and FLT-PET tracers. We found that all
three markers were able to detect the response to treatment. Each of PET and
13C MRS has it is own merit, and combination of both to assess the tumor
progression or remission can be of great value. Particularly, the possibility of
assessing tumor metabolism using [1-13C]pyruvate in a joint PET/MR scanner,
thus leaving the PET modality available for measuring other biological charac-
teristics, can be of great interest.
At this stage we have used fumarate with models in which the necrotic process
is very well studied and understood by our group and collaborators. The find-
ings from these studies will be used as a starting point for future researches
on monitoring therapy-induced necrosis in cancer with hyperpolarized [1,4-
13C2]fumarate. We also believe that hyperpolarized [1,4-
13C2]fumarate holds
great promise as an in vivo diagnostic tool for pathologies in which the necrotic
process plays a major role, like the case with acute kidney injuries.
The presented EPSI sequence allowed fast imaging with good SNR and no
artifacts from the imbalanced gradients. The sequence also facilitates kinetic
modeling in cancer, and this is now being investigated in rats with xenografted
tumors. Currently, the reconstruction algorithm is implemented oﬄine, and an
online implementation of the reconstruction algorithm is planned. We are also
investigating new excitation modules that utilize the non-recoverable magnetiza-
tion more efficiently, e.g., dynamically changing flip angles and spatial-spectral
selective excitations.
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 Abstract (203/250 words) 
Treatment of non-small-cell lung cancer (NSCLC) using tyrosine-kinase inhibitors (TKI) 
like Erlotinib, targeting the epidermal growth factor receptor (EGFR) is being established 
as a routine clinical treatment. Here, we demonstrate that the treatment response can be 
identified using hyperpolarized [1-13C]pyruvate-MRS, FLT-PET and FDG-PET in 
xenograft NSCLC tumors, probing different  glycolytic steps as well as proliferation. 
We show here a significant reduction in tumor lactate levels obtained by MRS, as well as 
lower FLT- and FDG-PET uptake in HCC-827 tumors treated with Erlotinib, compared to 
untreated tumors. Similarly, reduction in signal/ uptake was also observed for [1-
13C]pyruvate and was most pronounced in FLT-PET.  H-1975 tumors, which harbor a 
second EGFR mutation, yielding them insensitive to Erlotinib, showed no difference in 
either tumor lactate levels, FLT- or FDG-PET uptake with treatment. These findings were 
validated ex-vivo, demonstrating significantly lower LDH activity levels and Ki-67 IHC 
staining in treated HCC-827 tumors compared to untreated. Furthermore, the LDH 
activity levels found ex-vivo correlated to the lactate levels found using [1-13C]pyruvate-
MRS, an important validation of the technique. Finally, we performed two injections for 
several mice, in order to evaluate the robustness of [1-13C]pyruvate-MRS, which showed 
a strong correlation. Our findings indicate the [1-13C]pyruvate-MRS could replace FDG-
PET in a combined PET/MRI examination. 
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Introduction 
The scientific understanding of the complex individualism of cancer has grown 1 
immensely in the last years, thereby marking the coming of the personalized medicine 2 
paradigm. Traditionally, treatment response in cancer has been evaluated using 3 
anatomical imaging following the RESIST criteria (1), which is neither a very specific nor 4 
an early measure (2). Functional imaging has the potential to overcome these issues, 5 
and Positron Emission Tomography (PET) is a pivotal imaging modality in this setting. 6 
The continuous development of new PET tracers enables better diagnostics, staging and 7 
monitoring of treatment response.  8 
The workhorse of modern clinical PET imaging is 2’-deoxy-2’-[18F]fluoro-D-glucose 9 
(FDG), which is used as a marker of glucose uptake. More specifically, it reflects the up-10 
regulation of glucose transporters and hexokinase activity due to the ineffective, 11 
anaerobic metabolism observed in many cancer cells (3). The nature of the FDG tracer 12 
yields some limitations, however; high natural- or inflammation-induced background 13 
uptake can cloud the contrast and ultimately lead to false positive findings. 3’-deoxy-3’-14 
[18F]fluorothymidine (FLT) is a thymidine analog, which is intracellularly trapped after 15 
phosphorylation by thymidine kinase 1 (TK-1). TK-1 is responsible of the thymidine 16 
salvage pathway of DNA synthesis, making FLT a marker of TK-1 activity, and thereby 17 
to some extent cell proliferation (4). This newer tracer has previously been shown to be 18 
able to predict treatment response within 24 hours in a xenograft model similar to the 19 
one used in the present work (5-10). More recent, FLT has been incorporated into the 20 
clinical routine for evaluation of treatment response (11-13). 21 
Magnetic Resonance Imaging (MRI) is similarly superior with respect to anatomical 22 
imaging. Its functional cousin, Magnetic Resonance Spectroscopy (MRS) is a powerful 23 
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modality, but with limited clinical acceptance, primarily due to relatively low sensitivity 24 
(14). MRS of 13C-enhanced molecules has shown the ability to non-invasively probe the 25 
metabolic profile (15,16). This is facilitated by the use of Dynamic Nuclear Polarization 26 
(DNP) techniques that increase the MR sensitivity by more than 10,000-fold compared to 27 
thermal equilibrium, and allows for the hyperpolarized agents to be injected and imaged 28 
in-vivo (17). The use of 13C-enhanced pyruvate, which lies at a crossroad of major 29 
metabolic pathways, has been of particular interest (18-20) and most studies have 30 
shown elevated levels of lactate in some cancers compared to non-malignant tissue 31 
(21). This can be explained by the Warburg effect, in which neoplastic cells use 32 
inefficient anaerobic glycolysis for energy instead of mitochondrial metabolism, despite 33 
sufficient supplies of oxygen. 34 
Lately, combination of MRS of hyperpolarized 13C-labelled substrates and PET has 35 
emerged as a promising tool in the understanding of cancer biology [Gutte H]. This work 36 
aims  to evaluate these two modalities and present a comparison between 37 
hyperpolarized 13C-MRS and FDG- and FLT-PET in monitoring the treatment response 38 
of two non-small-cell lung carcinoma (NSCLC) xenograft tumor mouse models (HCC-39 
827 and NCI-H1975). HCC827 have previously been shown to elicit a high response to 40 
inhibition of the epidermal growth factor receptor (EGFR) by tyrosine kinase 1 (TK1) 41 
inhibitors, such as gefitinib or erlotinib, whereas H-1975 shows little response to similar 42 
treatment, due to a secondary mutation (24).  43 
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Materials and Methods 
Cell culturing and animal preparation 
Human HCC-827 and H-1975 non-small cell lung carcinoma cells were obtained from 44 
ATCC and cultured in RPMI-1640 media with GlutaMAX (Life Technologies) 45 
supplemented with 10% fetal calf serum (Biological Industries) and 1% penicillin-46 
streptomycin (Gibco, Life Technologies) in 5% CO2 at 37 °C.  47 
All animal care and experimental procedures were performed under the approval of the 48 
Animal Experiments Inspectorate in Denmark. Nude NMRI mice (n = 58) (Taconic, 49 
Denmark) weighing about 20-25 g were inoculated with 2 x 5⋅106 cells in 100 µl media 50 
and matrigel (1:1) subcutaneously in the flank region. Tumor growth was monitored 51 
twice a week by caliper measurement.  52 
When the tumors reached a size of about 300 mm3 (8-10 mm diameter, about 5 weeks 53 
after inoculation), the mice were randomized in two groups, one for PET imaging and 54 
one for DNP-MRS. Each group was again randomly divided into two subgroups, one to 55 
receive treatment, the other to receive vehicle. 24 hours before scanning, the mice 56 
received an oral gavage of either the tyrosine kinase 1 inhibitor Erlotinib (50 mg/kg, 100 57 
µL (PBS, 0.5% Tween 20)) or vehicle (PBS, 0.5% Tween 20) dose (same volume). The 58 
animals were fasted overnight before scanning in order to reduce background uptake. 59 
Hyperpolarization and MRI/MRS acquisition 
The pyruvate sample was prepared by mixing 13C pyruvic acid (Sigma Aldrich, denmark) 60 
with trityl radical OX063 (Oxford Instruments, UK) and Dotarem (Guerbet,France) to 61 
achieve concentrations of 14 M, 15 mM, and 1.5 mM for the three substances 62 
respectively. 20 uL (~26 mg) of the sample was polarized in a HyperSense polarizer 63 
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(Oxford Instruments, UK) and then dissolved in neutralizing buffer to yield a final 64 
concentration of 80 mM for the [13C] pyruvic acid.  65 
The MR imaging was conducted in a 4.7 T small animal scanner (Agilent Technologies, 66 
US). A 13C/1H transmit-receive coil and a 13C four-channel array coil (RAPID Biomedical, 67 
Germany) were used to acquire proton MR images and 13C phase-encoded chemical 68 
shift images (CSI). The animals were anaesthetized during scanning with 3% Isoflorane 69 
(Baxter) mixed with 35% O2 in N2. 70 
Proton images were acquired first to locate the two tumors. These images were a series 71 
of 15-20 axial slices acquired to cover a field of view of 50 mm x 50 mm x 15-20 mm 72 
around the tumor region. The images were acquired using Turbo Spin Echo (TSE) 73 
sequence with repetition time (TR) of 2 s, effective echo time (TE) of 22 ms, echo 74 
spacing of 7.5 ms, Echo Train Length (ETL) of 8 and a resolution of 0.25 mm x 0.25 mm 75 
x 1 mm in the readout, phase encoding and slice directions respectively.  76 
The CSI images were positioned to include the two tumors in one slice (figure 1). Two 77 
CSI images were acquired for each mouse, 8 and 14 s after the end of the injection of 78 
the 200 l hyperpolarized media, respectively. The imaging was done using a spiral 79 
phase encoding trajectory with a matrix size of 16 x 16, TR = 70 ms, TE = 0.65 ms, FOV 80 
= 35 mm x 35 mm, slice thickness = 5-6 mm, and with spectral bandwidth of 4000 Hz 81 
and 256 spectral points. 82 
Tumor perfusion was assessed using a Dynamic TSE that was acquired during 83 
administration of 200 l of 0.1 mM Dotarem (Guerbet). The TSE slice was positioned at 84 
the same site as the CSI image. The acquisition was done using TR = 200 ms, TE = 7.2 85 
ms, and a resolution of 0.25 mm x 0.25 mm and covered a field of view of 50 mm x 50 86 
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mm. The number of signal averaging was set to 5, yielding a scan time of about 12 s per 87 
dynamic frame. 88 
PET imaging 
One hour before each scan, mice were intravenously injected with 10-15 MBq of 18F-89 
FDG or 18F-FLT from the clinical production at Rigshospitalet (Copenhagen, Denmark). 90 
The animals were anaesthetized with 3% Sevofluran (Abbott Scandinavia) mixed with 91 
35% O2 in N2 and fixed on a custom-made, double subject bed. A 5-7 min PET scan was 92 
acquired using a Siemens Inveon MM combined PET/CT (Siemens Medical Solutions), 93 
followed by a CT scan for anatomical reference and attenuation correction. The 94 
parameters for CT acquisition was 70 kVp voltage, 500 µA current, binning factor 4 and 95 
350 ms exposure, yielding a final CT image with 210 µm isotropic resolution after down-96 
sampled reconstruction. PET data was arranged into static sinograms and reconstructed 97 
using the ordered subset expectation maximization (OSEM), maximum a posteriori 98 
(MAP) reconstruction algorithm using attenuation correction. The voxel size was 0.388 x 99 
0.388 x 0.796 mm, with a center field of view resolution of 1.4 mm full-width-at-half-100 
maximum. 101 
LDH activity assay 
LDH activity was estimated using a NADH-colorimetric assay (Sigma-Aldrich, 102 
Copenhagen, Denmark) in extracted tumors from mice that underwent HP-13C MRS. 103 
After each scan session, the mice were euthanized by cervical dislocation and tumors 104 
were quickly dissected, snap-frozen in liquid nitrogen, and transferred for storage at -80 105 
°C. Extracted tumor tissue was mixed with assay buffer (1 ml mg-1), homogenized and 106 
centrifuged for 15 minutes at 10000 rpm at 5 °C. The supernatant was removed and 107 
diluted 1:500. After mixing with reactant substance, the well plate was shaken and 108 
incubated for 150 seconds at 37°C. The plate was then read every 5 minutes using a 109 
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FLUOstar Omega microplate reader (BMG Labtech, Ortenberg, Germany), and 110 
calculations done as described by the assay manufacturer. The total protein content of 111 
the samples was estimated using a BCA protein assay kit (Thermo Scientific, Slangerup, 112 
Denmark) according to the manufactures protocol. 113 
Immunohistochemical staining 
Cell proliferation was estimated in tumor tissue from mice that underwent FLT-PET. The 114 
extracted tissue samples were fixed in 4% neutral buffered formalin, transferred to 70% 115 
EtOH after 24 hours and subsequently embedded in paraffin. A central cryostat section, 116 
8 μm thick, was cut from each tumor, and manual staining procedures were performed 117 
as follows: After air-drying, antigen was retrieved with microwave heating in citrate 118 
buffer, followed by rinsing in phosphate buffered saline (PBS) with 0.1% Tween. 119 
Endogenous enzyme activity was blocked through 8 minutes’ soak with Dako REALTM 120 
peroxidase-blocking solution (Dako, Glostrup, Denmark) and 10 minutes’ soak with 2 % 121 
bovine serum albumin (BSA). Incubation with monoclonal mouse anti-human antibody 122 
for Ki-67 antigen clone MIB-1 (Dako, Glostrup, Denmark) was then performed for 1 hour 123 
at room temperature at a concentration of 1:200. The secondary antibody, an anti-124 
mouse peroxidase labeled polymer (Envision+ System-HRP, Dako, Glostrup, Denmark) 125 
was linked to the primary antibody during 40 min of incubation and peroxidase activity 126 
was visualized through addition of DAB+ Subtrate Chromogen (Dako, Glostrup, 127 
Denmark) as detection system. Counterstaining was performed with Mayer’s 128 
haematoxylin (Clinical Pharmaceutical Service, Copenhagen University Hospital 129 
Pharmacy, Denmark) before dehydration and mounting of cover glass. Each of the 130 
described steps until and including DAB+ was followed by rinses with PBS, except 131 
between the BSA and primary antibody. A negative control, where the primary antibody 132 
was replaced with nonsense anti-body (FLEX Negative Control Mouse, Dako, Glostrup, 133 
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Denmark) was also included. Ki67 index was quantified using the ImmunoRatio plugin 134 
(25) for ImageJ (26). 135 
Image analysis and statistics 
PET and CT images were fused and analyzed using Inveon Research Workplace 136 
(version 4.2, Siemens Medical Solutions, Knoxville, USA). Tumor Regions of Interest 137 
(ROIs) were delineated on the CT scan, and the percentage-injected dose per gram 138 
(%ID/g) was quantified from the PET scan. Similar quantification was done for the MRS 139 
CSI images using the anatomical reference image in MATLAB (The Mathworks Inc., 140 
Natick, USA). 141 
The acquired Free Induction Decay (FID) signal at each voxel of the CSI data was first 142 
zero-filled to increase the spectral resolution and the signal was then apodized using an 143 
exponential function, ef.t with f = 20 Hz, to reduce the noise. General Linear Model 144 
(GLM) was used to decompose the frequency spectrum and to resolve the signal of 145 
each metabolite. The quantified lactate and pyruvate signals were used to generate 146 
metabolic maps that were resampled and registered onto the anatomical proton image. 147 
To compare the signal of the tumors in the different mice, the lactate signal from the 148 
tumor was normalized with respect to the lactate signal in the surrounding muscle 149 
tissues.  150 
To analyze the perfusion, the wash-in and washout coefficients were estimated in the 151 
tumor regions using the relative signal enchantment over time that was calculated from 152 
the MR perfusion images. A gamma-variate function was fitted to the dynamic contrast 153 
enhancement curves obtained from the perfusion images. 154 
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Statistical analysis 
Student’s t-test with Holm-Sidak correction was used to assess the difference between 155 
the two (treated and untreated) mice groups across all modalities using Prism 6.0 156 
software (GraphPad, La Jolla, US). Values are reported as mean ± SEM (standard error 157 
of the mean) unless otherwise indicated and p < 0.05 was considered statistically 158 
significant. 159 
Results 
Lactate levels determined by [1-13C]pyruvate-MRS predicts treatment 
response to Erlotinib after 24 hours 
A primary objective of this study was to determine if [1-13C]pyruvate-MRS can be used to 160 
predict a known treatment response in a xenograft tumor model. A clear lactate signal 161 
was observed in the tumors of both models (Figure 1), but when quantified, the average 162 
level of lactate detected in untreated HCC-827 tumors was 1.52 ± 0.17 (n=18) for the 163 
images acquired 8 s after injection (Figure 4a), which is significantly higher than the 164 
levels found in treated HCC-827 tumors, which was 0.76 ± 0.04 (n=14, p < 0.005). This 165 
is contrasted by the pattern seen in the H-1975 model (Figure 4b), where the lactate 166 
levels were found to be similar in the treatment and vehicle group (1.03 ± 0.18 and 0.95 167 
± 0.12, respectively, n=8 both groups, p = 0.718). 168 
The ratio of lactate to pyruvate conversion was also determined. In HCC-827 tumors, the 169 
difference between groups was not significant due to the observed increase in the 170 
pyruvate level in the untreated HCC-827 tumors compared to the treated, which was 171 
1.13 ± 0.15 and 1.35 ± 0.18 for the two injections respectively, versus 0.75 ± 0.06 and 172 
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0.97 ± 0.07 in the treated tumors (Figure 4). For the H-1975 tumors, the ratios were 173 
found to be 1.01 ± 0.06 and 1.00 ± 0.08 for the vehicle and treated group, respectively. 174 
Magnitude of treatment response is similar in FDG-PET uptake and MRS 
lactate level 
In theory, FDG-PET and [1-13C]pyruvate-MRS probe the same metabolic pathway at 175 
different stages, hence it is natural to compare the two modalities. We imaged the same 176 
tumor models at identical time points, with representative images of FDG uptake shown 177 
(Figure 1, top row), with the uptake quantified as percentage injected dose per gram (% 178 
ID/g). For HCC-827, the level was found to be 1.37 ± 0.13 and 0.85 ± 0.05 for the 179 
vehicle and treated group, respectively (p < 0.002, n=10 in each group). For H-1975, 180 
levels were 1.94 ± 0.09 in the vehicle group and 1.91 ± 0.06 in the treated group (p = 181 
0.766, n=8 in each group). 182 
FLT-PET shows most prominent response after 24 hours, which is supported 
by reduction in Ki-67 staining ex-vivo 
Similarly, we evaluated the treatment response using FLT-PET imaging in the same 183 
tumor models, with representative images of FLT uptake shown (Figure 1, bottom row). 184 
Uptake levels was for HCC-827 found to be 2.45 ± 0.22 and 1.12 ± 0.28 for the vehicle 185 
and treated group, respectively (p < 0.002, n=8 in each group). For H-1975, the levels 186 
were 2.39 ± 0.13 in the vehicle group and 2.39 ± 0.11 in the treated group (p = 0.965, n 187 
= 8 in each group). 188 
Slices of extracted HCC-827 tumors were immuno-histochemically stained for Ki-67 to 189 
evaluated cell proliferation, as done with FLT-PET imaging. Levels of Ki-67 were 190 
quantified as percentage of positively stained nuclei, and found to be 9.6 ± 0.6 (n=5) and 191 
6.6 ± 0.7 (n=6) for the untreated and treated groups, respectively (Figure 3, p < 0.02). 192 
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Levels of LDH enzyme ex-vivo correlates to levels of lactate found in-vivo by 
[1-13C]pyruvate-MRS 
To validate the [1-13C]pyruvate-MRS findings, we determined the levels of lactate 193 
dehydrogenase (LDH) normalized to total protein content in extracted HCC-827 tumors. 194 
Levels were quantified in units/mg protein, and found to be 0.54 ± 0.03 (n = 18) and 0.45 195 
± 0.03 (n=14) for the untreated and treated group, respectively (p < 0.05) (Figure 4c). 196 
In order to further substantiate the findings by [1-13C]pyruvate-MRS, the normalized LDH 197 
values were correlated to the levels of lactate found by [1-13C]pyruvate-MRS, yielding a 198 
positive correlation to lactate levels both when imaging 8 (Figure 4d, and 14 seconds 199 
following injection (Supplementary figure 1b, R2 = 0.20, p < 0.05). 200 
[1-13C]pyruvate-MRS is a highly robust method for assessing tumor 
metabolism 
During [1-13C]pyruvate-MRS of the HCC827 tumor model, two injections were performed 201 
for each animal with slightly different timing, in order to evaluate the robustness of the 202 
method. Strong correlations were found (Figure 6) between the levels from each 203 
injection on both pyruvate and lactate levels (R2 = 0.8253 and R2 = 0.6164, respectively.) 204 
To preclude differences in perfusion between the groups as an explanation of uptake 205 
differences, T1-weighted dynamic contrast enhancement (DCE) imaging was performed. 206 
The analysis showed that both groups of tumors (treated and untreated) exhibit typical 207 
DCE curves with fast wash in and slow wash out, indicating well-perfused tumors (Figure 208 
5). Furthermore, the analysis of the perfusion curves did not show significant difference 209 
between the two groups of tumors. 210 
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Discussion 
Overall, all the investigated imaging modalities were able to identify the response to 211 
treatment after 24 hours. Since 13C MRS and PET were acquired at two different sites it 212 
was impractical to evaluate the response to treatment in the same mouse using both 213 
imaging modalities.  Therefore the study population was divided into two separate 214 
groups. This limitation could be overcome by the use of combined PET/MRI scanners 215 
(27,28). 216 
As expected from previous reports (7,29), the most prominent response to treatment 217 
was observed from PET imaging using the thymidine analog FLT, and a less 218 
pronounced, but still significant response seen using FDG-PET, reflecting glucose 219 
uptake. We demonstrated that the response to treatment could also be identified using 220 
[1-13C]pyruvate-MRS metabolic imaging, and confirmed our hypothesis that the identified 221 
response in lactate levels are similar to those found by FDG-PET. We found that levels 222 
of lactate attained by 13C-MRS correlated with ex-vivo determined, normalized LDH 223 
activity, as reported elsewhere (30). This confirms the role of LDH as one of the primary 224 
mechanisms behind [1-13C]pyruvate-MRS contrast, as has also been reported elsewhere 225 
(31-33). 226 
The ratios between lactate and pyruvate did not prove significantly different between 227 
groups. However, this can be due to the significantly lower pyruvate uptake in the 228 
treatment group. This finding indicates that the transport of pyruvate into the cells, as 229 
facilitated by the mono-carboxylate transporters, might also be affected by treatment 230 
with erlotinib. Further studies are needed to clarify if this is indeed the case, and 231 
discover the mechanisms behind. 232 
 14 
Due to the rapid relaxation of the hyperpolarized signal, perfusion of the investigated 233 
tissue remains a vital parameter in hyperpolarized 13C-MRS. Hence, we performed 234 
contrast-enhanced perfusion imaging, which showed similar perfusion in both the treated 235 
and untreated groups. This is an important verification in order to validate the effect of 236 
increased lactate levels. As further expected, we also observed a significantly slower 237 
washout of the gadolinium in tumors compared to muscle tissue. This could be attributed 238 
to the enhanced permeability and retention (EPR) effect. 239 
In the present study, 13C-pyruvate and FDG-PET identified a similar response to 240 
treatment, which is expected, as they are both cancer metabolism markers. Although the 241 
two modalities image different phases of glycolysis, the resulting information seems to 242 
be the same in this specific setting. However, increased metabolic activity is seen in 243 
many physiological states, such as inflammation and muscle activity, making lactate 244 
levels a more specific cancer marker due to specific imaging of the Warburg effect (34). 245 
In this preclinical trial, the in-plane resolution of both techniques was comparable; about 246 
2.2 mm for the 13C spectroscopic maps and about 1.4 mm the PET images. PET images 247 
have an isotropic image resolution, whereas the CSI images have around 5 mm 248 
thicknesses, which give the PET modality an advantage with the current imaging 249 
techniques in the preclinical setting. However, when moving into the clinical domain, the 250 
game becomes more even, as both modalities can obtain a spatial resolution of 3-4 mm 251 
at present. 252 
Dividing the population into two separate groups, one undergoing MRSI and another for 253 
PET imaging, makes it hard to compare individual tumors and biological references. The 254 
introduction of combined PET/MRI scanners allows for direct comparison of these 255 
modalities, which is something we are pursuing (28). In the present study, we observed 256 
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lower levels of PET uptake than has previously been reported, which is ascribed to the 257 
animal handling between the injection of tracer and scanning. Finally, a technical issue 258 
with 13C MRS is the variation in signal level due to tumor positioning with respect to the 259 
coil, shimming conditions and coil degradation. All this can make the results, from 260 
different experiments, difficult to compare.  261 
In summary, we have evaluated the 13C-pyruvate as strong marker to monitor the 262 
response to treatment with erlotinib in NSCLC using MRSI. We also presented a 263 
comparison between the [1-13C]pyruvate and the more clinically established FDG- and 264 
FLT-PET tracers. We found that all three markers were able to identify the response to 265 
treatment, most pronounced was FLT-PET. Each method has it is own merit and 266 
combination of both assess the tumor progression or retreat can be of great value. 267 
Especially the possibility of assessing tumor metabolism using [1-13C]pyruvate MRS in a 268 
joint PET/MR scanner, leaving the PET imaging available for other biological targets. 269 
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Figure legends 402 
Figure 1 403 
Representative 13C metabolic maps of pyruvate, lactate and their ratio for both treated 404 
and untreated HCC-827 and H-1975 xenograft tumors. The metabolic maps are overlaid 405 
on proton images acquired at the same position as the CSI, with white arrows indicating 406 
tumor position. Individual, representative voxel spectra from the tumor are shown in the 407 
bottom row. Each spectrum is normalized to maximum peak value for comparison. 408 
Figure 2 409 
Representative PET/CT images showing FDG- (top row) and FLT- (bottom row) uptake 410 
60 minutes after injection in both treated and untreated HCC-827 (left) and H-1975 411 
(right) xenograft tumors. White arrows indicate the location of the two tumors on each 412 
mouse. Some central necrosis was observed, particularly in the H-1975 tumors. 413 
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Figure 3 414 
Top row: Quantitative comparison between FDG and FLT uptake for treated and 415 
untreated HCC-827 and H-1975 tumors by % ID / g. Significant reduction in uptake was 416 
seen for both FDG and FLT (both p < 0.002) in treated HCC-827 tumors compared to 417 
untreated. No significant change in uptake was observed for H-1975 tumors.  418 
Bottom row: Representative sections stained histologically for GLUT1, HK2 and Ki-67 is 419 
shown for treated and untreated HCC-827 tumors. Quantitative evaluation of Ki-67 420 
staining showed a significantly reduced number of stained cells in treated HCC-827 421 
tumors compared to untreated (p < 0.05). 422 
Figure 4 423 
Quantitative evaluation of pyruvate, lactate and ratio levels in HCC-827 (A) and H-1975 424 
(B) tumors. A significant reduction in lactate level (p < 0.005) was observed for treated 425 
HCC-827 tumors compared to untreated. No significant change in metabolite levels was 426 
seen for H-1975 tumors. 427 
C. Levels of LDH enzyme normalized to total protein content in HCC-827 tumor 428 
samples. A significant reduction was found in the treated compared to untreated tumors 429 
(p < 0.05). D. Correlation between levels of LDH enzyme normalized to total protein 430 
content and lactate level evaluated by 13C-MRSI (p < 0.01). 431 
Figure 5 432 
Quantification of perfusion imaging, showing inflow (A) and outflow (B) coefficients for 433 
treated and untreated HCC-827 and H-1975 tumors. No significant difference in 434 
coefficients was found between cell lines and treatment. C shows a representative 435 
temporal development in signal enhancement, as well as the fitted, gamma-variate 436 
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curves for computing slope coefficients. Corresponding representative images are 437 
shown for three time points (D), with arrows indicating tumors. 438 
Figure 6 439 
Correlation between lactate (A) and pyruvate (B) levels from the two injections, with 440 
corresponding Bland-Altman plots (C and D). Both correlations are highly significant (p < 441 
0.001) and have slopes of 0.96 and 0.81 for lactate and pyruvate, respectively. Three 442 
data points were removed as outliers; see Supplementary figure 2 for full dataset. 443 
Supplementary figure 1 444 
A: Quantitative evaluation of pyruvate, lactate and ratio levels in treated and untreated 445 
HCC-827 xenograft tumors. Similar to figure 4 A, although these levels were obtained 14 446 
seconds after injection of hyperpolarized [1-13C]pyruvate. B: Correlation between LDH 447 
enzyme level normalized to total protein content and lactate level determined by 13C 448 
MRS. 449 
Supplementary figure 2 450 
Correlation between lactate (A) and pyruvate (B) levels from the two injections, with 451 
corresponding Bland-Altman plots (C and D). Both correlations are highly significant (p < 452 
0.001) and have slopes of 0.87 and 0.81 for lactate and pyruvate, respectively. Three 453 
data points were deemed as outliers (marked in red) were removed from analysis in 454 
Figure 6.455 
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Appendix A. Treatment response in non-small-cell lung cancer estimated with
hyperpolarized 13C pyruvate, FLT- and FDG-PET
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Abstract 26 
A co-polarization scheme for [1,4-13C2]fumarate and [1-
13C]pyruvate is presented to 27 
simultaneously assess necrosis and metabolism in rats with hyperpolarized 13C MR. 28 
The co-polarization was performed in a SPINlab polarizer. In addition, the feasibility of 29 
simultaneous PET and MR of small animals with a clinical PET/MR is demonstrated. 30 
The hyperpolarized metabolic MR and PET is demonstrated in a rat model of necrosis. 31 
The polarization and T1 of the co-polarized [1,4-
13C2]fumarate and [1-
13C]pyruvate 32 
substrates were measured in vitro and compared to those obtained when the substrates 33 
were polarized individually. Polarization of 36±4 % for fumarate and 37±6% for pyruvate 34 
was obtained. We found no significant difference in the polarization values between the 35 
dual and single substrate polarization. 36 
Rats weighing about 400 g were injected i.m. in one of the hind legs with 200 μL of 37 
turpentine to induce necrosis. Two hours later, 13C metabolic maps were obtained with a 38 
Chemical Shift Imaging sequence (16x16) with a resolution of 3.1x5.0x25.0 mm3. The 39 
13C spectroscopic images were acquired in 12 s, followed by an 8 min 18F-FDG PET 40 
acquisition of 3.5 mm resolution. [1,4-13C2]malate was observed from the tissue injected 41 
with turpentine indicating necrosis. Normal [1-13C]pyruvate metabolism and 18F-FDG 42 
uptake were observed from the same tissue. 43 
The proposed co-polarization scheme provides a means to utilize multiple imaging 44 
agents simultaneously, and thus to probe various metabolic pathways in a single 45 
examination. Moreover, it demonstrates the feasibility of small animal research on a 46 
clinical PET/MR scanner for combined PET and hyperpolarized metabolic MR. 47 
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Introduction 48 
Since the introduction of the dissolution Dynamic Nuclear Polarization 49 
(dDNP) technique1 to enhance the 13C signal in applications like magnetic resonance 50 
spectroscopic imaging (MRSI), the metabolic fluxes of hyperpolarized 13C substrates 51 
have shown great potential to improve the detection and characterization of many 52 
pathologies, especially cancer. For instance, studies have indicated that the lactate 53 
signal 2-4, and in some cancer types the alanine signal 5, are higher in cancer than in 54 
normal tissue, after the administration of hyperpolarized [1-13C]pyruvate. This 55 
observation is referred to as the Warburg effect and it is due to the fact that most cancer 56 
cells have elevated glycolysis even in the presence of sufficient oxygen. Moreover, MR 57 
imaging with hyperpolarized [1,4-13C2]fumarate was shown to allow early detection of 58 
necrosis 6-8. The conversion of fumarate into malate is a normal step in the 59 
mitochondrial tricarboxylic acid (TCA) cycle and is catalyzed by fumarase. As the 60 
enzyme is not present in the extracellular space, but exposed by cells that undergo 61 
necrosis, it is hypothesized that the observation of an increased [1,4-13C2]malate 62 
production, after intravenous administration of hyperpolarized [1,4-13C2]fumarate, can 63 
be used as a marker of necrosis.  64 
In order for the DNP process to be effective, it is important to comply with certain 65 
requirements during sample preparation and polarization. First of all, the 13C labeled 66 
substrates must be in an amorphous (glassy) solid state with the appropriate electron 67 
paramagnetic agent uniformly distributed so that an efficient coupling between electron 68 
spin and nuclear spins is achieved in the solid state 1,9,10. Fumaric acid (FA) dissolved in 69 
dimethyl sulfoxide, for instance, requires rapid freezing to achieve this amorphous solid 70 
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state and to prevent the FA crystallization, which can significantly reduce the nuclear 71 
spin polarization. Pyruvic acid (PA), on the other hand, is a liquid at room temperature 72 
that glasses well without additives. Moreover, the concentration of the desired agents, 73 
solvent/glassing agents and the concentration and type of free radical must all be 74 
optimized to achieve optimal polarization for the 13C substrates. In addition, appropriate 75 
dissolution and neutralizing media must be prepared for each agent in order to ensure 76 
physiological pH and osmolarity/tonicity for in vivo use. 77 
The spectrum obtained following the in vivo infusion of a hyperpolarized 13C material is 78 
often sparse. In some cases, this sparsity can be exploited to combine more than one 79 
13C agent during the hyperpolarization and imaging. This way multiple enzymatic 80 
pathways can be probed simultaneously. Previous attempts of multi-agent polarization 81 
have been performed with the Hypersense (Oxford Instruments, UK) polarizer 11-14. This 82 
manuscript presents a co-polarization scheme for [1,4-13C2]fumarate and [1-83 
13C]pyruvate to simultaneously assess necrosis and metabolism. The co-polarization 84 
presented in this work is done in a SPINlab polarizer (GE Healthcare) 15,16. Although the 85 
SPINlab benefits from relatively higher magnetic field and lower temperature, which 86 
result in high polarization, the polarization build-up durations are considerably long (2~4 87 
hours). The SPINlab overcomes this in part by having four samples in parallel; however, 88 
the adoption of multi-substrate polarization scheme makes the polarization in SPINlab 89 
more appealing. The polarization of the co-polarized [1,4-13C2]fumarate and [1-90 
13C]pyruvate were measured in phantoms and compared to those obtained when the 91 
substrates were polarized individually. In vivo experiments were conducted in rats with 92 
induced necrosis via the injection of 200 μL of turpentine at the deep muscle of the left 93 
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hind leg. 13C metabolic maps were obtained to assess the cellular uptake and the 94 
conversion of [1-13C]pyruvate into [1-13C]lactate and to assess the conversion of [1,4-95 
13C2]fumarate into [1,4-
13C2]malate. In addition, 
18F-fluorodeoxyglucose (18F-FDG) 96 
Positron Emission Tomography (PET) images were acquired simultaneously with the 97 
13C MRSI.   98 
Experimental 99 
Sample preparation 100 
For pyruvate preparation, AH111501 trityl radical (GE Healthcare, Denmark) was added 101 
to a sample of [1-13C]pyruvic acid (PA) (14 M) (Sigma Aldrich, Denmark) to a final 102 
concentration of 15 mM. The fumarate was prepared by dissolving [1,4-13C2]fumaric 103 
acid (FA) (Cambridge Isotope Laboratories, MA, USA) in dimethyl sulfoxide (DMSO) 104 
(Sigma Aldrich, Denmark). Sonication and vortex mixing were used until all the FA 105 
crystals had dissolved. AH111051 radical was then added and dissolved in the solution. 106 
To optimize the formulation of FA, three different batches were prepared with FA/radical 107 
concentrations of 3.6 M/8 mM, 3.6 M/12 mM and 2.8 M/15 mM, respectively.  108 
The polarizer and fluid path assembly  109 
The co-polarization was made in a SPINlab polarizer (GE Healthcare, Denmark). Figure 110 
1-a shows the fluid path assembly designed for use with the SPINlab. The fluid path 111 
consists of a vial (1) containing the sample and connected to the dissolution syringe (2) 112 
via two concentric tubes (3). The tubes can be pushed into the polarizer through the 113 
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dynamic seal (4) without compromising the vacuum. The syringe has an exit port (5) 114 
that connects to a tube for transfer of the hyperpolarized solution. 115 
The regular sample preparation procedure for the SPINlab fluid path requires that the 116 
vial, after adding the 13C substrate, is frozen in liquid nitrogen (LN2). This freezing is 117 
necessary to perform pressure check and helium purging. Helium purging is needed to 118 
have a helium exchange gas inside the fluid path when the vial is cooled to <1 K. 119 
The regular procedure to load the sample into the SPINlab involves lowering the sample 120 
vial into the sample pot (see Figure 1-c), were the hyperpolarization take place, through 121 
multiple steps (gradual insertion over 15 min) to avoid excessive increase in the helium 122 
temperature. This multi-steps lowering process was found to result in FA crystallization. 123 
Therefore, to avoid the FA crystallization, the sample preparation and loading was 124 
modified as detailed in the next section. 125 
Co-polarization of FA and PA 126 
The fluid path was prepared by first placing 25 μL (around 350 μmol) of PA in the 127 
sample vial and then freezing it in liquid nitrogen (LN2). 100 μL (about 350 μmol) of FA 128 
was then added on top of the PA and the vial was placed in LN2 again (see Figure 1-b). 129 
The vial is then glued to the tube set with the tip immersed in LN2 and the neck above 130 
the liquid surface. The rest of the fluid path preparations (pressure check and He 131 
purging) were done according to the manufactures instructions. After the preparation, 132 
the fluid path was placed in the SPINlab and the vial containing the two compounds was 133 
initially placed at the airlock for 20 to 30 min, thus allowing the substrates to thaw before 134 
lowering the sample vial into the helium pot. During the melting period, it is assumed 135 
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that the difference in density prevents the mixing of the two substrates. The densities of 136 
PA and FA solutions are 1.3 and 1.2 g/mL respectively. Then the sample vial was 137 
directly lowered into the helium bath in either one (A: directly to the 1 K pot) or two steps 138 
(B: directly to the 1 K pot and then retracted to the 4 K thermal link for 10 min) instead of 139 
the normal scheme of going through multi-steps lowering process, to avoid the 140 
crystallization of the FA in the sample.  141 
For both in-vivo and in-vitro studies, the sample was irradiated with microwaves at 142 
139.64 GHz and 40 mW (the two samples have the same optimal microwave frequency) 143 
for at least 4 hours in the in vitro phantom studies to measure the liquid-state 144 
polarization. Before dissolving the samples, it was ensured that the polarization curve in 145 
SPINlab reached the flat plateau. For logistic reasons, some of the sample in the in vivo 146 
animal experiments were polarized for about 3 hours and dissolved before reaching the 147 
maximum achievable polarization. The polarization curve was fitted with a single 148 
exponential.  149 
The dissolution syringe was filled with about 15 g of a dissolution medium (DM) (WFI 150 
with 0.1 g/L EDTA). The dissolved sample was mixed with 0.95 g of neutralizing 151 
medium (NM) (WFI with 0.72 M NaOH, 0.4 M Tris and 0.1 g/L EDTA).  152 
Some of the dissolved samples were used after the in vitro study to measure the 153 
concentration. The concertation was measured by quantitative NMR using 9.4 T 154 
spectrometer (NMR AS400, Oxford Instruments) and 100 mM urea reference.  155 
Single substrate polarization 156 
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In addition to the dual polarization of FA and PA, the FA was polarized separately. This 157 
was to investigate if there are differences in the polarization values between the single 158 
and dual substrate polarization. The single FA polarization and dissolution was made in 159 
the same manner as described in the previous section for the dual substrate. About 350 160 
μmol (100 μL) of FA sample was loaded in the vial and dissolved with 15 g of DM and 161 
0.65 g of NM. 162 
Phantom MR experiments for polarization and T1 measurements 163 
All imaging was performed in a clinical 3T PET/MR scanner (Siemens mMR Biograph, 164 
Siemens, Erlangen, Germany). A dual-tuned transmit/receive flex surface coil (RAPID 165 
Biomedical) was used for both 1H and 13C acquisition. The coil consists of 110 mm loop 166 
for 13C and 180 mm x 244 mm butterfly for 1H. The 90° flip angle was calibrated from a 167 
13C-urea phantom at approximately the position of the rat. Phantoms and rats were 168 
placed in the center of the 11 cm loop coil. 169 
About 5 mL of the polarized material was injected into a previously shimmed phantom 170 
tube, approximately 30 s after the dissolution. 180 13C spectra were acquired without 171 
spatial encoding using an excitation pulse with 5 flip angle (315 us pulse duration) and 172 
repetition time TR of 5 s. The sampling spectral window was set to 6000 Hz with 512 173 
spectral points.  174 
For each spectrum of the dynamic acquisition, the signal integrals were calculated after 175 
baseline correction. A mono-exponential decay function, equation 1, was fitted for each 176 
of the two substrate signals to obtain the relaxation time, T1, and the initial longitudinal 177 
magnetization, 𝑀𝐼.  178 
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𝑆(𝑛)𝑀𝐼 𝑠𝑖𝑛(𝛼) cos
𝑛(𝛼) 𝑒−𝑛
𝑇𝑅
𝑇1                   (1), 
where 𝑆(𝑛) is the signal recorded after the 𝑛th excitations, 𝑇𝑅 is the repetition time, and 179 
𝛼 is the flip angle.  180 
A 13C-urea phantom (4 M) was placed next to the tube with the hyperpolarized solution 181 
and was used to calibrate the 90o flip angle and as a reference to measure the 182 
polarization. To quantify the polarization, the initial signal of the hyperpolarized sample 183 
was compared to the urea signal and corrected for the concentration difference. 184 
In-vivo rat experiment 185 
Animal handling and experimental procedures were performed according to the 186 
guidelines from Danish Animal Experiments Inspectorate (permit no. 2011/561−14). The 187 
in vivo study was conducted in two rats weighing (400 g). The first rat was only injected 188 
with hyperpolarized FA. The second rat received two injections separated by 10 min. 189 
The first injection was only hyperpolarized FA, and the second injection was dual 190 
polarized FA and PA. Necrosis was induced by intramuscular injection of 200 μL of 191 
sterile turpentine oil in one of the hind legs. This was followed by subcutaneous injection 192 
of 400 μL of Buprenorphine (TEMGESIC, 0.03 mg/mL) to control the acute paint from 193 
the turpentine injection. Two hours later, the animal was transferred to the PET/MR 194 
scanner to acquire 13C MRS and PET images. 195 
During the MR scanning, the animals were anaesthetized with 3 % Sevoflurane mixed 196 
in O2. A catheter was inserted in the tail vein for the administration of the hyperpolarized 197 
mixture of pyruvate and fumarate or fumarate alone. 2 mL (0.14 mmol/kg) of the co-198 
polarized substrates was injected in the rat. This injection was done approximately 20 s 199 
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after dissolution, during this period the co-polarized material was transferred to the MRI 200 
room from the SPINlab in a syringe that was then connected to the tail vein catheter. 201 
The hyperpolarized substrate was injected manually over a period of 10 s. 202 
Anatomical long axis proton MR images are acquired prior to the 13C MRS scans for 203 
spatial localization of the necrotic tissue within muscle. Chemical shift images (CSI) 204 
(with FA=10, TR= 80 ms, TE = 1.4 ms, FOV = 50 x 80 mm2, matrix=16x16, in-plane 205 
resolution 3.1 x 5 mm2, slice thickness = 25 mm) were acquired 20 s after the end of 206 
administration of hyperpolarised [1-13C]pyruvate and  [1,4-13C2]fumarate mixture.  207 
One hour before the PET/MR imaging session, the rats were intravenously injected with 208 
80 MBq of 18F-FDG. An 8 min PET scan (2 mm isotropic resolution) was acquired 209 
during the acquisition of the MR images. Dixon imaging was used to obtain fat and 210 
water maps that were used to correct for the attenuation in the PET images. 211 
The acquired free induction decay signal at each voxel of the CSI data was first zero-212 
filled to increase the spectral resolution and the signal was then apodized using an 213 
exponential function, 𝑒𝑓.𝑡 with 𝑓 = 15 Hz. Metabolic maps were generated for each 214 
metabolite from the peak amplitude in the real phased spectra after baseline correction. 215 
The metabolic maps were resampled to the same resolution of the anatomical proton 216 
images, 0.4x0.4 mm2, and registered onto them. Thresholding was applied to reduce 217 
remove the noise level.  218 
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Results 219 
Polarization of [1,4-13C2]fumarate and [1-
13C]pyruvate 220 
Figure 2 shows representative polarization build-up and the temperature curves 221 
recorded at the equilibrator and sample pot for multi-step lowering process, used 222 
typically for pyruvate, and two-step lowering, used for samples containing fumarate. The 223 
efficiency of the multi-step lowering in minimizing the temperature variation at the 224 
sample pot is evident.  225 
The polarization of samples containing 600 mg of FA from the three different batches 226 
(with fumarate/AH111051 concentrations of 2.8M/15mM, 3.6M/8mM and 3.6M/12mM) 227 
resulted in build-up time constants and final solid-state polarization values detailed in 228 
Table 1, for one and two insertion steps. The batches showed high discrepancy in build-229 
up time constant and less discrepancy in the saturation level. The batch with 230 
3.6M/12mM fumarate/AH111051 concentration had the lowest build-up time constant. 231 
This batch also showed no significant difference between the one (A) and two (B) 232 
lowering steps in the final saturation level but the build-up time constant was lower for 233 
(A) ; however, the one-step lowering can result in a higher increase in the sample pot 234 
temperature. The final solid state polarization values for these batches were 235 
comparable. The solid state NMR signals might vary significantly between 236 
measurements due to the uncontrolled position of the sample within the NMR coil that is 237 
dimensioned to hold up to four samples. However, the comparison is based on the 238 
liquid state polarization obtained post dissolution.  239 
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Table 1 also shows the liquid state polarization measurements obtained for the three 240 
formulations of fumarate via dynamic acquisition of 13C spectra in the PET/MR scanner 241 
30 s after dissolution. There was no difference between the batches in the measured 242 
polarization. Since all the batches gave similar polarization results, the subsequent 243 
experiments were conducted with the 3.6M/12mM fumarate/AH111051 batch. This 244 
batch gives higher concentration of fumarate, which results in higher MR signal. In 245 
addition, this batch had relatively faster polarization build-up.  246 
The results of the experiment to determine whether there is a difference in the 247 
polarization and T1 values between the dual and single substrate polarization is 248 
summarized in Table 2. No significant difference was found in the measured values of 249 
polarization of FA for single and dual FA/PA polarization. The polarization level of 250 
pyruvate, 37%, obtained with the dual polarization scheme agrees with the polarization 251 
values of PA in SPINlab found in the literature 17.  252 
After the dissolution of the polarized materials in the (15 g) dissolution medium and 253 
(0.95 g) neutralizing buffer, the measured concentrations of fumarate and pyruvate were 254 
about 31±2 mM (n=2). The measured pH value was 7.7±0.3 (n=8). The volume of the 255 
sample received after dissolution was 6±1 mL (n=3). The remaining volume was 256 
retained in the fluid path during the dissolution as dead volume. 257 
Animal experiment 258 
Figure 3 shows the expected position of the metabolite peaks. The spectrum is sparse 259 
enough to allow clear quantification the injected substrates and their products. Figure 4 260 
shows the anatomical image and the 13C spectrum at the necrotic tissue for the rat that 261 
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was injected with only hyperpolarized FA. The maps of fumarate and malate 262 
distributions within a slice covering the necrotic region are also shown in Figure 4. 263 
Figure 5, shows the anatomical image and the 13C spectrum at the necrotic tissue for 264 
the rat that received the dually hyperpolarized FA and PA. Clear malate signal was 265 
visible at the necrotic site with both the single fumarate and dual pyruvate/fumarate 266 
injections and no malate signal was observed elsewhere.  Figure 5 also shows the PET 267 
images acquired for the same animal during the same MR imaging session. The FDG 268 
uptake by the different organs is represented using maximum intensity projection. Slight 269 
increase in lactate production is observed at the necrotic tissue. There is no clear effect 270 
from the necrosis on the FDG-PET signature. 271 
Discussion  272 
The main aim of this study was to investigate the technical feasibility of a method to 273 
simultaneously polarize a low dose of FA and PA in a SPINlab polarizer and to image 274 
their metabolism in small animals with a clinical MR scanner. This setup provides a 275 
mean to utilize multiple imaging agents at once, and thus to probe various physiological 276 
characteristics and obtain valuable biological data, in one single exam session. 277 
Secondly, it enables small animal research on a typical clinical scanner setup. 278 
Increased conversion of pyruvate into lactate, also known as the Warburg effect, is a 279 
main hallmark of neoplastic activity 18 and has the potential to effectively monitor the 280 
response to treatment 19. The production of malate from fumarate has been proposed 281 
as sign for necrosis 6,8,20, and it is expected that the degree of necrosis induced by 282 
treatment, is proportional to the amount of malate produced. The amount of malate 283 
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observed in the 13C spectrum depends also on the time of imaging following the 284 
intervention as seen in the difference in malate signal between the two injections in rat 285 
two. This is because the fumarase is washed out of the tissue within a few hours to the 286 
blood plasma and then to the urine 21.  287 
Acquiring PET images at the same time as 13C hyperpolarized MR imaging adds 288 
additional molecular imaging characterization, and allows comparing PET tracers with 289 
their analogous MR counterparts. For instance, although 18F-FDG, unlike [1-290 
13C]pyruvate,  does not show the actual metabolic reactions, the concentrations of 18F-291 
FDG in the PET images reflects regional uptakes of glucose. Thus, FDG-PET, to a 292 
degree, also reflects tissues with high metabolic activity, and the two markers, 18F-FDG 293 
and 13C-pyruvate, can be complementary 22,23. The lactate signal was clearly detectable 294 
at various tissues from the 13C spectra of the CSI whereas the malate signal was 295 
confined to necrotic tissue. There was no change in the FDG uptake nor on the lactate 296 
production. 297 
We were able to demonstrate the feasibility of using a state-of-the-art clinical PET/MR 298 
scanner for in vivo imaging of rats. Good image quality that allows the evaluation of 299 
metabolic activities in various tissues was achievable with both PET and 13C-MRS 300 
imaging. In this study, the in-plane resolution used with CSI was 3.1 x 5 mm2, but finer 301 
spatial resolution can be achieved. The minimal in-plane resolution for the CSI allowed 302 
on our system is 3.1 mm with nominal gradient strength, which is the maximum value 303 
that the manufacturer recommends for reliable performance. However, in theory, a 304 
resolution as fine as 1.5 mm can be achieved with the maximum gradient strength that 305 
can be realized by the scanner. This is because, the CSI sequence does not require 306 
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very strong gradients, unlike other faster spectroscopic sequences, such as Echo 307 
Planar Spectroscopic Imaging (EPSI), which can be very demanding on gradient 308 
strength and slew rate. The gradient strengths and slew rate on the Siemens mMR 309 
Biograph are 42 mT/m and 180 mT/m/ms respectively. These are significantly lower 310 
compared to 1,000 mT/m gradient strength and 5,000 mT/m/ms slew rates on some of 311 
the state-of-the-art animal scanners.  312 
One of the major problems that faced previous attempts of multi substrate polarization 313 
was the limited sample volume that can be polarized stably and dissolved successfully 314 
in the Hypersense polarizer (Oxfords, Instruments, UK), which is used in these co-315 
polarization attempts. This limited sample volume that can be used in the Hypersense 316 
subsequently results in relatively smaller concentrations of the co-polarized substrates 317 
in the final volume (13).  SPINlab on the other hand is designed to efficiently polarize 318 
and dissolve larger substrate volumes (up to 2 g). 319 
Relatively high polarization was achieved for both FA and PA (more than 30%) when 320 
they were polarized simultaneously in the SPINlab. In addition, there was no significant 321 
difference in the polarization measurement when two substrates were polarized 322 
separately. The final concentration of the two agents after dissolution was reasonable 323 
(30 mM). This concentration however can be increased by increasing the initial volume 324 
of PA and FA in the sample vial, but will be at the expense of a larger waste. The 325 
dissolution volume can also be lowered for higher final concentration of PA and FA. The 326 
minimal effective dissolution volume that can be reliably used on the SPINlab is 327 
approximately 5-7 mL. 328 
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Using multiple 13C substrates, however, brings additional burden to resolve multiple 329 
peaks in the frequency spectrum with the possibility of overlapping between peaks; an 330 
issue which is less common in hyperpolarize 13C MRS compared to 1H MRS. Higher 331 
magnetic fields are more suitable for such tasks, since they give larger spacing between 332 
the peaks.  Fortunately, the malate doublet was quantifiable in both single fumarate and 333 
dual fumarate/pyruvate scheme. There is also the problem of the difference in the ideal 334 
microwave irradiation frequencies for the different 13C substrates, which can limit the 335 
solid state polarization for some of them. In our case, both FA and PA had the same 336 
frequency. 337 
Necrosis has been shown to play an important many pathological processes like in 338 
many central nervous system and neurodegenerative disorders 24,25, 339 
ischemia/reperfusion injuries 21, viral and microbial infections 26,27. Necrosis might also 340 
be playing an important rule in physiological processes like ovulation 28 341 
and embryogenesis 29, In addition, Many chemotheributical agents used for cancer 342 
treatment are known to induce death in cancer cells through necrosis 6. MRS of 343 
hyperpolarized [1,4-13C2]fumarate can play a big role in studying necrosis in vivo in 344 
these processes.  345 
Turpentine is a mixture of alkylated aromatic hydrocarbons designed to dissolve fat, and 346 
thus they can effectively cause lipid dissolution. Turpentine injection into living tissue 347 
provides a robust and easy to control method that causes necrosis and inflammatory 348 
response, and therefore can be useful in studying cellular death via necrosis.   349 
 350 
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In conclusion, we have demonstrated the feasibility of probing the dual enzymatic 351 
pathways of [1-13C]pyruvate and [1,4-13C2]fumarate in a clinical dual PET/MR system. 352 
The phantom measurements showed that the polarizations values achieved for two 353 
substrates when polarized together were comparable to those values obtained when 354 
each substrate is polarized individually. The experimental setup can be very useful to 355 
investigate the ability of various hyperpolarized 13C substrates and PET tracers, like 18F-356 
FDG, malate/fumarate ratio and lactate/pyruvate ratio in monitoring the response of 357 
cancer tissues to treatment. The setup also can be used to investigate the correlation 358 
between the analogous PET and 13C MRS markers. Moreover, clinical PET/MR 359 
scanners, that are becoming widely available, could contribute not only to human 360 
clinical routine examinations, but also to biomedical researches in small animals. 361 
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Figure legends 478 
Figure 1 479 
(a) The fluid path that goes into the SPINlab. The path consists of a syringe that 480 
contains the dissolution media and sample vial that contains the 13C substrate to be 481 
polarized. The two are connected by two concentric tubes. During the dissolution the 482 
dissolution medium is transferred through the inner tube to the sample vial where it 483 
dissolves the hyperpolarized substrate. The dissolved material flows back through the 484 
outer tube lumen toward the syringe and out of the SPINlab via the exit tube. (b) shows 485 
schematic draw of the sample vial. The vial is prepared by first adding the PA and then 486 
freezing it in LN2 and then adding the FA. The vial is then kept in LN2 during the rest of 487 
preparation of the fluid path to attain two separate layers in the vial. (c) shows the path 488 
of the vial once it is inserted in the SPINlab. The vial is initially placed in the airlock for 489 
20 min to allow the sample to melt. Then, it is lowered in multiple steps, back and forth, 490 
along the path until it settles at the He sample pot to avoid excessive increase in 491 
temperature at the He pot. 492 
Figure 2 493 
Typical polarization curve (shown with solid lines) starting from time = 0. The dashed 494 
and dash-dotted curves in the figure shows the temperature recorded at two positions in 495 
the SPINlab, which are the sample pot and the equilibrator, respectively. Before the 496 
start of the polarization build-up is the period during which the lowering process takes 497 
place. In (a) where multi-steps lowering is used, the variation in temperature at the 498 
equilibrator level is smaller compared with (b) where only two lowering steps were used. 499 
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At the helium pot, the temperature stays almost constant for multi-steps lowering, while 500 
for the two-step lowering there is a rise in temperature for some time (about 25 minutes) 501 
before the temperature settles at 0.8 K. 502 
Figure 3 503 
The expected positions of the peaks of interest following the administration of FA and 504 
PA. The figure illustrates that the 13C spectrum is sparse allowing co-polarization and 505 
simultaneous imaging of [1,4-13C2]fumarate and [1-
13C]pyruvate.  506 
Figure 4 507 
The anatomical axial image of the first rat (a) acquired at the location of the necrotic 508 
tissue. The image was acquired with turbo spin echo (TR= 5.7 s, TE= 84 ms, echo train 509 
length of 18, number of phase encoding steps 234, Number of averages of 5, final 510 
matrix size of 256x256 covering a FOV of 100 mm x 100 mm with slice thickness of 2 511 
mm). (b) shows the spectrum at the necrotic tissue with the fumarate peak and the 512 
malate doublet. Clear malate signal can be observed in the spectrum. The small peak at 513 
the right of the spectrum at 165 ppm is due to fold over of the 13C-urea phantom. (c) and 514 
(d) shows the metabolic maps of fumarate and malate, respectively. Notice that the 515 
malate production is confined to the necrotic region. 516 
Figure 5 517 
The anatomical axial image of the second rat (a) acquired at the location of the necrotic 518 
tissue. The proton image was acquired similar to Figure 4-a. A coronal maximum 519 
intensity projection image which shows the FDG uptake by the different organs is 520 
illustrated in (b). (c) shows an axial slice with 12 mm thickness (sum of 6 adjacent 521 
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slices) with the FDG uptake in a plane containing the necrotic tissue. (d) and (e) show 522 
the phased real part spectra at the necrotic tissue, the blue box in (a), acquired for 523 
single injection of FA and dual injection of FA and PA, respectively. The malate signal 524 
can be seen in both spectra. In dual FA and PA experiment additional peaks are 525 
observed for lactate, alanine, pyruvate-hydrate and bicarbonate. (f to i) shows the 526 
metabolic maps of pyruvate, lactate, fumarate and malate respectively. 527 
  528 
  529 
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Tables 530 
Table 1: Solid state DNP build-up data for three different samples with two different 531 
loading profiles 532 
Concentrations 
(FA/AH111501) 
2.8 M/15 mM 3.6 M/8 mM 3.6 M/12 mM 
No. insertion steps ONE TWO ONE TWO ONE TWO 
Build-up time constant 
(s) 
9448 5913 6718 6765 2725 3659 
S(t=∞) (a.u.) 1311 1054 740 1140 969 993 
Liquid-state 
polarization(%) 
39 38 37 
 533 
Table 2: Liquid state polarization and T1 measurements for the sample with FA (3.6 M) 534 
with 8 mM of AH111501 radical 535 
n=5 Fumarate Pyruvate 
 Dual Single Dual 
T1 (s) 57±2 58±2 70±3 
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35±5 37±6 37±6 
 536 
  537 
  
25 
 
Figure 538 
Figure 1539 
 540 
  541 
  
26 
 
Figure 2 542 
  543 
  
27 
 
Figure 3 544 
 545 
 546 
  547 
  
28 
 
Figure 4 548 
 549 
  550 
  
29 
 
Figure 5 551 
 552 
C
Fumarase activity: an in vivo and in
vitro biomarker for acute kidney injury
This paper was published in Scientific Reports 2017 (published online prior
to inclusion in an issue, DOI: 10.1038/srep40812). Some of the results from
this paper were presented in the Annual Meeting of International Society for
Magnetic Resonance in Medicine in May 2016.
151
1Scientific RepoRts | 7:40812 | DOI: 10.1038/srep40812
www.nature.com/scientificreports
Fumarase activity: an in vivo and 
in vitro biomarker for acute kidney 
injury
Per Mose Nielsen1, Abubakr Eldirdiri2, Lotte Bonde Bertelsen1, Hans Stødkilde Jørgensen1, 
Jan Henrik Ardenkjaer-Larsen2,3 & Christoffer Laustsen1
Renal ischemia/reperfusion injury (IRI) is a leading cause of acute kidney injury (AKI), and at present, 
there is a lack of reliable biomarkers that can diagnose AKI and measure early progression because 
the commonly used methods cannot evaluate single-kidney IRI. Hyperpolarized [1,4-13C2]fumarate 
conversion to [1,4-13C2]malate by fumarase has been proposed as a measure of necrosis in rat tumor 
models and in chemically induced AKI rats. Here we show that the degradation of cell membranes in 
connection with necrosis leads to elevated fumarase activity in plasma and urine and secondly that 
hyperpolarized [1,4-13C2]malate production 24 h after reperfusion correlates with renal necrosis in 
a 40-min unilateral ischemic rat model. Fumarase activity screening on bio-fluids can detect injury 
severity, in bilateral as well as unilateral AKI models, differentiating moderate and severe AKI as well as 
short- and long-term AKI. Furthermore after verification of renal injury by bio-fluid analysis the precise 
injury location can be monitored by in vivo measurements of the fumarase activity non-invasively by 
hyperpolarized [1,4-13C]fumarate MR imaging. The combined in vitro and in vivo biomarker of AKI 
responds to the essential requirements for a new reliable biomarker of AKI.
Acute kidney injury (AKI)1–3 occurs in 1.9% of all hospital in-patients4. The illness is especially common in 
critically ill patients, and the prevalence in this group is > 40% at admission to the intensive-care unit if sepsis is 
present4. The underlying causes of AKI include sepsis, toxins, and urethral obstruction. However, the main con-
tributor is renal ischemia/reperfusion injury (IRI), which accounts for up to 47% of all cases of AKI2. IRI can be 
caused by kidney transplants, hypovolemia, cardiogenic shock, and renal vascular diseases2,5. The effective treat-
ment of AKI should begin at the earliest sign of renal dysfunction, but the current preferred biomarkers of AKI 
such as plasma creatinine, creatinine clearance (CrCl), glomerular filtration rate (GFR) determined using Inulin 
or Cr-EDTA6,7 and blood urea nitrogen (BUN)8,9 lack specificity and sensitivity as they only rise substantially 
above the normal levels once renal damage has already occurred.
The parameters listed above reflect the residual glomerular filtration rate rather than injury itself10. 
Alternatively, renal biopsies can identify single-kidney or local IRI by measuring the protein or mRNA expression 
levels of lactate dehydrogenase, kidney injury molecule 1 (KIM-1), and neutrophil gelatinase-associated lipocalin 
(NGAL)11. Renal biopsies provide high sensitivity, but are associated with the high risk of additional chronic 
injury and hemorrhage that should ideally be avoided in critically ill patients12,13. Thus, precise and non-invasive 
methods, preferably imaging methods or the sampling of urine and blood to continuously and directly evaluate 
the severity of single-kidney IRI in patients and animals, are urgently needed.
Hyperpolarization of 13C-labeled molecules leads to a > 10,000-fold increase in signal compared to conven-
tional magnetic resonance imaging (MRI)14. This signal enhancement allows real-time imaging of metabolic 
pathways using 13C-labeled endogenous substrates15. We have recently demonstrated metabolic alterations in 
post-ischemic unilateral IRI rats following hyperpolarized [1-13C]pyruvate infusion16. Showing an upregulation 
of the anaerobic pathways, similarly to what has been demonstrated in diabetic kidney17–19, albeit lower total 
turnover, most likely caused by necrosis. In principle any small molecular probe can be hyperpolarized as long as 
they contain a nuclear spin, typically 13C20,21. Currently there is an large array of commercial available hyperpo-
larized of 13C-labeled molecules which have been utilized in many different animal models of cancer22,23, myocar-
dial ischemia24–26 and renal diseases27–30, and more recently in patients and healthy volunteers31,32 Additionally, 
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[1,4-13C]fumarate has been shown to be a reliable imaging biomarker for monitoring cellular necrosis33 in a rat 
model of xenograft tumors and subsequently in a rat model with folic acid-induced AKI34. These previous results 
showed an increased 13C-malate signal in kidneys with progressive tubular necrosis. In intact cells, the uptake and 
subsequent hydration of fumarate to malate occurs too slowly compared to the hyperpolarization signal decay, 
whereas in necrotic cells the cellular integrity is broken, allowing fumarate to enter the cell and fumarase to leak 
out. From this point, the enzymatic conversion via fumarase occurs rapidly and the malate product is detectable 
by MRI. This might also cause the release of fumarate in the urine and blood, yielding a biomarker detectable in 
the plasma and urine.
Based on the above, we question if hyperpolarized [1,4-13C]fumarate can be used to asses renal necrosis in 
connection with IRI, and will be associated with fumarase activity in both urine and blood.
Results
A significantly elevated kidney weight (p = 0.001) following 40 min of unilateral ischemia and 24 h of reperfu-
sion was observed. A tendency towards a reduction of body weight of 1.5% ± 4.5% (p = 0.46) and an increase in 
urine output of 52% ± 70% (p = 0.11) was observed, but did not reach statistical significance. Functional kidney 
parameters showed consistent signs of renal IRI with an elevated plasma creatinine level of 91% (p = 0.0002) and 
a reduced CrCl and BUN level of 44% (p = 0.04) and 30% (p = 0.003), respectively, when comparing pre-surgery 
with post-surgery values (Table 1). Figure 1 shows representative histological sections with hematoxylin and 
eosin stain from a CL kidney and a post-ischemic kidney. The CL kidney showed normal intact tubular epithelial 
cells compared to the post-ischemic kidney, with tubular lumina filled with cellular debris, complete sloughing 
of tubular epithelium, interstitial edema, and glomerular edema (Fig. 1A,B). The classical cortical kidney injury 
markers NGAL and KIM-1 were significantly elevated (p = 0.01 and p = 0.03) compared to those in the CL kidney 
(Fig. 1C,D). An elevated malate/fumarate ratio of 339% (p = 0.002) (Fig. 2C) in the ischemic kidneys compared 
that in the CL kidney was found. In order to examine the relationship between renal cortical injury and malate/
fumarate ratio, the correlation between NGAL and KIM-1 levels with the malate/fumarate ratio was investi-
gated. A linear correlation was found in both cases (R2 = 0.78, p = 0.008 and R2 = 0.80, p = 0.006, respectively) 
(Fig. 3A,B). To investigate the localization of fumarase in connection with renal IRI, molecular fumarase activity 
measurements were performed. Fumarase activity in the mitochondrial fraction and the whole tissue was signif-
icantly reduced by 48% (p = 0.002) and 54% (p = 0.007) when compared with the values of the CL (Fig. 4A,B). 
Fumarase activity measured in urine and plasma was significantly elevated (p = 0.004 and p = 0.0001), with prac-
tically no activity observed under control conditions (Fig. 4C,D). Fumarase activity measured in urine samples 
collected immediately after sacrifice was correlated with malate/fumarate ratios (R2 = 0.77, p = 0.02) (Fig. 5A), 
as was plasma fumarase activity (R2 = 0.72, p = 0.03) (Fig. 5B). A parallel investigation of fumarase activity in the 
urine of IRI and control rats showed a time and severity-dependent increase in urine fumarase activity. Elevated 
activity at as early as 30 min after reperfusion, followed by a reduction 24 h after and another increase in activity 
after 7 days was observed (Fig. 5C,D). Bilateral IRI was associated with a less pronounced increase in activity in 
the urine, while the plasma activity was greatly increased (Fig. 5C,D).
Discussion
The main finding of this study was the significantly elevated hyperpolarized malate/fumarate ratio in response 
to 40 min of unilateral ischemia and 24 h of reperfusion, and a time and severity-dependent increase in urine 
and plasma fumarase activity. This elevation correlated with the levels of the well-known renal cortical injury 
markers KIM-1 and NGAL. Furthermore, the findings verified the original report of Clatworthy et al.33, who 
demonstrated that an elevated malate/fumarate ratio could be used as a direct marker of necrosis in renal disease.
All rats included in this study showed evidence of injury in the post-ischemic kidney 24 h after surgery 
according to the functional kidney parameters plasma creatinine, CrCl, and BUN. Additionally, the histolog-
ical hematoxylin and eosin-stained sections showed typical signs of tubular necrosis. The molecular markers 
NGAL and KIM-1 were highly upregulated in the post-ischemic kidney. Although these markers are not spe-
cific to necrosis35,36, they do indicate general injury in the cortical region of the post-ischemic kidney, which in 
this study was directly correlated with the malate/fumarate ratio. The reduced fumarase activity measured in 
the post-ischemic kidney compared to that in the CL kidney (whole-tissue and mitochondrial fraction) might 
seem counter-intuitive, as the malate/fumarate ratio is higher in the post-ischemic kidney. However, as the 
polarization-relaxation decay of [1,4-13C2]fumarate is fast compared to the uptake of fumarate through dicarbox-
ylate transporters37, malate production is blocked in the CL kidney despite the relatively higher fumarase activity. 
Meanwhile, in the post-ischemic kidney, the observed signal of hyperpolarized [1,4-13C2]malate is interpreted as 
the release of fumarase caused by cellular membrane disruption in connection with necrosis38 to the interstitial 
space, plasma, and urine. Once released from the cells, fumarase, a highly potent enzyme, will produce malate in 
Body 
weight (g)
Kidney weight  
(mg/g bodyweight)
Urine output 
(μL/min/kg)
Plasma creatinine 
(μmol/L)
CrCl  
(mL/min/kg)
BUN  
(μL/min/kg)
Pre Surgery (n = 6) 247 ± 6.3 — 30.7 ± 9.4 15 ± 1.7 10.1 ± 1.5 4.9 ± 0.7
Post Surgery (n = 6) 243 ± 9.5 (NS)
IRI 4.5 ± 0.1* CL 
3.7 ± 0.04 41.6 ± 8.5 ns. 28.7 ± 2.4* 5.7 ± 3.2* 7.0 ± 0.5*
Table 1.  Renal function parameters before and after surgery. CL = contralateral kidney; IRI = ischemia/
reperfusion injury; CrCl = creatinine clearance; BUN = blood urea nitrogen; NS = not statistically significant. 
Values are given as mean ± s.e.m. *Indicate significant difference of P-value < 0.05.
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the presence of fumarate. This is caused by an equilibrium constant favoring malate formation (Kc = 4.3, pH 7.5)39, 
but also the fact that fumarase requires no co-substrates or co-enzymes to function, meaning that even though 
fumarase is exclusively intracellular, it functions just as well in the extracellular space under necrotic conditions.
Plasma and urine fumarase activity levels were highly increased after the onset of IRI, and were correlated 
with the hyperpolarized malate/fumarate ratios. Albeit giving rise to measurements characteristic of IRI, these 
values, like other blood/urine biomarkers of AKI, were unable to specify which kidney (or both) was suffering 
from necrotic injury. Several complementary MRI techniques have previously demonstrated promising results 
for AKI monitoring. Conventional perfusion imaging using either arterial spin labeling or contrast agents, have 
demonstrated reduced perfusion in the post-ischemic kidney40,41, similarly recently found with hyperpolarized 
13C-urea42. Diffusion weighted imaging (DWI), a well-suited imaging marker of renal complications have shown 
diffusion restrictions already at onset of AKI and this restriction is associate with the severity of AKI, inflam-
matory cell infiltration and interstitial renal fibrosis43. Relaxation mechanisms has been shown to be related to 
edema, fibrosis and renal (oxygenation blood-oxygen-level-dependent contrast imaging (BOLD))43–45. The ability 
to non-invasively monitor both anatomical, hemodynamic, metabolic renal changes associated with AKI with 
sufficient sensitivity and specificity, support the use of MRI in both animal and patients studies. The addition of 
hyperpolarized [1,4-13C]fumarate for local necrosis examinations to this powerful MR toolbox, further improves 
this toolbox. The combination of urine and plasma fumarase measurement with hyperpolarized MRI procedures 
shows great promise for future clinical translation. Figure 6 illustrates the proposed mechanisms for the new sen-
sitive biomarker of renal necrosis in AKI. Furthermore, in some cases, the animal’s fluid balance and fluid intake 
after IRI induction are associated with a high degree of variation, which will inevitably be reflected in the levels 
of plasma and urine fumarase activity. Interestingly, the bilateral IRI model showed comparable fumarase activity 
in the urine compared to that in the unilateral kidneys. While the plasma activity was significantly elevated, this 
is most likely due to a reduced urine output in the bilateral cases. The same situation was seen in the 60-min IRI 
model, wherein the post-ischemic animals had very little urine output, leading to very little secretion of fuma-
rase. Therefore, enzymes released from necrotic tissue are mainly seen in the circulation (plasma fraction). In the 
Figure 1. Verification of ischemia-reperfusion injury. Representative histological sections are shown in 
(A) a CL kidney showing normal intact tubular cells and glomeruli, and (B) a post-ischemic kidney showing 
a cellular cast in the tubular lumina (green arrow), complete sloughing of tubular epithelium (red arrow), 
interstitial edema (black arrow), and glomerular edema (yellow arrow). Magnification 20× , HE stain. The 
relative expression of injury markers indicated significant upregulation of (A) NGAL (p = 0.0145, n = 6) and 
(B) KIM-1 (p = 0.0256, n = 6). A paired two-sided Student’s t-test was used to compare the CL and IRI kidneys. 
Blocks indicate means, while bars indicate the s.e.m. CL = contralateral kidney; HE = hematoxylin and eosin; 
NGAL = neutrophil gelatinase-associated lipocalin; KIM-1 = kidney injury molecule 1; IRI = ischemia/
reperfusion injury.
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other IRI cases, there was elevated urine output, which is often seen in early/moderate IRI cases46. Therefore, we 
conclude that fumarase is mainly found in the urine.
In conclusion, these results highlight the potential for following disease progression using a simple urine 
and plasma test and the verification of the degree and location of the damage with more sensitive imaging tests 
such as MRI. We demonstrated a correlation between renal necrotic injury in connection with IRI with in vivo 
and in vitro fumarase activity, and described the underlying mechanisms of the proposed methods. We believe 
that the simple measurement of fumarase activity measurement in the blood and urine, in combination with 
Figure 2. Magnetic resonance imaging maps and malate/fumarate ratios. Representative anatomical  
1H kidney sections from the post-ischemic animals overlaid with (A) 13C-labeled fumarate images, and  
(B) 13C-labeled malate images. (C) A malate/fumarate ratio calculated from each kidney (n = 6 CL, n = 6 IRI), 
giving rise to an elevated ratio in the post-ischemic kidney (p = 0.0065). The green arrow indicates the CL. The 
red arrow indicates the IRI kidney. A paired two-sided Student’s t-test was used to compare the CL and IRI 
kidneys. Blocks indicate means, while bars indicate the s.e.m. All relevant abbreviations as in Fig. 1.
Figure 3. Correlation between renal injury and malate/fumarate ratio. A significant deviation from zero was 
found between (A) NGAL and malate/fumarate ratios (n = 7, p = 0.0017 and R2 = 0.88), and (B) KIM-1 and 
malate/fumarate ratio (n = 7, p = 0.0064, R2 = 0.80). The dashed line indicates the 95% confidence interval. The 
straight line indicates the regression line. All qPCR measurements were performed in duplicate. All relevant 
abbreviations as in Fig. 1. qPCR = quantitative PCR.
www.nature.com/scientificreports/
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hyperpolarized MRI, holds great promise as a future diagnostic tool for AKI. These findings should serve as a 
starting point for future research in human subjects.
Methods
Animal models. The imaging experiments were performed on male Wistar rats (weighing 200–250 g). The 
animals were provided with ad libitum access to a standard rodent diet (Altromin, Germany) and tap water, and 
were kept under a 12/12-h light-dark cycle at a temperature of 21 ± 2 °C and a humidity of 55 ± 5%. The studies 
were carried out in accordance with the Danish National Guidelines for animal care, and were approved by the 
Danish Animal Experiments Inspectorate under the Danish Veterinary and Food Administration (License no. 
2013/15-2934-00810).
During surgery (animal order randomized), the animals were placed on a heating pad (CMA 450 temperature 
controller, Harvard apparatus) to maintain a rectal temperature of approximately 36–37 °C, and respiration was 
visually monitored. A surgical incision was made in the abdomen, and the left renal artery was carefully dissected. 
A non-traumatic clamp was placed on the left artery for 40 min to induce ischemia, after which the clamp was 
released. Reperfusion was visually confirmed. The incision was sutured separately through both the muscle tis-
sue and skin. The contralateral (CL) kidney was left intact, and was used as the control kidney. During surgery, 
the animals were anesthetized with sevoflurane (induction 6%, sustained 2.5%) mixed with air (2 L/min). At the 
beginning of surgery, Temgesic (buprenorphine hydrochloride) sublingual tablets were provided subcutaneously 
(0.05 mg/kg), after which buprenorphine hydrochloride was supplied in the drinking water (0.3 mg/mL) until 
euthanization. To maintain post-operative water balance, 2 mL of isotonic salt water was injected subcutane-
ously at the beginning of the operation. Prior to surgery, the rats were kept in metabolic cages. After 24 h in the 
metabolic cage, urine was collected and the rats were anesthetized for blood sample collection and surgery. After 
surgery, the rats were again put in metabolic cages. At the time of euthanization (24 h after surgery), arterial blood 
and urine was collected again to estimate fumarase activity.
A total of seven animals were used for the imaging experiments. From six of these animals, urine and blood 
samples were successfully extracted and used to measure fumarase activity (unsuccessful blood sampling lead 
to the loss of blood and urine measurements from one animal). The same seven animals were then used for 
Figure 4. Biochemical analysis of fumarase activity. Fumarase activity was measured in (A) the 
mitochondrial fraction (n = 6, p = 0.0022), (B) whole-tissue biopsies (n = 6, p = 0.0067), (C) urine (n = 6, 
p = 0.004), and (D) plasma (n = 6, p = 0.0001) isolated from arterial blood samples. A paired two-sided 
Student’s t-test was used to compare the CL and IRI kidneys and the pre and post-surgery urine or plasma 
samples. All activity measurements were performed in duplicate. Tissue and mitochondrial activity was 
normalized to protein content, while urine and plasma levels were normalized to the sample volume. Blocks 
indicate means, while bars indicate the s.e.m. All relevant abbreviations as in Fig. 1.
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quantitative polymerase chain reaction (qPCR) measurements of tissue and mitochondrial fumarase activity fol-
lowing 40 min of unilateral ischemia and 24 h of reperfusion.
Urine and plasma sampling was performed on a total of 42 animals. The animals were placed in groups of 
six, and varying degrees of IRI were then induced. One group was exposed to 30 min of ischemia and 30 min of 
reperfusion. Two groups were exposed to 20 min and 40 min of ischemia, and urine and plasma samples were col-
lected after 24 h and 1 week of reperfusion. Two groups were exposed to 30 min and 60 min of ischemia and 24 h 
of reperfusion. One group was exposed to 40 min of bilateral ischemia followed by 24 h of reperfusion. Finally, a 
sham-operated group was included to serve as a control.
Renal histology. A 2-mm kidney section was dissected from both the CL kidney and post-ischemic kidney 
from each rat at the time of euthanasia. The kidney sections were fixed in 4% paraformaldehyde for 2 h and 
washed 3 times (10 min) with 0.01 M phosphate-buffered saline. The fixed kidneys were then dehydrated, embed-
ded in paraffin, and cut into 2-μ m sections on a rotary microtome (Leica Microsystems A/S, Herlev, Denmark). 
The paraffin-embedded sections were stained with hematoxylin and eosin to evaluate the presence of tubular 
necrosis. Evaluation was performed blinded under high magnification (20x). Representative images are shown 
at 20x magnification.
Activity assays. Fumarase activity was measured in plasma, urine, whole renal cortex tissue, and mito-
chondrial fractions according to the manufacturer’s instructions (Sigma Aldrich, Brøndby, Denmark). Fumarase 
activity in the mitochondria and tissue was normalized to the amount of protein in the sample. Plasma and 
urine fumarase activity was normalized to the amount of sample added to the assay. The mitochondrial frac-
tion was isolated using Dounce homogenization of freshly dissected renal tissue followed by several centrifu-
gal steps. Mitochondrial purity was verified by Western blotting. The tissue and mitochondrial fractions were 
then homogenized in the fumarase assay buffer. Analysis was performed in 96-well costar half plates using a 
PHERAstar FS micro plate reader (BMG Labtech, Birkerød, Denmark). Urine and/or plasma were distributed 
Figure 5. Correlation between urine and plasma fumarase activity and fumarase activity with varying 
degrees of ischemia/reperfusion injury. A deviation from zero was found between (A) Urine fumarase activity 
and fumarate/malate ratio (n = 6, p = 0.021, R2 = 0.77.), and (B) Plasma fumarase activity and fumarate/
malate ratio (n = 6, p = 0, R2 = 0.722). The dashed line indicates the 95% confidence interval. The straight line 
indicates the regression line. Fumarase activity in 30-min/30-min IRI plasma (p = NS) and urine (p ≤ 0.001), 
in 20-min/1-day IRI plasma (p = NS) and urine (p = NS), in 40-min/1-day IRI plasma (p = NS) and urine 
(p = 0.0005), in 20-min/1-week IRI plasma (p = NS) and urine (p = 0.0001), in 40-min/1-week IRI plasma 
(p = NS) and urine (p ≤ 0.0001), in 40-min/1-day bilateral IRI plasma (p ≤ 0.0001) and urine (p = 0.0006), in 
30-min/1-day IRI plasma (p = NS) and urine (p = 0.0003) and in 60-min/1-day IRI plasma (p = 0.0091) and 
urine (p = NS). In all examples lists, the length of the period of ischemia is given first, followed by that of the 
period of reperfusion. One-way ANOVA with a Holm-Sidak’s multiple comparisons test was used to compare 
values between the varying degrees of IRI. All relevant abbreviations as in Fig. 1. ANOVA = analysis of variance; 
NS = not statistically significant.
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without pre-treatment in 96-well costar half plates. Fumarase activity in urine was assessed at a wavelength of 
670 nm instead of the usual 650 nm because of the presence of background interference.
RNA extraction and quantitative PCR. Total RNA was isolated from the renal cortex using a NucleoSpin 
RNA II mini kit according to the manufacturer’s instructions (AH diagnostics, Aarhus, Denmark). RNA was 
quantified by spectrophotometry and stored at − 80 °C. cDNA synthesis was performed with a RevertAid First 
strand cDNA synthesis kit (MBI Fermentas, Burlington, Canada). qPCR was performed using Maxima SYBR 
Green qPCR Master Mix according to the manufacturer’s instructions (AH diagnostics, Aarhus, Denmark). 
Briefly, 100 ng of cDNA was used as a template for PCR amplification. The specificity of products was confirmed 
by melting curve analysis and gel electrophoresis. Primer sequences used included: 18 s forward 5′ -CAT GGC 
CGT TCT TAG TTG-3′ and reverse 5′ -CAT GCC AGA GTC TCG TTC-3′ designed from ascension no: M11188; 
Figure 6. Proposed hypothesis for the sensitive biomarker of renal necrosis in AKI. In healthy cells the 
transport of hyperpolarized [1,4-13C]fumarate across the cell membrane is slow compared to the decay of the 
hyperpolarized signal and thus no conversion to [1,4-13C]malate via fumarase is seen. In necrotic cells the 
plasma membrane is compromised and thus fumarase is freely available for the substrates [1,4-13C]fumarate and 
water to convert to [1,4-13C]malate. Additionally in the healthy rat little or no fumarase are present in blood or 
urine, however following AKI both blood and urine show necrosis dependent fumarase activity.
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KIM-1 forward 5′ -CCA CAA GGC CCA CAA CTA TT-3′ , and reverse 5′ -TGT CAC AGT GCC ATT CCA GT-3′ 
designed from ascension no: AF035963; and NGAL forward 5′ -GAT CAG AAC ATT CGT TCC AA-3′ and 
reverse 5′ -TTG CAC ATC GTA GCT CTG TA-3′ designed from ascension no: BC089053.
Hyperpolarized experiments. At the MRI scanning session 24 h after IRI surgery, tail vein catheteriza-
tion was performed for hyperpolarized [1,4-13C2]fumarate administration. The animals were placed in a clinical 
3 T MRI scanner (GE Healthcare, Waukesha, US) for imaging. Throughout the experiment, the animals were 
anesthetized with sevoflurane (2.5% sevoflurane and 2 L/min air). Rectal temperature, pO2, and respiration 
were monitored throughout the MRI session. Each animal was injected with 1.5 mL of hyperpolarized 30 mM 
[1,4-13C2]fumarate. The pH was 7.4 and the solution was isotonic.
The [1,4-13C2]fumarate was polarized in a SPINlab based on Ardenkjaer-Larsen et al.’s original polarizer 
design47. (GE Healthcare, Brøndby, Denmark). The [1,4-13C2]fumarate sample was prepared by dissolving [1,4-
13C2]fumaric acid (FA) (Cambridge Isotopes, Cambridge, UK) to a final concentration of 3.6 M in dimethyl sul-
foxide containing the trityl radical (12 mM AH111501, GE Healthcare, Brøndby, Denmark). The fluid path was 
prepared by placing 100 μ L (about 350 μ mol) of the FA solution in the sample cup and then freezing it in liquid 
nitrogen. The remainder of the fluid path preparation was performed according to the manufacturer’s instruc-
tions. The FA solution was allowed to melt for 10–30 min before lowering the fluid path into the helium bath. The 
sample vial was lowered in a fast two-step scheme to avoid the crystallization of the FA in the sample. The sample 
was polarized for approximately 3 h to a reproducible polarization of approximately 40%. The dissolution syringe 
was filled with approximately 15 g of a dissolution media (sterile water with 0.1 g/L EDTA). After dissolution, the 
sample was mixed with 0.54 g of neutralizing buffer (sterile water with 0.72 M NaOH, 0.4 M TRIS, and 0.1 g/L 
EDTA).
MRI scans were performed using a 3 T clinical MRI system (GE Healthcare, Brøndby, Denmark) equipped 
with a dual tuned 13C/1H volume rat coil (GE Healthcare, Brøndby, Denmark). A slice-selective 13C IDEAL 
spiral sequence was used to detect hyperpolarized [1,4-13C2]fumarate, and images were acquired every 5 s, 
initiated 20 s after the start of injection. The spiral acquisition was performed using a flip angle of 10°, 11 
IDEAL echoes, and one initial spectrum per IDEAL encoding48. The following parameters were also used: 
TR/TE/Δ TE = 100 ms/0.9 ms/1.45 ms; field of view = 80 × 80 mm2; 5 × 5 mm resolution interpolated to a 0.3-mm 
resolution; and an axial slice thickness of 15 mm covering both kidneys. The 13C/1H images were converted to 
the DICOM format and analyzed using Osirix software49. Images of [1,4-13C2]fumarate and [1,4-13C2]malate 
were overlaid on anatomical 1H images: representative images are provided in Fig. 3A,B. Analysis was performed 
according to the region of interest (ROI). The ROIs were placed around each kidney on the 1H images and trans-
ferred to the 13C images. The area under the time curve ratio between the hyperpolarized [1,4-13C2]malate signal 
and the hyperpolarized [1,4-13C2]fumarate signal from each individual kidney was calculated50.
Statistics. All data are presented as means ± s.e.m. Normality was assessed with quantile plots. A 
P-value < 0.05 was considered statistically significant. A paired Student’s t-test was used to compare values 
between the CL kidney and the post-ischemic kidney. The linear correlation was tested between the kidney injury 
markers Kim-1, NGAL, and the corresponding malate/fumarate ratio.
One-way analysis of variance with a Holm-Sidak’s multiple comparisons test was used to evaluate fumarate 
activity in the urine and blood collected from animals with varying degrees of IRI. A linear regression test was 
performed on the qPCR measurements of KIM-1 and NGAL, which were tested against the corresponding 
malate/fumarate ratios. The goodness of fit was calculated to provide R2 values, and the deviation from zero was 
also calculated. Statistical analyses were performed using GraphPad PRISM 6.
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 Abstract (200/200):  
Purpose: Symmetric echo planar spectroscopic imaging (EPSI) sequence for hyperpolarized 13C 
imaging in clinical PET/MRI system is presented.  
Methods: The sequence employs parallel reconstruction pipelines to separately reconstruct the data 
from odd and even echoes to reduce artifacts from gradient imbalances. The ramp sampled data in 
the spatio-temporal frequency space is regridded to compensate for the chemical shift 
displacements. The sequence was compared with conventional phase-encoded chemical-shift-
imaging (CSI) in phantoms, and was evaluated in a canine cancer patient after injection of 
hyperpolarized [1-13C]pyruvate.  
Results: The relative SNR of EPSI with respect to CSI was 0.88, which is consistent with the 
decrease in sampling efficiency due to ramp sampling. Data regridding in spatio-temporal frequency 
space reduced spatial blurring compared to direct FFT. EPSI was able to capture both the spatial 
distributions of the metabolites and their dynamics in vivo with improved spatial resolution of 5 x 9 
mm2 in-plane and 3 s temporal resolution.  
Conclusion: Higher spatial and temporal resolution was achieved for EPSI metabolic maps 
compared to CSI’s maps, which were more prone to blurring. The sequence showed promising 
results with short acquisition time and sufficient spectral bandwidth of 500 Hz, and allowed adjusting 
the tradeoff between SNR and encoding-speed. 
 
Key words: hyperpolarization; echo planar spectroscopic imaging; regridding; metabolic imaging; 
cancer; molecular Imaging; PET/MRI; hyperPET   
 Introduction 
Since the introduction of the dissolution Dynamic Nuclear Polarization technique (dDNP) [1], 
Magnetic Resonance Spectroscopy (MRS) of hyperpolarized 13C has emerged as an attractive 
modality that enables imaging of the metabolic activity in vivo [2–5]. Currently, hyperpolarized 13C 
metabolic imaging is widely being examined in combination with the more established Positron 
Emission Tomography (PET) [6,7] to study its potential for clinical use. The hybrid PET/MRI systems 
are well suited for such tasks [8–10]. The enhanced magnetization obtained from hyperpolarization 
methods is short-lived, and the magnetization consumed on excitations is non-recoverable. This 
dictates the use of optimized imaging sequences that efficiently utilize the decaying magnetization. 
The conventional 2D phase-encoded chemical shift imaging (CSI) sequence encodes the k-space 
using two phase encoding gradients [11,12]. This results in a total imaging duration of CSI that is 
relatively long compared to the longitudinal relaxation time, and gives poor resolution for mapping the 
dynamics of metabolism. Accelerated spectroscopic imaging sequences, such as Echo Planar 
Spectroscopic Imaging (EPSI)  [13–19], multiecho bSSFP (ME-bSSFP) [20–22], spiral MRSI [23–26], 
and IDEAL spiral [27], require fewer excitations because more than one k-space position is sampled 
for each excitation, e.g. one k-space line in the case of EPSI and ME-bSSFP and one image frame in 
the case of spiral acquisition. Therefore, the total imaging time for these sequences is reduced, 
typically by one order of magnitude. The short imaging time and reduced number of excitations make 
such sequences attractive for imaging of hyperpolarized nuclear spins, enabling observation of the 
conversion of the hyperpolarized substrates to their metabolic products with acceptable temporal 
resolution. These sequences, however, are characterized by a limited spectral bandwidth due to 
gradient slew rate constraints. The dwell time (time elapsed between consecutive acquisitions of the 
same point in k-space) is governed by the gradient echo spacing in the case of ME-bSSFP [20–22] 
and EPSI [13–19], and the echo time increment between spirals in the case of spiral MRSI and 
IDEAL spiral [23–27]. This reduced spectral bandwidth is usually not a limitation for hyperpolarized 
MRI, since the spectrum of the hyperpolarized 13C substrate and its metabolic products is sparse, 
and spectral aliasing can be controlled to avoid peak overlap. However, compared to conventional 
 CSI, these fast acquisition sequences are more demanding in terms of gradient strength and slew 
rate, and require extensive ramp sampling on clinical MR scanners as opposed to preclinical 
systems, which reduces the signal-to-noise-ratio (SNR) per unit time. These limitations of gradient 
performance make it challenging to translate the use of these sequences from small animals to 
human studies. 
EPSI is the most established sequence to achieve dynamic imaging of the metabolism in clinical 
studies [28] with hyperpolarized pyruvate. This sequence employs oscillating gradients in the readout 
direction during the data acquisition to efficiently sample one line at each TR interval at the expense 
of reduced spectral bandwidth. EPSI with symmetric readout gradients typically suffers from aliasing 
artifacts [29,30] due to gradient imperfection, which require reference scans to estimate and correct 
the discrepancies between the odd and even echoes [31]. Flyback EPSI is sometimes preferred over 
symmetric EPSI to avoid the need to correct these differences [32,33]. However, flyback EPSI suffers 
from lower SNR because the receiver is idle for longer duration [16,34]. We argue that symmetric 
EPSI with separate reconstruction of the odd and even echo data is sufficient and simple, if the 
resultant smaller spectral bandwidth is acceptable. The simplest way to reconstruct the even and odd 
data is via FFT assuming that the data are collected on a Cartesian grid. However, the data in the k-t 
space are acquired on a zig-zag trajectory, so the phase evolution during the acquisition of individual 
k-space lines must be corrected before carrying out FFT to avoid spatial blurring due to chemical 
shift artifacts in opposite directions for odd and even gradient echoes.  
In this study, we present symmetric 13C EPSI with separate reconstruction of the odd and even 
echo data and ramp sampling for application on a clinical PET/MRI system. The EPSI technique is 
based on our proton-echo-planar-spectroscopic-imaging (PEPSI) methodology [35–38], which 
provides high sampling efficiency without aliasing and acceptable spectral bandwidth. Moreover, we 
introduce a correction of the phase evolution during the acquisition of the zig-zag trajectory in k-t 
space [39,38], to avoid spatial blurring due to chemical shift artifacts in opposite directions for odd 
and even gradient echoes. This reconstruction algorithm is extended to give optimal reconstruction 
 for sufficiently band-limited signals, even for aliased non-overlapping peaks. Both free induction 
decay (FID) and spin echo excitation methods were evaluated. The sequence was validated and 
compared with CSI using a phantom with multiple compartments of 13C labeled compounds. 
Moreover, a version of the sequence with centric phase encoding was evaluated in vivo with 
hyperpolarized [1-13C]pyruvate in a canine cancer patient undergoing PET/MR, as part of the 
diagnostic work up for acanthomatous ameloblastoma. 
 
  
 Methods 
Hardware 
All experiments were performed on a 3 T PET/MR (mMR Biograph, Siemens Healthcare, 
Erlangen), with maximum gradient strength of 43 mT/m, maximum slew rate of 180 mT/m/ms, 
gradient raster time of 10 µs, analog-to-digital converter (ADC) raster time of 100 ns, and minimum 
delay between ADC readout events of 100 µs. The raster time is the smallest temporal unit that can 
be used to specify the timing of the ADC event. The acoustic resonances of the gradient coil were in 
the frequency bands of 530-630 Hz and 1010-1230. 
Two coils were used in this work, a 13C birdcage head coil (RAPID Biomedical, Germany) with 
265 mm inner diameter and a 1H/13C transmit/receive flex coil (RAPID Biomedical, Germany) (110 
mm loop for 13C and 180 mm x 244 mm butterfly for 1H). The head coil was used with a thermal 
phantom, and the flex coil was used with a hyperpolarized [1-13C]pyruvate phantom and in vivo with 
the canine cancer patient. A 7 mL vial with 4.0 M 13C-urea doped with Gadolinium (Dotarem, 
Guerbet, France) (0,23% v/v) was used for flip angle calibration in the hyperpolarized phantom 
experiments and for the canine cancer patient. Two phantoms were used. To compare the SNR 
between the sequences, a cylinder with diameter of 250 mm and length of 200 mm was used. It had 
four cylindrical compartments with inner diameters of 19 mm each. The outer volume of the phantom 
was filled with ethylene glycol with natural abundance of 13C, and three of the inner compartments 
were filled with 13C-bicarbonate, [1-13C]acetate and 13C-urea (all three compounds are from Sigma 
Aldrich, Denmark). The concentration of each substrate is 1.0 M. The three compounds were doped 
with Omniscan (GE Healthcare, USA) to T1 values of 0.4 s, 0.7 s, and 0.7 s, respectively (measured 
at 9.4 T and 295 K). The fourth compartment was left empty. 
A hyperpolarized phantom made from a rectangular bottle (200x185x125 mm3) was initially filled 
with 4.5 L of saline solution. A hyperpolarized sample containing 14 mmol of [1-13C]pyruvate was 
added to the phantom after dissolution. Then the phantom was briefly shaken, placed on top of the 
 surface 1H/13C coil and the dynamic imaging was acquired. To prepare the hyperpolarized sample, 1 
mL of [1-13C]pyruvic acid with 15 mM of electron paramagnetic agent, AH111501 (Syncom BV, 
Netherlands), was polarized in  a SPINlab polarizer (GE Healthcare, USA) for 4 hours. The sample 
was then dissolved in 49.8 mL of dissolution media containing 0.1 g/L of EDTA 
(ethylenediaminetetraacetic acid disodium salt dehydrate) (Sigma Aldrich, Denmark) in water. The 
sample was neutralized with 14.6 mL of neutralizing media containing 0.72 M NaOH, 0.4 M 2-Amino-
2-(hydroxymethyl)-1,3-propanediol (Tris) (Sigma Aldrich, Denmark) and 0.1 g/L EDTA disodium salt 
in water.  
Design of 13C EPSI 
Echo Planar Readout Gradient 
Both the desired spatial resolution and the target spectral bandwidth with separate processing of 
even and odd echo data [35,36,40] were taken into account when designing the trapezoidal echo 
planar readout gradient with ramp sampling. The echo spacing (𝐸𝑆) was chosen to avoid acoustic 
resonances, which must be outside of the ranges of 1.58-1.89 ms and 810-990 μs. A 𝑆𝑊 of about 
500 Hz in a 3 T magnet, which avoids acoustic resonances, is acceptable for the case of 
hyperpolarized [1-13C]pyruvate. The pyruvate and its products alanine, pyruvate-hydrate and lactate 
are located at 171.1, 176.3, 177.6, and 183.2 ppm respectively (i.e. a range of 372 Hz in a 3T 
scanner).  
The iterative design process for the targeted spectral bandwidth, 𝑆𝑊 = (2𝐸𝑆)−1, was initiated 
with a trapezoidal readout gradient waveform 𝐺𝑅𝑂 such that, 
𝛥𝑥 =
1
𝛾 ∫ 𝐺𝑅𝑂(𝑡) 𝑑𝑡
𝑡=𝑇𝑅𝑂
𝑡=0
                                     (1) 
where 𝛥𝑥 is the pixel dimension in the readout dimension, 𝛾 is the gyromagnetic ratio for the nucleus 
of interest, 𝑡 = 0 is the start time of signal recording, and 𝑇𝑅𝑂 is the readout time, 𝑇𝑅𝑂 < 𝐸𝑆. Further 
 increase in spatial resolution requires increasing the readout time 𝑇𝑅𝑂 and thus reducing the spectral 
bandwidth.  
A 𝑆𝑊  of about 500 Hz in a 3 T magnet is acceptable for the case of hyperpolarized [1-
13C]pyruvate. The pyruvate and its products alanine, pyruvate-hydrate and lactate are located at 
171.1, 176.3, 177.6, and 183.2 ppm respectively (i.e. a range of 372 Hz in a 3 T scanner).  
The Iterative optimization of the gradient waveform under the given hardware constraints, yielded a 
spectral bandwidth of 495 Hz corresponding to gradient lobe duration of 1010 μs. Using trapezoidal 
gradients with ramp up and ramp down durations of 170 μs, the maximum gradient strength 
achievable during ramping at the maximum slew rate was 30 mT/m. The ADC was switched on 57 μs 
after the start of the gradient and switched off 57 μs before the end of the gradient lobe to ensure 
more than 100 μs between successive ADC periods. The effective gradient moment accumulated 
during the readout was 26.6 mTs/m, which provided a maximum achievable spatial resolution of 3.75 
mm with 495 Hz spectral bandwidth on the mMR Biograph. The corresponding ADC period was 896 
μs.  
If the reference frequency is chosen to be exactly in the middle between pyruvate and lactate, 
then the resultant spectrum acquired with a bandwidth of 495 Hz will be as shown in Figure 1a 
(lactate at 186 Hz, pyruvate-hydrate at 24 Hz, alanine at -21 Hz and pyruvate at -186 Hz). The 
bicarbonate signal will be aliased to the center of the spectrum at 1 Hz, between alanine and 
pyruvate-hydrate. The peak positions of the three substrates in the multi-compartment phantom were 
acetate at 155 Hz, bicarbonate at 494 Hz (aliased to 71 Hz), and urea at 424 Hz (aliased to 1 Hz), 
Figure 1b. 
Phase encoding gradient 
The total duration of the phase encoding gradient was set to 1700 μs giving a maximum 
resolution of 1.9 mm in the phase encoding direction. An EPSI version with centric phase encoding 
was designed and used in the hyperpolarization experiments in phantom and in vivo. 
 Radiofrequency pulses 
An excitation pulse (Hanning-filtered sinc with time bandwidth product of 4) with total duration of 
1,280 μs and central lobe duration of 640 μs was used. The smallest slice thickness achievable with 
this pulse was 6 mm with a slice selection gradient of 43 mT/m. The excitation pulse used had an 
approximate bandwidth (𝐵𝑊) of 3000 Hz. The chemical shift displacement 𝛿𝑝,𝑙  between pyruvate and 
lactate in the slice direction was therefore 
𝛿𝑝,𝑙 =
𝛥𝑓𝑝,𝑙
𝛾 𝐺𝑧
=
𝛥𝑓𝑝,𝑙
𝐵𝑊
𝛥𝑧 = 0.12 𝛥𝑧                                                 (2) 
where 𝛥𝑓𝑝,𝑙 is the chemical shift between pyruvate and lactate (372 Hz at 3 T) and 𝛥𝑧 is the slice 
thickness. 
In addition, a spin echo (SE) EPSI was implemented with Hanning-filtered sinc refocusing pulse 
with time bandwidth product of 8.The duration of the refocusing pulse was set during the pulse 
preparation, and the smallest allowed duration is assumed (2600 μs) without exceeding the B1 limit. 
The maximum bandwidth of the pulse is therefore 2.2 kHz. The maximum allowed duration for the 
refocusing pulse was 7200 μs, giving a minimum bandwidth of 780 Hz. This sequence was used in 
the phantom SNR evaluation 
SNR efficiency 
We characterized the sensitivity of PEPSI as a function of field strength and computed the ramp 
sampling efficiency as in [40]. Pohmann et al [41] compared different chemical shift imaging methods 
and analyzed their sensitivity with respect to the conventional phase encoded CSI. For an EPSI 
sequence, the sensitivity, 𝛹𝐸𝑃𝑆𝐼, can be related to the CSI sensitivity, 𝛹𝐶𝑆𝐼, as follows  
𝛺𝐸𝑃𝑆𝐼 =
𝛹𝐸𝑃𝑆𝐼
𝛹𝐶𝑆𝐼
= √1 −
𝜏𝑠
𝐸𝑆
                                 (4) 
where 𝜏𝑠 is the time needed for gradient switching, and 𝐸𝑆 is the echo spacing. 
 Pipe and Duerk [42] showed that the variance in the reconstructed image depends on the shape 
of the gradient waveform used to record the signal. The smallest variance for even sampling occurs 
in the case of constant gradient, in which case the variance in the reconstructed image is equal to the 
variance of the thermal noise, σ2.  They also showed that the variance in the reconstructed image, 
𝜎𝑖
2, can be expressed in terms of the first and second moments of the gradients waveform 𝐺(𝑡), the 
thermal noise variance σ2, and the measurement duration 𝑇: 
𝜎𝑖
2
𝑇
=
𝜎2 ∫ 𝐺2(𝑡)  𝑑𝑡
𝑇
0
(∫ 𝐺(𝑡) 𝑑𝑡
𝑇
0
)
2                                         (5) 
Reconstruction and post-processing  
Initially, 1D regridding was applied to compensate uneven k-space sampling over the ramp. After 
regridding, the odd and even echoes were separated into two matrices. Time reversal was performed 
on the odd echo data. Temporal Fourier transformation was applied to the two data sets to obtain two 
kx-ky-f arrays. Before applying the spatial Fourier transform, a linear phase correction was introduced 
along the readout direction kx [39,38] to account for the time evolution, which would otherwise results 
in a chemical shift displacement in the spatial domain, differing between even and odd numbered 
echoes. Subsequently, spatial Fourier transform was applied to obtain odd and even x-y-
f matrices. The data corresponding to odd echoes were phase adjusted and then added to the even 
echo data to obtain a 13C spectroscopic image. The reconstructed spectra were interpolated to 256 
points using zero-filling in the time-domain. No apodization was used in the temporal 
dimension. Figure 2 shows the reconstruction pipeline. The chemical shift correction described above 
assumes there is no aliasing of metabolites in the spectrum, which may occur in practice since the 
spectral bandwidth is relatively small. Therefore, any aliased peaks should be unfolded to its true 
frequency position before applying the corrections. This can be done if peaks do not overlap in the 
aliased spectra by simply applying phase ramps corresponding to spatial shifts of non-aliased peak 
frequencies.  
 Phantom experiment 
An experiment was conducted to evaluate the SNR and the localization of the EPSI sequence 
using the birdcage coil and the multi-compartment cylindrical phantom. A product CSI sequence 
served as the SNR reference. The CSI data were acquired with repetition time (TR) of 1,000 ms, field 
of view of (FOV) 100x100 mm2, spatial matrix 16x16, flip angle 90o, slice thickness 100 mm, spectral 
bandwidth 5,000 Hz, number of spectral points 512, sampling time of 102.4 ms, and no averaging, 
resulting in a CSI scan time of 4 min and 16 s. The time between excitation and sampling was 2.3 
ms. EPSI data were acquired with TR of 1,000 ms, FOV 100x100 mm2, spatial matrix 16x16, flip 
angle 90o, slice thickness 100 mm, Echo Train Length (ETL) 128, ES 1,010 μs, 16 averages, 
resulting in a scan time of 4 min and 16 s, echo train duration of 129.3 ms and a spectral bandwidth 
of 495 Hz. The time between excitation and the start of the first readout gradient lobe was 2.4 ms. 
Additionally, a SE-EPSI was acquired with the same parameters as for the EPSI, except TE was 8.8 
ms. For noise estimation, both CSI and EPSI sequences were run after nulling the transmitted signal. 
These sequences were also evaluated using the 7 mL vial of 13C-urea and the surface coil. 
To quantify the SNR of each substrate, the signal was estimated at each voxel from the peak 
amplitude (real phased spectrum). Then the signal was averaged in a 4x4 pixel region of interest 
(ROI) encompassing the substrate, and normalized by the noise standard deviation in the spectra in 
the same ROI. 
To assess the localization of the spectroscopic sequences, the proton image was taken as a 
reference. For each substrate, the location of the center of the cylinder in the 13C image and proton 
image were compared. The shift in millimeters between the two locations was reported. Since each 
substrate is in a cylinder, a circle was fitted to the contour spatial distribution and the center of the 
circle was taken as the location in the proton image. The 13C images were obtained using general 
linear model (GLM) fitting. Then spline fitting was applied to the 13C spatial distribution of each 
substrate to achieve sub-voxel precision at the same resolution as the proton image. The position of 
 the peak intensity in the metabolite distribution after spline fitting was used as the substrate location 
in the 13C image. 
A final phantom experiment was conducted with hyperpolarized [1-13C]pyruvate and the surface 
coil. Two different dynamic measurements were acquired, one with EPSI and the second with CSI. 
The EPSI acquisition was made using a FOV 200x200 mm2, 32x32 matrix with central phase 
encoding, ETL 64, flip angle 6o, TR 80 ms, and TE 2.4 ms. The acquisition time per frame was 2.5 s 
and an image was acquired every 5 s. The CSI was acquired using FOV 200x200 mm2, truncated 
16x16 matrix, flip angle 3o, TR 80 ms, and TE 2.3 ms. The acquisition time per frame was 12 s and 3 
images were acquired sequentially without delay. 
Clinical study in a canine cancer patient 
A 9-year-old female intact Samojed weighing 27 kg, with a histopathologically confirmed 
ameloblastoma of the left mandible, underwent PET/MR examination as part of the diagnostic and 
staging workup prior to therapy. Hyperpolarized 13C MRSI was included in this examination. The 
owner gave informed consent and the study was approved by the Ethical and Administrative 
Committee, Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, 
University of Copenhagen. 
Three 500 μL samples of [1-13C]pyruvic acid with 15 mM of AH111501 were hyperpolarized in the 
SPINlab polarizer for 4 hours. The samples were dissolved in 29.1 mL dissolution media and 
neutralized with 7.3 mL of neutralizing media. After dissolution, 18 mL (0.68 mL/kg) of 250 mM [1-
13C]pyruvate was injected intravenously over 7–8 s. 
Coronal, transversal and sagittal anatomic 1H MR images were acquired for planning using a T2 
weighted turbo spin-echo (TSE) sequence (TR 4,000 ms; TE 89 ms; voxel size 0.5 x 0.5 mm2; 19 
slices of 3 mm thickness). 
 The dog received three injections of hyperpolarized [1-13C]pyruvate with 10 min intervals. A 
dynamic FID sequence with no in-plane spatial encoding was started at the beginning of the sample 
injection with the following parameters: slice thickness 4 cm, TR 1 s, flip angle 5o, acquisition delay 
2.3 ms, spectral bandwidth of 6,000 Hz and 512 points. The purpose of the dynamic FID was to find 
the time point with maximum lactate signal, which was used to determine the start time of the 
subsequent CSI acquisition. Acquisition of a CSI data set was initiated 30 s after the start of the 
injection of the second pyruvate sample with TR 80 ms, FOV 150x180 mm2, matrix size 16x16, slice 
thickness 15 mm, flip angle 10o, acquisition delay 2.3 ms, spectral bandwidth 10,000 Hz, and number 
of spectral points 512.  A dynamic EPSI acquisition was started at the end of the injection of the third 
hyperpolarized sample using a FOV of 150x180 mm2, 16x32 matrix with central phase encoding, 
slice thickness 15 mm, ETL 64, flip angle 6o, TR 80 ms, and acquisition delay 2.4 ms. The acquisition 
time per frame was 1.3 s and a frame was acquired every 3 s (with idle time of 1.7 s between 
frames). 
PET images were acquired as a single-bed with 5 min acquisition duration, after intravenous 
injection of 216 MBq (8 MBq/kg) of 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) 1 hour prior to imaging. 
PET reconstruction used 3D OP-OSEM with 4 iterations, 21 subsets, matrix 344x344, 4 mm 3D 
Gaussian post-filter, pixel size 2.1x2.1 mm2 and 2.0 mm slice thickness.  
 Results 
Phantom Experiments 
To calculate the theoretical relative SNR between the CSI and the EPSI, Eq. (4) was used. The 
EPSI acquisition time was 896 μs with 114 μs delay between acquisitions reducing the SNR by 5% 
compared to CSI. To account for ramp sampling, Eq. (5) was used to calculate the SNR efficiency 
relative to a square readout gradient waveform, which amounts to 94%. Therefore, the relative 
theoretical SNR of EPSI with respect to CSI was 89%. 
Figure 3 shows the signal for the three substrates 13C-urea, 13C-bicarbonate and [1-13C]acetate in 
the multi-compartments phantom obtained with CSI and EPSI using the birdcage coil, superimposed 
on the proton image. The strength of the signal varied between the substrates due to differences in 
T1 relaxation time constants and line width. For the CSI, the SNR values were 290, 153 and 113 for 
13C-bicarbonate, 13C-urea and [1-13C]acetate, respectively. For EPSI the SNR values were 257, 135 
and 99 for the three phantoms respectively. This corresponds to relative SNR values of 0.89, 0.87, 
and 0.88 respectively, which are close to the theoretical values. The SNR values for SE EPSI were 
170 for 13C-bicarbonate, 86 for 13C-urea and 67 for [1-13C]acetate, which correspond to relative SNR 
of 0.59, 0.56 and 0.59 relative to CSI. The CSI had the smallest spatial offsets with discrepancy of 
0.8 mm for [1-13C]acetate, 0.9 mm for 13C-bicarbonate and 1.5 mm for 13C-urea. The offsets were 
larger for the EPSI sequence; 1.9 mm, 1.7 mm and 3.1 mm, respectively. 
The SNR values obtained with the 13C-urea vial and the surface coil were 283 for CSI, 245 for 
EPSI and 263 for SE EPSI. This corresponds to relative SNR values of 0.87 and 0.93 for EPSI and 
SE EPSI with respect to CSI, respectively. 
Figure 4 shows the comparison between EPSI reconstruction algorithms. Direct FFT 
reconstruction, Figure 4a, results in spatial blurring of the substrates in the 13C image due to 
chemical shifts in opposite directions for even and odd echoes. On the other hand, spectral-spatial 
regridding using the apparent frequency positions, Figure 4b, results in narrower and more accurate 
 spatial representation of 13C-urea and 13C-bicarbonate. [1-13C]acetate, however, was outside of the 
critically sampled bandwidth, and therefore aliased, which resulted in increased spatial broadening. 
When accounting for aliasing by using the actual frequency offset of the non-aliased peak when 
calculating phase ramps, the chemical shift displacement of [1-13C]acetate was compensated as well, 
Figure 4c. The dynamic signal acquired for hyperpolarized [1-13C]pyruvate in the 4.5 L rectangular 
phantom (sum of the signal over the phantom) with both CSI and EPSI is shown in Figure 5c. For the 
dynamic measurements obtained with CSI (see Figure 5), the time resolution was very coarse, 12 s, 
despite the smaller matrix size used, and thus coarser spatial resolution. The coil profile derived from 
the EPSI image of the phantom is shown in Figure 5a.  
Canine Cancer Patient PET/Hyperpolarized MR Evaluation 
Figure 6 shows the anatomical images used to plan the positioning of the spectroscopic grids for 
both CSI and EPSI. The 16x12 mm tumor is located at the buccal side of the left mandible, as shown 
in Figure 7a. The dynamic FID (Figure 9a) shows that pyruvate starts accumulating in the slab 
containing the tumor about 10 s after the start of the injection, and reaches a peak value 9 s later. 
Lactate starts building up 22 s after the start of the injection and reaches a maximum value after 32 
s. The CSI acquisition was timed to start 30 s after injection to obtain the highest possible lactate 
signal from the slice. Figure 7b,e shows the pyruvate and lactate signals at the slice containing the 
tumor. Relatively high pyruvate uptake and an increased lactate production can be observed at the 
tumor site. Additionally, lactate signal can be seen at the masticator muscle in the lower right region. 
The PET-FDG image (Figure 7d) also shows high metabolism at the tumor site in addition to the 
typical high FDG uptake in the brain.  
In Figures 8, the series of metabolic maps obtained with EPSI are given. These maps show the 
buildup and decay of pyruvate and lactate across the slice. To allow for comparison with the dynamic 
FID, the pyruvate and lactate signals in each frame were summed over the entire frame, to obtain the 
time plots shown in Figure 9b. The pyruvate and lactate signals were also integrated at the tumor 
and masticator muscle to obtain the dynamic build-up and decay at these two sites, Figure 9c,d. 
 Moreover, the pyruvate and lactate series were integrated into one pyruvate and one lactate image, 
Figure 7c,f, for comparison with the corresponding CSI maps in Figure 7b,e. The signal level in all 
the metabolic maps in figures 7 and 8 were normalized with respect to the standard deviation of the 
noise.  
 Discussion 
This work presents an implementation of a symmetric EPSI sequence for hyperpolarized 13C in a 
hyprid clinical PET/MR system and evaluates this sequence in phantoms and in vivo. The SNR 
obtained with this sequence was around 88% compared to CSI, and this agrees with the theoretical 
estimation and literature [33]. Although EPSI is susceptible to errors from gradient waveform 
imperfection, these errors were minor in this work. However, higher resolution can increase the 
demand on gradients, and this in turn could increase artifacts with this sequence. This may explain 
the error in localization where the substrates were slightly shifted outward. However, on average the 
localization error was less than one-third of the voxel dimension and the estimate may also be 
influenced by noise. Although all the substrates in the multi-compartment phantom had the same 
concentration, the SNR as measured from the CSI and EPSI acquisitions varied significantly due to 
the differences in T1 relaxation times. 
With the birdcage coil the SNR of the SE EPSI was about 58% of the CSI SNR, in contrast to 
93% with the surface coil. This discrepancy in SNR values of SE EPSI is because of the difference in 
the refocusing pulse durations used with the two coils. Due to the relatively high power needed with 
the birdcage coil, the bandwidth of the refocusing pulse was limited to around 1000 Hz. This range is 
sufficient for the pyruvate-lactate range, but insufficient to uniformly cover the range from bicarbonate 
to acetate in the phantom experiments (peak separation of 650 Hz).  
The reconstruction employed in this work provides better accuracy compared to direct FFT.  For 
EPSI with flyback readout [33], direct FFT will cause less artifacts since the chemical shift 
displacement is in one direction and no broadening occurs. Aliased metabolites caused an error in 
the spatial-spectral regridding. This error was removed by adapting the algorithm to exploit that the 
13C spectrum in the hyperpolarization experiments is sparse and the metabolite frequencies known a 
priori. Other examples of hyperpolarized 13C substrates that give sparse spectra, with two or three 
peaks, and for which this EPSI sequence can be used without major modifications include, but not 
 limited to, hyperpolarized 13C-bicarbonate used measure pH values [34] and [1,4-13C]fumarate used 
in imaging necrosis [44]. 
In the phantom experiment with hyperpolarized [1-13C]pyruvate, EPSI allowed dynamic imaging 
with reasonable temporal resolution. However, faster imaging could have been achieved using fewer 
phase encoding steps, since the surface coil had a relatively superficial localized sensitivity and most 
of the signal came from a small part of the FOV. Similarly, for the in vivo evaluation of the canine 
cancer patient most of the observed signal came from the jaw close to the surface coil, where the 
tumor was located.  
Higher spatial resolution was achieved for the metabolic maps obtained with EPSI compared to 
CSI in the hyperpolarization experiments. Despite employing dynamic acquisition with EPSI in the in 
vivo hyperpolarization experiment, using a larger matrix size was feasible, compared to the matrix 
size of CSI. Moreover, CSI is prone to blurring from T1 decay due to the relatively long acquisition 
duration per frame. Therefore, the pyruvate and lactate signals were sharper and better localized in 
the EPSI metabolic maps, whereas the maps obtained from the CSI acquisition were blurry.  
The dynamic measurements of pyruvate and lactate in Figure 9b obtained from EPSI agree with 
those obtained from the dynamic FID sequence (Figure 9a). Lactate reached the maximum about 27 
s after the end of the injection (34 s after the start) in the EPSI series, whereas pyruvate was highest 
13 s after the end of injection (20 s from the start of injection).  The maximum lactate signal relative 
to maximum pyruvate was higher for the dynamic FID sequence compared to EPSI. This is probably 
due to higher number of excitations per unit time in the EPSI sequence that consumes more pyruvate 
magnetization before the conversion to lactate (5.3 excitations/s with 6° flip angle reduces the signal 
by 2.9%/s, compared to the 5° flip angle every second for the FID giving 0.4%/s signal reduction). 
Both the EPSI and the CSI sequences showed similar metabolite distributions. The slight differences 
could be because the imaging windows for the two sequences were different: CSI was acquired over 
 12 s from 30 s after injection, whereas EPSI was acquired over 60 s from the end of the injection. 
Also, the spatial resolution of CSI was lower than that of EPSI.  
In conclusion, an implementation of a symmetric EPSI sequence in a clinical PET/MR system 
was presented with an adopted reconstruction that provides more accurate spatial mapping of the 
hyperpolarized signal compared to direct FFT, including for aliased non-overlapping peaks. EPSI 
provided an acceptable tradeoff between encoding speed and SNR in the phantom and in vivo 
experiments. Moreover, the in vivo experiment showed that the designed sequence provides high 
temporal and spatial resolution for mapping hyperpolarized metabolites and their dynamic behavior.  
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 Figure legends 
Figure 1: A diagram showing the spectral positions of the metabolites with a spectral bandwidth of 
495 Hz and a reference frequency chosen midway between lactate and pyruvate. (a) After injection 
of hyperpolarized [1-13C]pyruvate  lactate at 186 Hz, pyruvate-hydrate at 24 Hz, alanine at -21 Hz, 
pyruvate at -186 Hz and bicarbonate aliased to 1 Hz (true position at -494 Hz). The Figure also 
shows the peak positions of the substrates used in the phantom experiment (b); acetate at 155 Hz 
and the aliased urea and bicarbonate at 71 Hz (true position -424 Hz) and -1 Hz (true position 494 
Hz), respectively. In the phantom experiment, however, the actual reference frequency was chosen 
at the middle between bicarbonate and acetate to ensure uniform excitation for the substrates. These 
frequency positions were calculated based on a synthesizer frequency of 30.995 MHz which 
corresponds to a magnetic field of 2.8954 T. The chemical shift values in ppm are obtained from:  
http://www.utsouthwestern.edu/education/medical-school/departments/airc/tools-
references/chemical-shifts/chemical-shifts-sorted-by-compound-name.html 
Figure 2: The pipeline used for the reconstruction of the raw data and the correction of the 
broadening due to chemical shifts in opposite directions for odd and even echoes. 
Figure 3: The [1-13C]acetate, 13C-bicarbonate and 13C-urea maps acquired by CSI and EPSI. Only 
the central part of the phantom is shown. The signal level in the maps is normalized with respect to 
the bicarbonate signal acquired with CSI. The spectrum from a single voxel at the center of each 
substrate is also shown for both CSI and EPSI.  The line width (full width at half height) obtained with 
CSI was 12.2 Hz, 9.2 Hz and 10.6 Hz for [1-13C]acetate, 13C-bicarbonate and 13C-urea respectively, 
whereas the line width obtained with EPSI  was 11.7 Hz, 8.7 Hz  and  9.8 Hz. 
Figure 4: A comparison of chemical shift displacement with (a) direct FFT reconstruction and (b, c) 
with reconstruction after spectral-spatial regridding (b, c). The Image from odd (green) and even 
(magenta) echoes are overlaid. The locations of overlap appear in white and the non-overlap 
locations appear colored. In (b) spectral-spatial regridding removes the chemical shift displacement 
 of bicarbonate and urea, which are within the spectral bandwidth, but increases the chemical shift 
displacement of acetate that is aliased. In (c) the chemical shift displacement of the acetate peak is 
additionally corrected using its non-aliased frequency location in the reconstruction. 
Figure 5: The first dynamic image acquired for hyperpolarized [1-13C]pyruvate in a 4.5 L phantom 
with EPSI in (b) and the coil profile (a). (c) shows the decay of the signal from hyperpolarized 
pyruvate obtained by both EPSI and CSI dynamics. An exponential function was fitted to the EPSI 
signal giving a time constant of 52 s.  
Figure 6: The anatomical images (transversal, coronal and sagittal) acquired with TSE and used to 
position the spectroscopic grids for both CSI and EPSI (a, b and c). The green box is at the location 
of the tumor. 
Figure 7: The acanthomatous ameloblastoma in the left mandible of the canine cancer patient (a). 
The PET-FDG image (slice thickness 2 mm) with high uptake in the tumor and brain regions is 
shown in (d). (b and e) show the pyruvate and lactate signals, obtained from the CSI acquisition 
using GLM, at the slice containing the tumor. Increased lactate production can be observed at the 
tumor and muscle sites. (c and f) show pyruvate and lactate images calculated from the dynamic 
EPSI by integrating over the frames in Figure 8.    
Figure 8: Pyruvate and lactate build-up and decay across the slice containing the tumor. The figure 
also shows the spectrum with GLM fitting at the tumor site in the EPSI frame acquired 27 s after the 
end of injection. 
Figure 9: (a) The build-up of pyruvate and its conversion to lactate obtained with dynamic FID 
acquisition over a 4 cm axial slab that includes the tumor region. (b, c and d) show the time curves 
for lactate and pyruvate obtained from the EPSI series (Figure 8) by integrating the pyruvate and 
lactate signals in each frame at the whole image, at the tumor region, and at the masticator muscle, 
respectively.   
 Figures  
 FIG 1: 
 
  
 Fig 2: 
  
 FIG 3: 
 
  
 FIG 4: 
  
 FIG 5: 
 
  
 FIG 6: 
  
 FIG 7: 
 
  
 FIG 8: 
 
  
 FIG 9 
 
